Isolation and Elucidation of Structures of Biologically Active Secondary Metabolites from Various Organisms, Including Cyanobacteria, Sponges, and Areca catechu. by Neupane, Ram P.
 1
 
ISOLATION AND ELUCIDATION OF STRUCTURES OF 
BIOLOGICALLY ACTIVE SECONDARY METABOLITES 
FROM VARIOUS ORGANISMS, INCLUDING 
CYANOBACTERIA, SPONGES AND ARECA CATECHU  
 
 
 
A DISSERTATION SUBMITTED TO THE OFFICE OF GRADUATE 
EDUCATION OF THE UNIVERSITY OF HAWAI‘I AT MĀNOA IN PARTIAL 
FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF 
 
 
DOCTOR OF PHILOSOPHY 
 
IN 
 
CHEMISTRY 
 
 
DECEMBER 2017 
 
 
 
By 
 
Ram Prasad Neupane 
 
 
 
 
 
Dissertation Committee: 
 
Philip G. Williams, Chairperson 
Marcus A. Tius 
Joseph T. Jarrett 
Ho L. Ng 
Qing X. Li 
  
 ii 
 
i
i 
 
 
 
In most likelihood, I would not have taken off on this academic journey without the selfless 
involvement of my primary school teacher Mr. Ganga Prasad Shrestha many years ago. This 
dissertation is dedicated to him. 
 
 
  
 iii 
 
i
ii 
ACKNOWLEDGMENTS 
 The work described in this dissertation has been possible because of the 
contributions of many key figures. I am deeply indebted to Professor Philip Williams for his 
support, guidance, teaching and endless patience over the last several years. I have been 
extremely fortunate to find an adviser like you. I am also very grateful to the entire dissertation 
committee for their unwavering support during the course of this academic journey. Thank you, 
Professors Marcus Tius, Joseph Jarrett, Ho Ng and Qing Li! Professor John Head’s help with 
computational chemistry has been extremely invaluable. My gratitude also goes to the rest of the 
faculty and the support structure in the chemistry department at the University of Hawai‘i at 
Mānoa and I would like to especially acknowledge Wesley Yoshida for his incredible help with 
NMR spectroscopy. 
A lot of the work described here was made possible by the efforts of coworkers and 
collaborators. I am appreciative of the help and data provided by Casey Philbin, Dr. Stephen 
Parrish, Dr. Jingqiu Dai, Zhibin Liang, Joshua Gurr, Professor Reinhold Penner, Dr. Malika 
Faouzi, members of the Turkson group and the Matter group at the University of Hawai‘i Cancer 
Center, and Professor Alison Sherwood. Thank you to my current and former lab mates and 
fellow graduate students for important conversations throughout my time here.  
This journey would not come this far without my family. I cannot find words to 
express my deepest appreciation to my parents and siblings for their love and support even in the 
most difficult times.  Jayanti, thank you for the unconditional support I have received from you 
over the last five years that we have spent together.  
 iv 
 
i
v 
ABSTRACT 
Investigation of extracts of several biological specimens, including cyanobacteria, 
sponges and Areca nut, for activity in various biological assays led to the isolation of several 
known and new secondary metabolites. Sesquiterpene quinones and hydroquinones isolated from 
the sponge Dactylospongia elegans Thiele (Thorectidae) showed strong to moderate cytotoxicity 
(CC50 between 2.4 and 22.6 µM) against human glioblastoma (U251MG) and human pancreatic 
carcinoma (Panc-1) cell lines. Furthermore, ilimaquinone (IC50 65 µM) and smenospongine (IC50 
78 µM) exhibited moderate inhibition of BACE1, an enzyme implicated in the pathogenesis of 
Alzheimer’s disease. The aqueous fractions of the extracts of Areca catechu L. (Arecaceae) 
displayed Ca-signaling effects in immune (Jurkat, U937 and RBL-2H3) cell lines and the 
components responsible for this activity may be oligomeric or polymeric flavonoids.  The utility 
of prediction of 1H and 13C NMR chemical shifts using density functional theory computations 
was demonstrated in the elucidation of structures of three new molecules. 
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CHAPTER 1 
Introduction 
1.1 A Brief History of Natural Products  
Throughout history, mankind has depended on Nature for medicinal agents to combat 
a wide variety of diseases and illnesses. While it is extremely difficult to trace the precise origin 
of traditional medicine, several ancient documents describe the use of formulations from various 
plant extracts to cure illnesses. Some of the earliest descriptions were documented in the “Ebers 
Papyrus” in Egypt, the Chinese Materia Medica, the Charaka and the Sushruta and Samhitas 
from the Indian subcontinent, all of which came before the Common Era.1 Many of the 
formulations used in ancient civilizations, such as oils of Cedrus spp. (cedar), Cupresses 
sempervirens L. (Cupressaceae) (cypress) and Glycyrrhiza glabra L. (Fabaceae) (licorice), which 
were originally documented in Mesopotamia before 2500 BCE, are used in many parts of the 
world even today to fight illnesses ranging from cough to infections and inflammations.1  
Nature has remained an important source of pharmaceutical agents, even in modern 
medicine. The switch from complex medicinal formulations to single components, i.e. the advent 
of modern pharmacognosy, in the nineteenth century led to the isolation and characterization, 
followed by synthesis, of biologically active natural products derived from plants. The earliest 
single agents described were the alkaloids, including morphine2 1.1 (by Derosne and Sertuerner 
in the early 1800s), strychnine3 1.2 (Pelletier and Caventou, 1817), quinine4 1.3 (Pelletier and 
Caventou, 1820), codeine5 1.4 (Robiquet, 1832) and atropine6 1.5 (Mein, 1833). Ladenburg’s 
synthesis of coniine7 1.6 in 18868 marked the first instance of a complete set of isolation, 
 2 
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structure elucidation and synthesis of a plant natural product. Synthesis has ever since been an 
integral arm of natural product research, often serving as the only avenue for delivering enough 
supply of bioactive molecules and generating analogues for various stages of pharmacological 
testing. 
 
Figure 1: Alkaloid natural products of medicinal importance 
 
In the twentieth century, discovery of drugs and drug leads from Nature intensified 
and various classes of drugs, including antibacterial, antifungal, anticancer and antiviral agents, 
were introduced in relatively quick time. Following Alexander Fleming’s isolation and 
recognition of the activity of penicillin G 1.7 in the late 1920s,9 it saw widespread use as a life-
saving antibiotic, particularly during the later stages of the Second World War, and ushered in the 
era of antibiotics. 
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Figure 2: Penicillin G and streptomycin, antibiotic natural products 
 
The successful implementation of penicillins and streptomycin10 1.8 as antibiotics 
paved the way for the discovery of new classes of drugs from microbial sources. Antifungal 
agents amphotericin B11 1.9 and nystatin (fungicidin)12 1.10 were isolated in the 1950s from 
Streptomyces nodosus Trejo (Streptomycetaceae) and Streptomyces noursei Brown 
(Streptomycetaceae), respectively, and their structures were elucidated in the 1970s. 
 
Figure 3: Polyene antifungal natural products amphotericin B and nystatin 
 
More than half of anticancer agents in clinical use come from natural sources or are 
inspired by natural products.13 Among the first natural product anticancer agents were the vinca 
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alkaloids, vinblastine 1.11 and vincristine 1.12, which were isolated from the Madagascar 
periwinkle, Catharanthus roseus (L.) G. Don (Apocynaceae), in the 1950s.14 These were 
followed by taxanes and camptothecins, which are also plant-derived natural products. Paclitaxel 
1.13, a promoter of tubulin polymerization, was originally isolated from the bark of the Pacific 
Yew, Taxus brevifolia Nutt. (Taxaceae),15 but is also present, along with its analogs, in leaves of 
several Taxus species. Camptothecin 1.14, which was isolated from the Chinese plant 
Camptotheca acuminata Decne. (Nyssaceae),16 was abandoned in clinical trials due to severe 
toxicity to the bladder. Semisynthetic analogues of camptothecin, such as irinotecan 1.15,17 
however, are currently in clinical use. 
 
Figure 4: Anticancer agents, and a semisynthetic analogue, derived from plants 
 5 
 
5
 
Many of the antiviral drugs and drug leads in clinical use today are synthetic. 
However, it is important to note the work done by Werner Bergmann as his discovery of 
spongonucleosides18 – spongouridine 1.16 and spongothymidine 1.17 – from the sponge 
Cryptotethya crypta de Laubenfels (Tethyidae) in 1951 led to the realization that biologically 
active natural products could have sugars other than ribose and deoxyribose. Consequently, many 
analogues containing unnatural sugars were synthesized, including arabinosyladenine 
(vidarabine or Ara-A) 1.18, arabinosylcytosine (cytarabine or Ara-C) 1.19, acyclovir 1.20 and 
azidothymidine (AZT) 1.21. Many of them have been approved as clinical antiviral and 
antitumor agents. 
 
Figure 5: Spongonucleosides and their synthetic derivatives 
 
Bergmann’s pioneering work on marine sponges also led to a surge in investigations 
of the organisms from the marine environment for the discovery of new classes of biologically 
active secondary metabolites and drug leads. In the latter half of the twentieth century, aided by 
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advances in SCUBA, researchers began to scour the seas and oceans for novel pharmaceutical 
agents from sponges, mollusks, tunicates, corals, algae, fungi and bacteria. The marine habitat 
proved to be a prolific source of biologically active compounds with diverse structural features, 
such as manzamine A19 1.22, trabectedin20 1.23 (originally called ET-743 by Rinehart), 
ziconotide21 1.24, salinosporamide A22 1.25, dolastatin 1023 1.26, and bryostatin 124 1.27. 
Trabectedin and ziconotide are FDA approved drugs as anticancer and pain management agents. 
 
 
Figure 6. Diverse natural products isolated from organisms found in the marine habitat 
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Dolastatin 10 was one of the most potent anticancer agents at the time of its 
discovery, when it was originally isolated from the sea hare Dolabella auricularia Lightfoot 
(Aplysiidae). Further research, however, revealed that the compound was in actuality produced 
by the cyanobacterium Symploca sp.25 Bryostatin 1, a potent protein kinase C activator currently 
in clinical trials for various forms of cancer, was initially isolated from the bryozoan Bugula 
neritina L. (Bugulidae) but its biosynthetic origin was traced to the symbiont bacterium 
Candidatus Endobugula sertula Haygood (Cellvibrionaceae).26 These revelations illustrate the 
role of cohabitating microorganisms in the biosynthesis of biologically active secondary 
metabolites, sometimes in symbiosis with the host organism. Importantly, a significant 
percentage of these microbes are amenable to culturing, allowing for large-scale production of 
secondary metabolites of interest as well as discovery of new classes of natural products. 
Additionally, there have been reports of induction of bioactive secondary metabolites when 
organisms are co-cultured27 or introduced to chemical entities from foreign organisms,28 likely in 
competition for resources or as part of a defense mechanism. These approaches relying on 
complex interactions between organisms have been identified as possible routes toward 
discovery of new classes of bioactive natural products.  
 
1.2 Significance of Natural Products Research 
Natural products remain the most reliable sources of drugs and drug leads, as 
illustrated by Newman and Cragg in their serial reviews of new chemical entities as drugs.13, 29 In 
the most recent review, they highlight that more than half of all new small molecule drugs 
approved in the timeframe 1981–2014 are natural products, close mimics or synthetic derivatives 
with natural product pharmacophores (Figure 7).13 This, unequivocally, highlights the occupation 
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of a unique chemical space by natural products, one that correlates well to the chemical space of 
drugs. 
 
 
Figure 7. Distribution of all small molecule approved drugs between 1981 and 2014.  
Key: N: Natural product, NB: botanical drug, ND: natural product derivative, S: synthetic, S*: synthetic molecule 
with a natural product pharmacophore, NM: mimic of natural product. Figure obtained from Ref. 13. 
 
Despite a strong push by pharmaceutical companies away from natural products 
based drug discovery in favor of combinatorial synthetic libraries over the past few decades, the 
latter has not reaped success as initially predicted. One of the major issues with synthetic 
libraries is their inability to replicate the structural complexity, diversity, and drug-like properties 
of natural products. Molecular scaffold analysis shows that combinatorial libraries are farther 
away than natural products from the chemical space occupied by drugs.30 Nature, owing to its 
complex biosynthetic machinery comprising numerous enzymes, has the ability to efficiently 
synthesize complex molecules with defined stereochemical configurations which are not always 
readily accessible by synthesis. The continued successes of natural products as new drugs or drug 
 9 
 
9
 
leads and the failure of combinatorial approaches amplify the importance of natural products 
based drug discovery processes.  
The similarities between the chemical spaces of drug molecules and natural products 
has been attributed to closely related protein fold topologies during the interaction of drugs with 
target proteins and the interaction of natural products with their biosynthetic enzymes.31 A 
modeling study showed that flavonoid biosynthetic enzymes and their kinase targets share 
similar secondary structures, i.e. protein fold topology around the active site.32 This study 
suggests that natural products have a built-in advantage of being recognized by target proteins 
because of favorable major secondary structures and topological arrangements.  
The Dictionary of Natural Products33 and the Dictionary of Marine Natural Products34 
contain over 290,000 and 55,000 natural products, respectively. However, only a fraction of the 
natural products in the database have been investigated thoroughly in drug discovery 
campaigns.35 While 15% of drugs in clinical trials listed at ClinicalTrials.gov are plant natural 
products, the majority (~60%) of these come from only 10 taxonomic families,36 despite the fact 
that natural products from plants have been studied far longer than from other sources. It 
illustrates continued opportunities for drug discovery from natural products. A renewed focus on 
investigating natural products for novel drugs and drug leads is certainly warranted. 
 
 
1.3 Challenges in Natural Products Research 
Limited supply and extremely low yields from isolation procedures often impede 
drug discovery research on bioactive natural products. In the absence of an easily accessible 
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synthetic route, enough material for testing may not be generated without serious detriment to 
the environment and without incurring significant labor and monetary costs. Often, the miniscule 
amount of natural product obtained precludes researchers from determining the structure and 
carrying out rigorous biological assessments in spite of a promising early outlook. Synthesis of 
natural products is often impractical because of their complex structures and difficulty in 
efficiently installing the correct stereochemistry. Moreover, a modular synthesis of natural 
product derivatives is not always possible, preventing effective structure-activity relationship 
studies. New approaches toward sustainable production and modification of natural products are 
essential.  
We also often rely on a needle in a haystack approach, i.e. a trial and error approach, 
toward finding new classes of natural products and drug leads. A more strategic, target oriented 
discovery of new natural products is necessary.  
Rediscovery of known secondary metabolites is a chronic problem facing researchers. 
In absence of a robust database for reliable dereplication, natural products researchers have to 
rely on traditional practices and often isolate known compounds with known biological activity. 
In recent years, encouraging advances in automated high throughput screening, computational 
methods, and molecular networking platforms have been made. We need to continue to make 
crucial advances in technological innovations for the growth of the field.  
 
1.4 Current Areas of Research in Natural Products 
A group of leading researchers in marine natural products chemistry from the United 
States and Japan convened for the 8th US-Japan Symposium under the theme of 21st Century 
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Innovations in Natural Products in Honolulu in November 2016. A wide range of topics were 
presented and discussed, highlighting the state-of-the-art of natural products research.37 At the 
conclusion of the symposium, William Gerwick highlighted the contemporary areas of focus in 
the field and summarized the direction the broader natural products research community is 
headed in. These are briefly described in the following paragraphs. 
In recent years, there have been increasing reports of microbial resistance in humans 
to pharmaceutical agents used in treatment of bacterial38 and viral39 infections. Since the efficacy 
of several existing drugs is diminishing, discovery of new classes of drugs and molecular 
scaffolds to combat these resistances are of utmost clinical importance. There continues to be a 
strong push to discover novel classes of natural products from new organisms, particularly from 
sparsely investigated habitats and regions. Additionally, the advances in instrumentation have 
resulted in high throughput screening systems that allow for testing of large batches of known 
natural products against various targets, creating the possibility for discovery of new biological 
activity from existing natural product libraries. 
As the cases of dolastatins and bryostatins have revealed, many natural products 
isolated from macro-organisms have biosynthetic origins in cohabitating organisms. This works 
to our advantage as the microbes producing the natural products may be cultured, giving access 
to a sustainable supply of natural product drug candidates. Newman and Cragg point out that 
“the interface between the microbial interactions with their hosts and commensals” has the 
greatest potential for the discovery of novel structures from natural sources.40 Another advantage 
of culturing microbes is targeted production of natural products by means of functional genomics 
and genetic engineering. Combinatorial biosynthesis,35, 41 in which biosynthetic genes from 
different gene clusters or organisms are mixed together to produce compounds with desired 
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pharmacophores or functionalities, is emerging as a viable route to new natural products, new 
analogues of existing ones,42 or toward increasing production of known high value compounds.  
Advances in DNA sequencing have the ability to shift the paradigm on isolation of 
natural products. Ready access to biosynthetic genome sequences now facilitates a bottom-up 
approach toward discovery of novel natural products.43 The traditional top-down approach, in 
which organisms are collected or cultured and natural products are isolated based on desired 
biological activity or spectroscopic profiles and then characterized, is very suitable for 
compounds that are produced in abundance and survive the traditional extraction and isolation 
methods. Genome sequence driven bottom-up approach allows one to predict the structures of 
natural products and selectively focus on the novel ones. Several studies show that there are far 
more biosynthetic gene clusters in organisms than those accounted for the production of 
secondary metabolites,44 suggesting a vast potential for new discoveries.  
The genomic approach to discovery of natural products, coupled with sensitive 
spectroscopic techniques, is amenable toward detection of novel chemical scaffolds; however, 
for applications in medicine, sufficient quantities still need to be isolated. We can only fully take 
advantage of the prospects of the genomic approach when advances in isolation, spectroscopy 
and dereplication allow for routine analysis of compounds produced in miniscule amounts. That 
ability has already been demonstrated in the case of the phorbasides, aided by cryo-microprobe 
NMR spectroscopy.45 The global natural product social (GNPS) molecular networking project46 
is a collaborative project aimed at quick dereplication of natural products and discovery of novel 
scaffolds based on MS/MS libraries. Natural product chemistry has the ability to bounce back in 
a major way when advances of this nature come to fruition.  
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1.5 Research Objectives 
Multitudes of medical challenges exist today.  Despite significant advances in 
biomedical research over the last several decades, there remain pressing issues that need to be 
tackled. Many diseases still have no cure and microbial drug resistance in humans is increasing.    
Alzheimer’s stands alone as the only disease among the ten leading causes of deaths 
in the United States that cannot be cured, slowed down or prevented.47  An estimated $236 
billion was spent on dementia care in the United States in 2016, incurring a huge socioeconomic 
burden. In 2015, nearly 47 million cases of dementia were estimated worldwide and this number 
is projected to double every twenty years.47 The lack of a single drug to slow down, prevent or 
cure this disease presents a pressing need toward discovery of anti-Alzheimer’s drug leads. 
While the root cause of Alzheimer’s is not fully understood, there are a few strategic approaches 
toward discovery of anti-Alzheimer’s drugs. One of the approaches relies on finding inhibitors of 
the β-site of amyloid precursor protein cleaving enzyme (BACE1), implicated in the formation of 
signature neurotoxic amyloid plaques in the neural cells of Alzheimer’s patients, as described in 
the amyloid cascade hypothesis.48 While there are small molecule BACE1 inhibitors in clinical 
trials for efficacy against Alzheimer’s, there is a concern that these may cause various 
mechanism-based side effects.49 Hence, discovery of viable inhibitors of BACE1 is very much 
needed. A major objective of this research was to identify extracts from cyanobacteria, marine 
algae, sponges and other invertebrates that showed BACE1 inhibitory activity and to carry out 
bioactivity-guided isolation and structure elucidation of active components. Efforts toward 
discovery of BACE1 inhibitors are discussed in both chapters 2 and 3. 
In collaboration with researchers at the University of Hawai’i Cancer Center, many of 
the extracts were screened against other relevant targets. These include cytotoxicity assays 
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involving cancer cell lines, such as glioma and breast cancer, that show elevated levels of the 
activated signal transducer and activator of transcription 3 (STAT3) protein.50 Tumor cells secrete 
vascular permeability factors, such as vascular endothelial growth factor A (VEGF-A), 
increasing permeability in the cells and releasing toxins in the blood stream.51 This deadly 
condition is known as sepsis and accounts for nearly a tenth of all cancer related deaths.52 Our 
objectives from these collaborations were to find inhibitors of STAT3 activation and vascular 
permeability for potential therapeutic uses. These are described in chapters 2 and 5, respectively. 
  Areca catechu L. (Arecaceae), commonly known as betel nut, is the fourth most 
used psychoactive substance in the world. Betel nut chewing has been implicated in various oral 
cancers, such as oral squamous cell carcinoma.53 It is not clear what components of Areca 
catechu are responsible for oral cancer incidences nor is anything known about the mechanism of 
action. A recent study suggested that incubation of polymorphonuclear leukocytes with areca nut 
extracts resulted in Ca2+ mobilization and release of pro-inflammatory agents such as leukotriene 
B4.54 However, it was not clear where the Ca2+ was mobilized from or which leukocytes were 
responsive to the areca nut extracts. In collaboration with Dr. Reinhold Penner’s team at the 
Queen’s Medical Center in Honolulu, we sought to identify components of Areca catechu that 
were responsible for the Ca2+ mobilization in immune cells and to understand the mechanism 
behind the mobilization. Details on this investigation are provided in chapter 4. 
    In addition to these major objectives, this dissertation describes various aspects of 
structure elucidation of natural products. Computational studies, in which 1H and 13C NMR shifts 
were calculated based on density functional theory, have played an integral role in determining 
planar structures and stereochemical configurations of some of the molecules discussed herein. 
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1.6 Work Flow and Biological Evaluation 
  Extraction and fractionation. Samples are either collected in the field (marine 
species by snorkeling or SCUBA-diving) or cultured in the laboratory. A voucher specimen for 
each unique field-collected sample is preserved in alcoholic solution for taxonomic 
identification. Field collected samples, or culture harvests, are typically freeze-dried prior to 
extraction. The general extraction and fractionation scheme of biological material is outlined in 
Figure 8. Compounds from the broth of cell cultures (cyanobacteria) are extracted separately, 
using HP-20 resin, which is then filtered, re-suspended in organic solvent (methanol), filtered 
again before removal of solvent to afford a crude media extract. Initial fractionation on a small 
scale is carried out for preliminary biological evaluation against various targets. Samples 
considered hits in various assays are then subjected to a large scale extraction and purification 
process, followed by re-evaluation of biological activity and elucidation of structure of purified 
secondary metabolites with the aid of modern spectroscopic tools. On some occasions, samples 
lacking activity against the specific biological targets are also advanced to further processing 
based on a few criteria. These criteria include detection of chlorinated or brominated species by 
mass spectrometry as these halogens are likely to be found in secondary metabolites and not 
primary metabolites. Likewise, if an initial dereplication of a sample leads to no obvious hits 
based on the mass of the molecular ion of the compound and features present in its 1H NMR 
spectrum, it may indicate the discovery of an as yet unreported secondary metabolite and that 
sample is also given priority for further processing. 
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Figure 8. Bioactivity-guided extraction and fractionation workflow 
 
Dereplication and structure elucidation. SciFinder55 is the most comprehensive 
database of chemistry journals, patents and other scientific literature with a massive repository of 
chemical substances and their reactions. More specialized but less comprehensive natural 
product libraries include the MarinLit56, AntiBase57 and AntiMarin58 databases. All of these 
databases offer dereplication tools using experimental and predicted data. Mass spectrometric 
and NMR spectroscopic data are most commonly utilized to search for prior occurrences of a 
natural product in the literature. Absence of a match in any of these databases would suggest that 
a natural product may be unreported, unless it was discovered recently and/or not yet indexed in 
the databases. 
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 When a metabolite appears to be novel, including a new analogue of an existing 
natural product, its structure is elucidated using the modern spectroscopic tools at our disposal. 
The full complement of spectral data – mass spectrometry, infrared spectroscopy, ultraviolet-
visible spectroscopy, one-dimensional and two-dimensional NMR spectroscopy, optical rotation 
and the like – are obtained in efforts to deduce structural information of the metabolite. 
Occasionally, synthetic and computational methods are necessary to confirm the proposed 
structure of a secondary metabolite. Finally, each purified metabolite is evaluated for a wide 
range of biological activities that may be available. 
Biological evaluation. The primary goals of our research, as stated previously, is to 
identify potential inhibitors of BACE1, STAT3 and vascular permeability from the extracts of 
marine invertebrates, algae, cyanobacteria as well as cyanobacteria cultured in the laboratory. A 
brief description of these targets and the assays involving these targets follows. Additionally, we 
continue to pursue the identity of Ca-mobilizing components of Areca catechu and details on the 
fluorimetric Ca-signaling assay are provided in Chapter 4. 
BACE1 as a therapeutic target in Alzheimer’s disease. Alois Alzheimer described 
the presence of neurofibrillary tangles and senile plaques as signature pathological features of 
presenile dementia.59 Detailed studies on the senile plaques led to the widely used Amyloid 
Cascade Hypothesis (ACH), which was first proposed by Hardy and Higgins in 1992.48a The 
ACH proposes the beta-amyloid protein (Aβ), the main component of the senile plaques, as the 
chief causative agent in the pathogenesis of Alzheimer's disease. The neurofibrillary tangles, cell 
degeneration and dementia have been claimed to be consequences of the deposition of Aβ. This 
hypothesis implies that the buildup of Aβ is a result of the initial cleavage of the amyloid 
precursor protein (APP) by the protease β-secretase (BACE1) (Figure 9).60 
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Figure 9. Formation of Aβ40 and Aβ42, according to the Amyloid Cascade Hypothesis 
Image reproduced from Ref. 60. 
 
Neurofibrillary tangles, the other physiological markers of Alzheimer's disease, are 
mainly composed of hyperphosphorylated tau protein.61 These tau filaments are also present in 
other cognitive disorders, such as Pick's disease and Parkinson-dementia complex, in which the 
plaques are absent.60 Hence, the ACH remains controversial because no definitive link has been 
established between Aβ and hyperphosphorylated tau-protein. Nevertheless, significant research 
on Alzheimer drug discovery is geared toward prevention of the deposition of Aβ through 
inhibition of BACE1. BACE1 inhibitors, in theory, should slow down Alzheimer's disease, an 
action that falls outside the capabilities of the current treatment methods. The existing United 
States Food and Drug Administration (FDA) approved Alzheimer drugs, which are mostly 
acetylcholinesterase inhibitors, slow down symptoms of the disease and provide short-term relief 
to the patients but do not stop or slow down the disease itself (Figure 10).62  
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Figure 10. Current FDA approved medications for Alzheimer’s disease 
Key: 1.28 rivastigmine (Exelon), 1.29 donepezil (Aricept) and 1.30 galantamine (Razadyne) are acetylcholinesterase 
inhibitors; 1.31 memantine (Namenda) is an N-methyl-D-aspartate receptor antagonist 
 
BACE1 assay. The preliminary screen for BACE1 inhibitors relies on an enzyme 
fragment complementation (EFC) assay (Figure 11).63 A cyclic peptide containing an enzyme 
donor (ED) fragment is cleaved by BACE1 before the ED fragment can complement with an 
enzyme acceptor (EA) fragment to form an active β-galactosidase enzyme. The β-galactosidase 
enzyme cleaves off galactose from the Galacton-Star substrate 1.32, triggering 
chemiluminescence, which is measured using a plate reader. Compounds that inhibit BACE1 
cannot trigger this series of events, resulting in the absence of chemiluminescence. The 
calculated percent activity is proportional to the concentration of the protease and lower percent 
activity equates to stronger inhibition of BACE1. Samples that appear to contain potent 
inhibitors of BACE1 are then evaluated under a secondary screen. A secondary assay is essential 
as the enzyme fragment complementation assay could lead to false positives if the components in 
the extract inhibit complementation of the enzyme donor and enzyme acceptor fragments or the 
active β-galactosidase itself. 
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Figure 11. The primary BACE1 enzyme fragment complementation assay 
 
A homogeneous affinity assay constitutes the secondary screen of this two-step 
protocol (Figure 12).64 Prioritized samples are incubated overnight with BACE1 and the 
inhibitor-protease complex is then separated from the crude mixture using a micro spin column. 
The inhibitor is directly analyzed by liquid chromatography-mass spectrometry (LC-MS) 
following dissociation from the protease. This method provides the retention time and the 
molecular weight of a potential inhibitor, which is information that can simplify the process of 
isolation of the inhibitor from a complex mixture. 
 
Figure 12. The secondary homogeneous BACE1 affinity assay 
 
 
BACE1 cleavage site 
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STAT3 as a therapeutic target in cancer cell lines. The signal transducer and 
activator of transcription (STAT) family of proteins are latent in the cytoplasm until activated, via 
phosphorylation, by extracellular-signaling proteins such as cytokines and growth factors (Figure 
13).65 The cytokines and growth factors can activate tyrosine kinases in the cell, which in turn 
can phosphorylate STAT proteins.  Activated STAT proteins can dimerize, disengage from 
receptor proteins and accumulate in the nucleus to regulate transcription.65 STAT3, specifically, 
regulates the expression of genes related to cell cycle, cell survival, and immune response 
associated with cancer progression and malignancy in a number of cancer types.66 Elevated 
levels of activated STAT3 are among the common features of a variety of cancers, including 
leukemia, glioma, breast cancer, lung cancer, melanoma and pancreatic adenocarcinoma.67 Poor 
prognosis for many of these cancers has been attributed to elevated levels of activated STAT3.68 
Therefore, inhibition of the STAT3 signaling pathway is a promising strategy for the 
development of anticancer therapeutics. 
 
 
Figure 13. STAT3 signaling pathways in cells 
Figure reproduced from Ref. 67 
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A large number of STAT3 inhibitors, several of which are small synthetic molecules 
or natural products derived from herbal sources, are in clinical trials for effects on patients with 
cancer.69 These inhibitors act at various sites of action in the STAT3 signaling pathway. However, 
most of them suffer from toxicities and lack of efficacy, potency or specificity to STAT3. While 
STAT3 remains an attractive target in cancer therapy, there is a need for development of novel 
inhibitors of STAT3 that can overcome the deficiencies observed with current therapeutic 
candidates. Marine natural products have not been investigated thoroughly for their ability to 
inhibit activation of STAT3, hence the collaboration with Prof. James Turkson at the University 
of Hawai‘i Cancer Center is aimed at discovering new classes of STAT3 inhibitors from marine 
organisms. As part of the collaboration, various marine natural product extracts and fractions are 
first screened for cytotoxicity against cancer cell lines with elevated levels of activated STAT3, 
such as human glioblastoma (U251MG), human breast adenocarcinoma (MDA-MB-231) and 
human pancreatic adenocarcinoma (Panc-1). Recently, the Panc-1 assay has also been set up to 
be performed in-house. Compounds with promising activity are then advanced for further 
biological evaluation.  
Pursuit of inhibitors of vascular permeability from marine organisms. 
Hyperpermeability of the endothelial membrane and resulting microvascular failure are a 
hallmark of sepsis and linked to multiple organ failures and increased mortality in humans.70 
Currently, there are no clinical drugs for the treatment of sepsis. The mechanisms of vascular 
hyperpermeability are not fully understood but the interaction between the GTPase R-Ras and 
Filamin A has been found to be critical in maintaining endothelial barrier.71 Deficiency of R-Ras 
or Filamin A has been found to increase leakage in the endothelial barrier. R-Ras, unlike other 
Ras proteins known to cause malignant transformations, promotes endothelial cell survival.72 
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Agonists of R-Ras are therefore suitable therapeutic targets against vascular leakage. In 
collaboration with Prof. Michelle Matter at the University of Hawai‘i Cancer Center, we pursued 
the discovery of novel vascular permeability inhibitors from marine organisms. 
The scheme of the vascular permeability assay is shown in Figure 14. Endothelial 
cells are seeded on a semipermeable membrane pre-coated with collagen to form a monolayer in 
the permeability insert (Figure 14A), which is then treated with an extract from marine 
organisms as well as tumor necrosis factor alpha (TNFα), a cytokine that enhances permeability 
of the monolayer (Figure 14B). After replacement of the media, fluorescence indicator FITC-
Dextran is added and allowed to pass through the permeable monolayer (Figure 14C-D). The 
permeability insert is then removed and fluorescence in the receiver plate well is measured to 
evaluate the degree of permeability. Extracts or samples that block vascular permeability lead to 
reduced fluorescence readings in the assay. 
 
 
Figure 14. Schematic representation of the vascular permeability assay 
 
 
  
A 
D 
B 
C 
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CHAPTER 2 
Biologically Active Secondary Metabolites from Dactylospongia elegans 
2.1 Sponges as Rich Sources of Secondary Metabolites 
Bergmann’s original discovery of spongonucleosides from a sponge (vide supra) 
initiated a wide-spread investigation of the marine habitat for biologically active secondary 
metabolites. There are over 10,000 species of sponges (porifera)73 and they are among the most 
interesting sources of bioactive natural products because these primitive filter-feeding marine 
organisms have survived and thrived for over hundreds of millions of years74 despite lacking 
physical defense features (shells, spines, etc.) or an immune system. Organisms without an 
immune system or physical defense features are known to be prolific producers of secondary 
metabolites, presumably as their chemical defense against predation and competition for 
resources.75 In support of the chemical defense argument, sponges that grow exposed have been 
observed to be more toxic than those that grow unexposed.75b 
  In a five-decade timeframe between 1963 and 2013, almost 25,000 new compounds 
were discovered from the marine environment, with sponges producing a third of them.76 
Furthermore, the majority of the novel natural product chemotypes reported from sponges 
occupy a unique space and have no close analogs in terrestrial plant and microbial natural 
products or in natural products isolated from other marine organisms.77 The prolificacy and 
diversity of sponge natural products is complemented by their activity in a wide array of 
biological targets. Therefore, sponges continue to attract significant interest in natural product 
chemistry. Currently, there are three sponge natural product-inspired drugs in clinical use and 
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many others are in clinical trials or that have potent biological activities.78 In addition to the 
aforementioned vidarabine 1.18 and cytarabine 1.19, eribulin mesylate 2.1 is a clinically 
approved drug for the treatment of metastatic breast cancer. Eribulin mesylate is a synthetic 
analogue of halichondrin B 2.2, a polyether macrolide isolated from the sponge Halichondria 
okadai Kadota (Halichondriidae) (Figure 15).79 
 
Figure 15. Eribulin mesylate is a synthetic analogue of halichondrin B, a sponge metabolite 
 
2.2 Collection Details and Identification of Dactylospongia elegans 
A sponge specimen (ID: 10-Kauai-08) was collected by SCUBA diving from a depth 
of 55 feet below sea level at the Sheraton Caverns dive site off the coast of Kaua‘i (coordinates: 
21 51.920 N and 159 27.097 W) on June 09, 2010. In a subsequent recollection trip, another 
sponge specimen (ID: 11-Kauai-80) believed to be an identical organism was collected from the 
same location at a depth of 55 feet below sea level on May 29, 2011. LC-MS analysis showed 
identical metabolic profiles for the extracts of both samples. A voucher sample of 10-Kauai-08 
was preserved in alcoholic solution for future taxonomic identification.  In 2016, Mary Kay 
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Harper (University of Utah) identified the 10-Kauai-08 specimen as Dactylospongia elegans 
Thiele (Thorectidae). We inferred that 11-Kauai-80, based on similarities in collection site, 
appearance and LC-MS profiles of the two specimens, belonged to the same species. 
Both sponges (Figure 16) were collected as encrusting yellow sponges, which were 
heavily fouled with various growths, exuded red solution, and turned brown on standing.  
 
Figure 16. Photos of sponge samples collected from Kaua‘i 
 
2.3 Isolation of Secondary Metabolites from Dactylospongia elegans 
In our quest to discover new inhibitors of BACE1 from marine organisms, an extract 
of Dactylospongia elegans displayed activity against the enzyme in the in vitro assay described 
in section 1.6. Bioactivity-guided purification of the extract led to the isolation of ilimaquinone80 
2.3, a sesquiterpene quinone containing a 4,9-friedo-rearranged drimane skeleton. Other 
sesquiterpene quinones and hydroquinones isolated from the extract included 5-epi-
ilimaquinone81 2.4, smenospongine82 2.5, smenospongorine82 2.6, smenospongiarine82 2.7, 
smenospongidine82-83 2.8, dictyoceratin A82, 84 2.9, dictyoceratin B84 2.10 and dictyoceratin C85 
10-Kauai-08 11-Kauai-80 
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2.11 (Figure 17). The structures of these compounds were confirmed, except in one instance, by 
comparison of experimental spectroscopic data with the values reported in the literature. We 
discovered and confirmed by simple synthesis that the 1H and 13C NMR literature data for 
smenospongidine 2.8 contained obvious errors or omissions, which are discussed in depth in 
section 2.6. 
 
Figure 17. Natural products isolated from Dactylospongia elegans 
 
In addition to these compounds, which have previously been isolated from sponges of 
the genus Dactylospongia, a new chlorinated compound 2.12 with a rare 11-membered 
heterocyclic framework was also isolated. The description of structure elucidation of this 
compound is presented in sections 2.4 and 2.5. 
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2.4 Planar Structure of Kauamide 
The chlorinated compound 2.12 was present in an inactive fraction but we 
nonetheless pursued the isolation and purification of this metabolite, which we have named 
kauamide. Herein, we describe the elucidation of the structure of kauamide based on 
spectroscopic, chemical and computational methods. We also demonstrate the utility of 
computational tools in addressing questions of stereochemical configuration when the 
availability of sample may be too low to employ conventional methods. 
High resolution mass spectrometry of kauamide suggested the molecular formula of 
C19H32ClNO3, with four degrees of unsaturation. Two carbonyl units - an amide and an ester – 
were inferred from the 13C NMR shifts at 177.4 ppm and 171.1 ppm as well as the infrared 
signals at 1734 cm-1 and 1653 cm-1. The appearance of two additional sp2 type signals in the 13C 
NMR spectrum at 138.9 ppm and 116.7 ppm indicated the presence of an olefin and implied that 
a ring fulfilled the degrees of unsaturation in the molecule.  
From the 1H, 13C and HSQC NMR data of kauamide (Table 1), five methyl groups, 
including one bonded to a nitrogen atom (δC 30.3, δH 2.84), six methylene units and four methine 
fragments were identified. Furthermore, the tri-substituted nature of the olefin was confirmed, as 
only one sp2 carbon was connected to a single hydrogen atom. The majority of the planar 
structure was put together based on the COSY and HMBC data (Figure 18), paving way for the 
placement of the chlorine atom on the terminal carbon of the exocyclic olefin. The E-olefin 
geometry was determined from the presence of nOe correlations between H-15 and H-10 and the 
absence of such correlations between H-15 and H-8.      
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Table 1. NMR Spectroscopic Data of Kauamide (2.12) in CDCl3 (500 MHz) 
Position δC, type δH (J in Hz) COSY HMBC
a
 
2 171.1, C    
3 55.7, CH 5.49, dd (11.5, 4.9) 15 2, 5, 16, 18 
5 177.4, C    
6 36.0, CH 3.11, m   
7 26.5, CH2 1.68, m   
  2.07, m 6, 8 5 
8 26.1, CH2 2.50, m   
  1.86, t (12.0)  9, 10 
9 138.9, C    
10 40.2, CH2 2.36, dd (14.5, 4.2) 11 9, 20 
  2.28, dd (14.6, 2.8)   
11 73.5, CH 4.98, m  2, 10, 13 
12 34.6, CH2 1.52, m (15.6, 13.5, 6.9) 11, 13  
  1.43, m   
13 19.0, CH2 1.26, m   
14 13.8, CH3 0.92, t (7.3) 13 12 
15 116.7, CH 5.83, s  8, 10 
16 14.3, CH3 1.14, d (6.7) 6 5 
17 30.3, CH3 2.84, s  3, 5 
18 35.7, CH2 1.79, m (14.8, 10.1, 4.9)   
  1.68, m  2 
19 24.7, CH 1.58, m 18, 20, 20’  
20/20’ 23.3, CH3 0.97, d (6.7)  18 
20’/20 21.1, CH3 0.95, d (6.7)  18 
 
a HMBC correlations, optimized for 7 Hz, are from proton(s) stated to the indicated carbon. 
 
 
Figure 18. Depiction of COSY (bold lines), HMBC (red solid arrows) and NOE (black dashed 
arrows) correlations in kauamide (2.12) 
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2.5 Stereochemical Assignment of Kauamide 
With three stereogenic centers of kauamide separated from each other by quaternary 
carbons and heteroatoms in a non-rigid ring structure, we were unsuccessful in determining the 
relative stereochemical configuration in the molecule using empirical NMR methods. The 
absolute configuration of each stereogenic center could be assigned individually using 
irreversible (for practical purposes) chemical modifications of the compound – advanced 
Marfey’s method86 (C-3), Mosher’s method87 (C-11) and Kusumi’s method88 (C-6) – but the 
latter two require a considerable amount of sample for unambiguous determination with the aid 
of standard NMR equipment. We had isolated only 2 mg of kauamide which was going to be 
insufficient to carry out these chemical modifications. Therefore, we turned to a protocol that 
relies on density functional theory-based computations of 1H and 13C NMR chemical shifts and 
the use of statistical tools to assign the experimental data to the correct isomer of a compound.89 
Similar approaches, sometimes in conjunction with synthesis, have been successfully employed 
toward assignment of stereochemical configurations of complex natural products, such as 
cernupalhine A90 2.13, leiodermatolide91 2.14 and gambierone92 2.15, and revision of incorrectly 
assigned structures of nobilisitine A93 2.16 mandelalide A94 2.17, and hexacyclinol95 2.18 to 
name a few (Figure 19). Recently, Grimblat and Sarotti have reviewed the role of GIAO NMR 
calculations on the structural assignment of complex molecules.96  
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Figure 19. Examples of natural product structures that were established or revised based on DFT 
predictions of NMR chemical shifts 
 
On our hands, the floppy nature of the two alkyl groups at C-3 and C-11 would amass 
a high computational cost because each diastereomer of kauamide resulted in more than two 
hundred and fifty conformers within 5 kcal/mol of the lowest energy conformer. To simplify the 
computational operations, we truncated the alkyl groups at those positions to methyl groups, as 
shown in the structure of 2.19 (Figure 20), which resulted in an approximately ten-fold reduction 
in the number of conformers.   
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An unambiguous match between the experimentally obtained 1H and 13C shifts of 
kauamide and the predicted values of the (3S,6S,11S)-diastereomer of 2.19 (Table 2) was 
established from various statistical comparisons between empirical and computed data. The 
chemical shifts of this diastereomer had the best fit to the 1H and 13C data of kauamide by any 
statistical measure, including mean absolute error (MAE), DP497 and DP4+98 probabilities 
(Figure 20). From these studies, we propose that kauamide bears the (3S,6S,11S) relative 
configuration. The absolute configuration, (3S,6S,11S) and as drawn on 2.12, was established 
after hydrolysis of kauamide and subsequent confirmation of the L-configuration of leucine 
residue by advanced Marfey’s analysis.  
 
Table 2. 1H and 13C NMR shifts of kauamide 2.12 (experimental) and all four diastereomers of 
2.19 (predicted by DFT computations) 
Key: SRR = (3S,6R,11R)-2.19; SSR = (3S,6S,11R)-2.19; SRS = (3S,6R,11S)-2.19; SSS = (3S,6S,11S)-2.19 
  Computed  Computed Computed 
H Experimental SRR SSR SRS SSS C Experimental SRR SSR SRS SSS 
15 5.83 5.73 6.04 5.94 5.86 9 138.9 145.1 142.0 145.2 144.1 
11 4.98 5.13 5.31 4.60 4.82 8 26.1 26.7 28.7 29.3 26.9 
10a 2.36 1.98 2.10 2.19 2.43 7 26.5 32.1 31.6 29.8 26.2 
10b 2.28 2.79 2.59 2.39 2.18 6 36.0 38.1 37.0 37.5 37.1 
8a 1.86 2.12 1.82 1.81 1.98 5 177.4 174.8 174.8 173.1 174.3 
8b 2.50 2.68 2.77 2.73 2.52 3 55.7 60.1 57.0 56.6 52.9 
7a 2.07 1.74 1.88 1.91 2.12 2 171.1 170.4 170.7 172.0 171.4 
7b 1.68 1.54 1.50 1.54 1.67 11 73.5 68.0 69.4 74.4 69.9 
6 3.11 2.78 2.15 2.72 3.07 10 40.2 39.1 39.3 42.4 42.2 
3 5.49 3.42 4.20 4.38 5.36 15 116.7 116.5 121.2 119.5 119.3 
16 1.14 1.01 1.14 1.13 1.09 16 14.3 15.4 15.7 15.6 12.7 
17 2.84 3.05 3.15 2.80 2.74 17 30.3 34.6 30.8 27.4 28.8 
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Figure 20. Relative configuration of kauamide 2.12 was established by statistical analyses of the 
computed and experimental 1H and 13C NMR shifts of all possible diastereomers of 2.19 
 
Kauamide, which is a mixed polyketide-peptide natural product, has a structural 
framework, including the vinyl chloride motif, which suggests that it may have been produced by 
a marine cyanobacterium. The 11-membered ring, however, is very rare in this class of molecules 
and natural products in general. The closest structural similarities are observed in jamaicamides 
A-C99 2.20-2.22, which were isolated from Moorea producens Engene (Oscillatoriaceae),100 a 
cyanobacterium formerly identified as Lyngbya majuscula and in kanamienamide101 2.23, which 
was isolated from the cyanobacterium Moorea bouillonii Engene (Oscillatoriaceae) (Figure 21). 
These precedents strongly suggest that kauamide was produced by cyanobacteria cohabitating in 
the heavily fouled specimen of Dactylospongia elegans. The polyketide fragment in kauamide 
has the same carbon framework and identical olefin geometry as in the C1-C10 segment of 
jamaicamides A-C, whereas the 11-membered ring including the leucine residue is present in 
kanamienamide. Kanamienamide, however, lacks the vinyl chloride motif and has opposite 
configuration at C6, the carbon alpha to the amide carbonyl in the ring. The 1H and 13C NMR 
data for kanamienamide were acquired in benzene-d6, precluding a direct comparison with 
Isomer DP4 probability DP4+ probability 
(3S,6R,11R)-2.19 0.00 0.00 
(3S,6S,11R)-2.19 0.00 0.00 
(3S,6R,11S)-2.19 0.00 0.00 
(3S,6S,11S)-2.19 1.00 1.00 
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kauamide of the chemical shifts for protons and carbons in the 11-membered ring. Nevertheless, 
there is a reasonable match between the predicted 1H NMR chemical shifts of (3S,6R,11S)-
diastereomer of 2.19 and the experimental values reported for kanamienamide 2.23, which bears 
the same configuration at the specified stereogenic centers. This provides further support to the 
assignment of relative configuration of kauamide through prediction of NMR chemical shifts. 
 
Figure 21. Cyanobacterial metabolites with partial structural similarity with kauamide 2.12  
 
2.6 Detailed Analysis of 1H and 13C NMR Data of Smenospongidine 
Smenospongidine 2.8, which is a biologically active quinone sesquiterpenoid, was 
first isolated from the sponge Smenospongia sp. by Kondracki and Guyot in 1989.82 The authors 
proposed the structure of 2.8 based on analysis of HRMS, 1H NMR and 13CNMR data, but 
omitted carbon chemical shift data from the manuscript. In 1992, Rodríguez et al. published the 
first tabulated 13C NMR data of 2.8.83 In the intervening years, 2.8 has been isolated from various 
sponge sources102 with each reporting close agreement to the published data. In 2002, 
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Theodorakis and coworkers reported an enantioselective total synthesis of 2.8, which, in addition 
to the usual statement about good agreement with published data, was accompanied by 
supplementary information with 1H and 13C NMR spectra of the synthesized molecule.103 
Recently, we also isolated 2.8 from Dactylospongia elegans and found significant discrepancies 
between our spectral data, and previous reports. Herein, we summarize the discrepancies and 
report corrected data for 2.8. This case story demonstrates the value of depositing raw NMR data 
by showing how errors (omission, assignment, typographical, etc.) propagate through the 
literature when we are forced to rely on reproduced, tabulated, or listed data. This story also 
highlights the difficulties in locating original NMR data decades after publication of the original 
work. While 2.8 is a specific example, the problems are nonetheless widespread and persistent in 
the literature. 
 
Figure 22. Structure of smenospongidine 2.8, annotated with atom numbers. 
 
The spectral data of smenospongidine obtained from this study are tabulated (Table 3) against 
those reported by Rodríguez et al.  Rodríguez et al. did not report signals for the quaternary 
carbons C-10, C-16 and C-18 in 2.8 (Figure 22). Aside from that, the only major difference (> 2 
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ppm) between the two 13C NMR data sets occurs at C-20 (150.0 vs. 154.7 ppm), with our value 
of 150.0 being more consistent with their data for the C-5 epimer of 2.8. The partial 1H NMR 
data reported in that manuscript has two main inconsistencies. First, a singlet reported at 5.41 
ppm assigned as the hydroxyl proton may instead be the vinyl proton H-16 in the quinone ring. 
Second, a doublet at 0.77 ppm assigned to methyl protons (H-13) is more appropriate for H-10, 
an axial methine proton at the trans-decalin junction in quinone-containing analogues of 2.8 with 
identical stereochemical configuration.82 With access to the original spectra, these issues of 
unreported or possibly misassigned signals are easy to resolve. For example, the last issue (H-10 
vs H-13) could possibly be distinguished by the integrals, multiplicity (d vs dd) or the magnitude 
of observed coupling as the axial methine H-10 should display a larger J value (> 10 Hz), due to 
coupling with the neighboring axial proton (H-1), than the typical 7 Hz observed from methyl 
doublets. It should be noted that it is highly unlikely that even modern day spectra submitted as 
SI would possess adequate resolution or sufficient peak-picked expansions to resolve the matter. 
To resolve these issues and clarify the identity of our sample of 2.8 with only proton 
and carbon data, we turned to the reported synthesis. As is typical, no specific proton or carbon 
assignments are reported in the manuscript describing the synthesis of 2.8 for the listed chemical 
shifts, so we have assigned them to the best of our ability for this comparison (Table 3) with the 
major differences highlighted in gray.  Unfortunately, this data raised more questions. The listed 
1H NMR data on S19 does not include the signal for H-10, the proton at the A/B ring juncture 
possibly misassigned by Rodríguez et al., but does include a signal at  0.97 (3H, d, J = 6.0 Hz) 
that we have assigned to H-13, a signal missing altogether from Rodríguez et al.  Despite the 
inclusion of 1H NMR spectra in the SI, the presence of these signals could not be conclusively 
confirmed because of the unavailability of an appropriate expansion of the spectrum. Other   
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Table 3. Comparison of 1H and 13C NMR Data of Smenospongidine 2.8 in CDCl3. 
 Data from this study Data from Rodríguez et al. Data from Ling et al. 
No. δC  δH  (500 MHz) δC  δH  (250 MHz) δC
‡
  δH
‡
(400 MHz)
 
 
1 23.2 2.08, m 
1.43, m 
23.4  24.5  
2 27.9 1.38, m 27.8  29.3  
3 33.0 2.32, m 
2.06, m 
33.7  33.7  
4 160.5  161.9  167.7  
5 40.4  41.3  39.1  
6 36.6 1.51, m 
1.35, m 
37.8  35.6  
7 28.6 1.83, m 
1.11, m 
30.4  29.9  
8 37.8 1.18, m 38.3  37.9  
9 42.9  43.3  44.2  
10 49.8 0.77, dd (11.9, 2.0)   51.1  
11 102.5 4.44, brs 
4.45, brs 
102.6 4.45, brs 103.7 4.44, d (5.2) 
12 20.5 1.06, s 21.0 1.05, s 21.9 1.04, s 
13 17.9 0.97, d (6.5) 18.7 0.77, d 19.3 0.95, d (6.8) 
14 17.3 0.84, s 17.7 0.82, s 18.7 0.82, s 
15 32.4 2.39, d (14.0) 
2.49, d (14.0) 
34.0 2.48, m 32.1 2.38, d (14.0) 
2.51, d (14.0) 
16 113.6      
17 157.0  155.3  161.5  
OH  8.35, brs  5.41, s   
18 178.3    180.2  
19 91.8 5.40, s 91.7  93.0 5.39, s 
20 150.0  154.7    
NH  6.47, brs  6.53, brs  6.47, s 
21 182.7  184.3  182.8  
1’ 44.0 3.42, q (6.8) 44.6  45.3 3.42, m 
2’ 34.3 2.95, t (7.0) 34.0 2.95, m 34.3 2.94, m 
3’ 137.4  139.1    
4’ 128.6 7.18, d (7.0) 129.5 
7.27, m 
(H-4’ – H-6’) 
129.7 
7.10-7.40, m 
(H-4’ – H-6’) 
5’ 128.9 7.33, t (7.3) 129.5 130.0 
6’ 127.0 7.26, m 127.5 128.2 
‡
 Assignments were made by matching the proton and carbon nuclei with the closest reported chemical shift values. 
No chemical shift values could be assigned to C-16, C-20 and C-3’; signals at 69.0, 65.9 and 31.0 ppm were extra. 
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issues apparent from the listed 1H NMR values are the mischaracterization of resonances that we 
have assigned to the terminal exocyclic alkene H-11 (reported as  4.44 (2H, d, J = 5.2 Hz)) and 
H-2 (reported as  2.94 (2H, m)). The latter resonance should be a triplet as the protons 
responsible for the signal are adjacent to only two equivalent protons, while the characterization 
of the  4.44 (2H, d, J = 5.2 Hz) resonance is clearly erroneous – as a J value of 1.2 Hz, typical 
of the coupling between two non-equivalent protons of the exocyclic terminal alkene, can be 
calculated from peak picking in the SI.   
The 13C NMR spectrum provided in the supplementary information and the chemical 
shift values extracted from the spectrum raise further questions on the interpretation of the NMR 
spectral data. Twenty-seven unique 13C NMR resonances are expected for 2.8. The SI of Ling et 
al. lists 25 signals for 2.8, omitting two carbonyl signals. Of these 25 signals, only 7 out of the 12 
required sp2 carbon signals are reported and the list includes signals at  69.0 and 65.9 clearly 
inconsistent with the proposed structure, as it lacks oxygenated sp3 carbons. The 13C NMR 
spectrum with the poor signal-noise included in their SI sheds some light on the situation, but 
also raises questions as it includes the two carbonyl signals omitted from their list. The two 
carbonyl signals are labeled at 182.8 and 180.2 ppm but both appear between the chemical shifts 
of 181 and 182 ppm in the 13C NMR spectrum perhaps due to peak picking errors.  
There is little question smenospongidine was isolated or synthesized, as published in 
these articles. We have in fact synthesized smenospongidine from ilimaquinone using the method 
described by Ling et al., and independently confirmed the structure (Scheme 1).  Throughout the 
process the corresponding authors of those reports graciously offered assistance and searched for 
their original data at our request, but decades later were unsurprisingly unable to locate it. The 
difficulties of individual labs or departments maintaining NMR records over 40 years are 
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significant. Our laboratory (Prof. Philip Williams) receives frequent requests for copies of NMR 
data generated by the late Paul Scheuer and Richard Moore with a success rate of less than 50%. 
Most recently, we were unable to fulfill a request for data on the cyanobacterial compound 
micromide due to degradation of the CD backups. The fact remains that our community's 
reliance on tabulated or summarized data introduces the possibility of a litany of errors into the 
literature. Availability of raw NMR data would undoubtedly play a major role in curbing the 
propagation of these errors. 
 
Scheme 1. Synthesis of smenospongidine 2.8 from ilimaquinone 2.3 
 
 
2.7 Structure of Smenospongidinimine 
In replicating the one-step synthesis of smenospongidine from ilimaquinone and 
phenethylamine,103 we also discovered smenospongidinimine 2.24, a previously unreported side 
product. Smenospongidinimine, which was produced in a 3:5 ratio with smenospongidine 
because of the presence of excess phenethylamine, displays symmetry in the quinone ring of the 
molecule because of the equilibrium between two rapidly interconverting tautomers (Figure 23).  
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Figure 23. (a) The two tautomeric forms and (b) the resonance hybrid of smenospongidinimine 
  
2.8 Evaluation of Biological Activity 
Ilimaquinone 2.3 and smenospongine 2.5 displayed moderate inhibition of BACE1, 
whereas the other analogs showed weak or no activity (Table 4). Sesquiterpene quinones and 
hydroquinones are known to be cytotoxic to a variety of cancer cell lines, which was reaffirmed 
when we screened these compounds against human glioblastoma (U251MG) and human 
pancreatic carcinoma (Panc-1) cell lines. Compounds 2.3-2.11 all exhibited considerable 
cytotoxicity toward U251MG cells, with smenospongine 2.5 and dictyoceratin A 2.9 showing the 
most potent effects. Furthermore, compounds 2.3 and 2.6-2.9 were significantly cytotoxic toward 
Panc-1 cells as well. Kauamide showed no biological activity in any of the three assays but will 
be examined in antimicrobial and other assays.  
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Table 4. Biological activity of metabolites isolated from Dactylospongia elegans 
Compound IC50 (BACE1) CC50 (U251MG) CC50 (Panc-1) 
2.3 65 µM 19.3 µM 20.4 µM 
2.4  19.4 µM  
2.5 78 µM 2.4 µM  
2.6  19.4 µM 22.6 µM 
2.7  4.5 µM 15.1 µM 
2.8  4.0 µM 12.6 µM 
2.9  2.8 µM 21.7 µM 
2.10  8.4 µM  
2.11  4.1 µM  
2.24
b
  19.3 µM  
b Synthesized from ilimaquinone 2.3 
2.9 Conclusions 
Nine known cytotoxic sesquiterpene quinones and quinols and kauamide, a new 11-
membered heterocycle, were isolated from the extracts of Dactylospongia elegans. Ilimaquinone 
and smenospongine also exhibited moderate BACE1 inhibition. A detailed study of 1H and 13C 
NMR spectral data of smenospongidine revealed errors in the literature data. During the process, 
a previously unreported side-product smenospongidinimine was also isolated and characterized.  
 
 
 42 
 
4
2 
CHAPTER 3 
Isolation and Characterization of Secondary Metabolites from the Culture 
Broth of HCC1088, Nostoc sp. 
3.1 Significance of Cyanobacteria and their Metabolites 
Cyanobacteria are among the oldest and the most successful microorganisms on earth. 
They were the first organisms to utilize photosynthesis for energy, thereby releasing oxygen into 
the earth's atmosphere.104 Also known as blue-green algae, these Gram-negative bacteria have 
been found to inhabit a variety of environments, including marine and fresh water, hot springs, 
ice, soil, rocks, plants, and animals.105  Their long and successful history – spanning 
approximately three billion years – has attracted immense interest as scientists try to uncover the 
reasons why these organisms have been able to flourish in various environments across different 
geological and biological eras.106 
One of the factors that keep cyanobacteria successful is their ability to produce a 
variety of secondary metabolites that serve specific purposes.107 Toxins help them ward off 
grazers whereas UV-screening agents and antifreeze compounds protect them from severe 
environmental elements.108 In addition to serving these functions, many of the metabolites have 
shown powerful bioactivity. Consequently, several cyanobacterial secondary metabolites and 
their analogues have been developed as small molecule drug targets.109 
Cyanobacteria have been known to produce a variety of structurally diverse 
secondary metabolites, such as alkaloids, polyketides, peptides, terpenes and combinations 
thereof.105b The biosynthetic machinery of the blue-green algae allows for the incorporation of 
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the structural features of peptides and lipids, and additional functionalizations, such as unusual 
oxidations, methylations and halogenations.110 While natural products from terrestrial 
cyanobacteria have been reported as early as the 1930s, work on marine cyanobacteria began in 
the 1970s. The late professor Richard Moore of the University of Hawaii pioneered the research 
on natural products from marine cyanobacteria and continued his work until the 2000s.110a, 111  
The studies carried out by Moore and others to date have revealed that marine and 
terrestrial cyanobacteria produce a rich collection of metabolites with neurotoxic, anti-infective, 
anti-proliferative and anti-inflammatory properties.112 Many of these molecules, such as 
cryptophycin 1113 3.1, dolastatin 1025, 114 1.26 and curacin A115 3.2, have shown potent biological 
activity and are of interest for the development of pharmaceuticals (Figure 24). Dolastatin 10 and 
cryptophycin 52116 3.3 (a synthetic analog of cryptophycin 1), which are microtubule-binding 
agents, entered clinical trials for breast cancer and solid tumors, respectively, but have been 
abandoned due to ineffectiveness and adverse side effects.117 Analogues of dolastatin 10 have 
already been approved as drugs or are currently in clinical trials.117 The active component in 
brentuximab vedotin, which is an FDA approved monoclonal antibody-drug conjugate for the 
treatment of Hodgkin lymphoma,118 is monomethyl auristatin E 3.4, a synthetic analogue of 
dolastatin 10 (Figure 24). Romidepsin 3.5, which was originally isolated as FR901228 from the 
broth culture of Chromobacterium violaceum Bergonzini (Neisseriaceae),119 is a cyclic 
depsipeptide analogue that has been approved by the FDA for the treatment of cutaneous T-cell 
lymphoma.120 
 44 
 
4
4 
 
Figure 24. Cyanobacterial natural products and synthetic analogues of pharmaceutical interest 
 
The unique structural features coupled with powerful bioactivity make metabolites 
from marine and terrestrial cyanobacteria attractive targets in the development of drug leads 
against other diseases as well, including Alzheimer's. Moreover, many of these microbes are 
amenable to laboratory cultures using existing techniques,112a potentially allowing for large-scale 
production and harvesting. However, the application of cyanobacterial cultures for industrial-
scale synthesis of compounds and products of interest is technologically challenging and needs 
further development.121 As part of our studies to isolate novel bioactive molecules, we cultured 
several cyanobacterial strains and screened their extracts for activity against various targets. The 
culture broth of HCC1088 showed initial activity against BACE1; hence, we pursued the 
isolation of potential BACE1 inhibitors from this strain. 
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3.2 Culture Details, Appearance and Phylogenetic Information of 
HCC1088 
HCC1088 is a cyanobacterial strain obtained from the cryogenically preserved 
Patterson cyanobacteria collection housed at the University of Hawai‘i at Manoa. The strain, 
tentatively identified as a species of the genus Nostoc, was acquired from the Mitsui-Miami 
collection (ID: 102201) and its original collection location is unknown. A cryovial of HCC1088 
was thawed and cultured in a 10 mL tube containing the BGM cyanobacterial growth medium 
(BG-11 prepared with 3-(N-morpholino)propanesulfonic acid (MOPS) buffer). The culture, 
through a series of propagation steps in various sized flasks, was eventually grown in multiple 20 
L carboys with aeration. The timeframe for the growth of cyanobacteria from a preserved 
cryovial to 20 L cultures is typically 6-9 months. HCC1088 is a filamentous cyanobacterium 
with short to medium strands which grows from light green to dark green as cell density 
increases in the culture medium (Figure 25). Microscopic imaging showed that the culture 
contained fungal and possibly bacterial contaminants. 
 
Figure 25. (a) Photographs of 20 L cultures of HCC1088 at various stages of growth (b) 
microscopic image of the culture  
 
A B 
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In efforts to determine phylogeny of the strain HCC1088, genomic DNA was isolated 
from the cells and its 16S ribosomal RNA gene sequence was obtained. The sequence was then 
searched for close matches in the 16S rRNA gene sequence database and the nucleotide 
collection database using NCBI’s basic local alignment search tool (BLAST). The sequences 
with the most similar alignments were then subjected to a molecular phylogenetic analysis using 
available bioinformatics tools. The evolutionary history, as depicted in Figure 26, was inferred 
by using the Maximum Likelihood method based on the Tamura-Nei model.122 
The phylogenetic analysis of the closely matched gene sequences obtained from the 
16S rRNA sequence database revealed no obvious phylogenetic match for the strain HCC1088; 
however, the most analogous sequences were found in the nucleotide collection database (Figure 
26). These sequences belong to uncultured cyanobacteria with no phylogenetic information, 
precluding us from making any inference on the phylogeny of the strain HCC1088. While 
morphological evaluation was consistent with a Nostocalean strain, no firm conclusions could be 
reached.  
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Figure 26. Molecular phylogenetic analysis by maximum likelihood method, using MEGA7  
 GQ443447.2 Anabaena cylindrica UTAD A212 16S ribosomal RNA gene partial sequence
 AF247592.1 Anabaena cylindrica NIES19 16S ribosomal RNA gene partial sequence
 KM019919.1 Anabaena cylindrica PCC 7122 16S ribosomal RNA gene partial sequence
 HF678486.1 Anabaena inaequalis CCAP 1446/1A partial 16S rRNA gene
 KT290324.1 Anabaena inaequalis CCAP 1446/1A 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 NR 102457.1 Anabaena cylindrica strain PCC 7122 16S ribosomal RNA gene complete sequence
 HE975014.1 Anabaena cylindrica PCC 7122 partial 16S rRNA gene strain CCAP 1403/2B
 AJ630458.1 Anabaena augstumalis SCMIDKE JAHNKE/4a partial 16S rRNA gene strain SCMIDKE JAHNKE/4a
 KT290354.1 Anabaena sp. 7-Soos11-BA 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KT290373.1 Anabaena sp. HBU3 16S ribosomal RNA gene partial sequence
 KT290375.1 Anabaena sp. HBU8 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KT290346.1 Anabaena sp. 5-Frant09 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KT290334.1 Anabaena sp. 1-Kutnar09 16S ribosomal RNA gene partial sequence
 KT290348.1 Anabaena sp. 5-Kutnar09 16S ribosomal RNA gene partial sequence
 KT290329.1 Anabaena sp. Ladakh09-L2 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KC346266.1 Hydrocoryne sp. CENA398 16S ribosomal RNA gene partial sequence 16S-23S ribosomal RNA intergenic spacer tRNA-Ile and tRNA-Ala genes complete sequence and 23S ribosomal RNA gene partial seqe
 KC346265.1 Hydrocoryne sp. CENA393 16S ribosomal RNA gene partial sequence 16S-23S ribosomal RNA intergenic spacer tRNA-Ile and tRNA-Ala genes complete sequence and 23S ribosomal RNA gene partial seqe
 KC346268.1 Hydrocoryne sp. UFV-ANT32 16S ribosomal RNA gene partial sequence
 KC346267.1 Hydrocoryne sp. UFV-ANT31 16S ribosomal RNA gene partial sequence
 AJ781150.1 Cyanobacterium BECID34 16S rRNA gene strain BECID34
 EU022718.1 Anabaena sp. SKSF1 16S ribosomal RNA gene partial sequence EU022719.1 Anabaena sp. SKJF11 16S ribosomal RNA gene partial sequence
 HF678491.1 Calothrix sp. CCAP 1410/13 partial 16S rRNA gene
 KM019918.1 Gloeotrichia longicauda SAG 32.84 16S ribosomal RNA gene partial sequence
 KT290327.1 Dolichospermum viguieri SAG 27.79 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KT290323.1 Anabaena catenula SAG 1403-1 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 DQ234832.1 Trichormus variabilis strain KCTC AG10180 16S ribosomal RNA gene partial sequence
 DQ234829.1 Trichormus variabilis strain KCTC AG10008 16S ribosomal RNA gene partial sequence DQ234831.1 Trichormus variabilis strain KCTC AG10178 16S ribosomal RNA gene partial sequence
 EU022720.1 Anabaena sp. KVSF7 16S ribosomal RNA gene partial sequence EU022721.1 Anabaena sp. KVJF17 16S ribosomal RNA gene partial sequence
 AJ630457.1 Trichormus variabilis GREIFSWALD partial 16S rRNA gene strain GREIFSWALD
 AM230703.1 Gloeotrichia echinulata PYH6 partial 16S rRNA gene strain PYH6
 HQ386386.1 Uncultured cyanobacterium clone LiUU-5-324.2 16S ribosomal RNA gene partial sequence
 HQ386385.1 Uncultured cyanobacterium clone LiUU-5-444.2 16S ribosomal RNA gene partial sequence
 AM230704.1 Gloeotrichia echinulata PYH14 partial 16S rRNA gene environmental colony PYH14
 FJ815303.1 Uncultured Nostoc sp. clone UK16 16S ribosomal RNA gene partial sequence
 KP762334.1 Cyanobacterium UTEX B 3002 16S ribosomal RNA gene partial sequence
 HCC1088
 KP762335.1 Uncultured cyanobacterium clone 3 16S ribosomal RNA gene partial sequence
 KP762336.1 Uncultured cyanobacterium clone 6 16S ribosomal RNA gene partial sequence
 KP762337.1 Uncultured cyanobacterium clone 7 16S ribosomal RNA gene partial sequence
 KM438192.1 Nostocales cyanobacterium NapMSlm13 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KP762338.1 Uncultured cyanobacterium clone 8 16S ribosomal RNA gene partial sequence
 KP762343.1 Uncultured cyanobacterium clone 22 16S ribosomal RNA gene partial sequence
 KP762341.1 Uncultured cyanobacterium clone 11 16S ribosomal RNA gene partial sequence
 KP762342.1 Uncultured cyanobacterium clone 13 16S ribosomal RNA gene partial sequence
 KP762340.1 Uncultured cyanobacterium clone 10 16S ribosomal RNA gene partial sequence
 KP762339.1 Uncultured cyanobacterium clone 9 16S ribosomal RNA gene partial sequence
 HM235817.1 Anabaena sp. BHUAR002 16S ribosomal RNA gene partial sequence
 HM235816.1 Anabaena sp. BHUAR001 16S ribosomal RNA gene partial sequence
 KC695854.2 Halotia wernerae CENA160 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence and tRNA-Ile and tRNA-Ala genes complete sequence
 KC695853.2 Halotia wernerae CENA159 16S ribosomal RNA gene partial sequence 16S-23S ribosomal RNA intergenic spacer tRNA-Ile and tRNA-Ala genes complete sequence and 23S ribosomal RNA gene partial see
 KC695852.2 Halotia wernerae CENA158 16S ribosomal RNA gene partial sequence 16S-23S ribosomal RNA intergenic spacer tRNA-Ile and tRNA-Ala genes complete sequence and 23S ribosomal RNA gene partial see
 KJ843313.1 Halotia longispora CENA420 16S ribosomal RNA gene partial sequence 16S-23S ribosomal RNA intergenic spacer tRNA-Ile and tRNA-Ala genes complete sequence and 23S ribosomal RNA gene partial e
 DQ185207.1 Nostoc sp. Mollenhauer 1:1-067 16S ribosomal RNA gene partial sequence
 KR137579.1 Nostocaceae cyanobacterium CENA358 16S ribosomal RNA gene partial sequence
 KR137610.1 Nostocaceae cyanobacterium CENA389 16S ribosomal RNA gene partial sequence
 AM711543.1 Nostoc sp. Cam2S01 partial 16S rRNA gene strain Cam2S01
 KR137600.1 Nostocaceae cyanobacterium CENA379 16S ribosomal RNA gene partial sequence
 KR137594.1 Nostocaceae cyanobacterium CENA373 16S ribosomal RNA gene partial sequence
 AB093486.1 Tolypothrix sp. IAM M-259 gene for 16S ribosomal RNA partial sequence
 KM019924.1 Calothrix membranacea SAG 1410-1 16S ribosomal RNA gene partial sequence
 KU668914.1 Tolypothrix sp. 9k 16S ribosomal RNA gene partial sequence
 AB325535.1 Tolypothrix tenuis PCC 7101 gene for 16S rRNA partial sequence
 FJ661000.1 Tolypothrix sp. PCC 7504 isolate DBSU 17 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 JX827161.1 Tolypothrix sp. PCC 7601 UTEX B 481 16S ribosomal RNA gene partial sequence
 FJ660998.1 Tolypothrix sp. PCC 7504 isolate DBSU 19 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 FJ660997.1 Tolypothrix sp. PCC 7504 isolate DBSU 21 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KM019923.1 Scytonema bohneri SAG 255.80 16S ribosomal RNA gene partial sequence
 KM019930.1 Nodularia sphaerocarpa PCC 7804 16S ribosomal RNA gene partial sequence
 AJ133181.1 Nodularia sp. PCC 7804 partial 16S rRNA gene strain PCC7804 DQ185243.1 Nodularia sphaerocarpa PCC 7804 16S ribosomal RNA gene partial sequence
 KC912774.1 Nodularia sphaerocarpa PCC 7804 strain SAG 50.79 16S ribosomal RNA gene partial sequence
 AM711554.1 Nodularia harveyana partial 16S rRNA gene strain Lukesova 18/94
 AJ781143.1 Nodularia harveyana 16S rRNA gene strain Bo53
 AJ781145.1 Nodularia harveyana 16S rRNA gene strain BECID27
 KM019929.1 Nodularia harveyana SAG 44.85 16S ribosomal RNA gene partial sequence
 KT290322.1 Anabaena sp. SAG 12.82 16S ribosomal RNA gene and 16S-23S ribosomal RNA intergenic spacer partial sequence
 KC883980.1 Nostoc calcicola BDU 40302 16S ribosomal RNA gene partial sequence
 KC883981.1 Nostoc calcicola BDU 180601 16S ribosomal RNA gene partial sequence
 AJ781142.1 Nodularia harveyana 16S rRNA gene strain Huebel 1983/300
 AF268020.1 Nodularia harveyana strain CDAC1983/300 16S ribosomal RNA gene partial sequence
 DQ185231.1 Nodularia harveyana Huebel 1983/300 16S ribosomal RNA gene partial sequence
 KC912766.1 Nodularia cf. harveyana HBU11 16S ribosomal RNA gene partial sequence
 AJ781146.1 Nodularia harveyana 16S rRNA gene strain BECID29
 KM020015.1 Anabaenopsis elenkinii SAG 252.80 16S ribosomal RNA gene partial sequence
 AM773302.1 Anabaenopsis cf. AB2002/25 abijatae partial 16S rRNA gene strain AB2002/25
 JX462677.1 Uncultured Anabaenopsis sp. clone LBK 16S ribosomal RNA gene partial sequence
 FR774775.1 Cyanospira capsulata CC87E partial 16S rRNA gene strain CC87E FR774777.1 Cyanospira capsulata CCAX partial 16S rRNA gene strain CCAX
 FR774774.1 Cyanospira rippkae CR86F7 partial 16S rRNA gene strain CR86F7
 AM773295.1 Anabaenopsis abijatae AB2002/08 partial 16S rRNA gene strain AB2002/08 AM773296.1 Anabaenopsis abijatae AB2002/09 partial 16S rRNA gene strain AB2002/09 AM773297.1 Anabaenopsis abijatae AB8
 JX462679.1 Uncultured Anabaenopsis sp. clone LNK 16S ribosomal RNA gene partial sequence
 FR774770.1 Cyanospira rippkae 7NR8 partial 16S rRNA gene strain 7NR8
 FR774768.1 Cyanospira rippkae NMBCl partial 16S rRNA gene strain NMBCl FR774769.1 Cyanospira rippkae 5NR8 partial 16S rRNA gene strain 5NR8 FR774771.1 Cyanospira rippkae 8NR8 partial 16S rRNA gene st5
 AY038036.1 Cyanospira rippkae 16S ribosomal RNA gene partial sequence
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3.3 Isolation of Secondary Metabolites from HCC1088, Nostoc sp. 
Secondary metabolites from the culture broth of HCC1088 were of interest because 
its extract showed significant inhibitory activity in the BACE1 enzyme fragment 
complementation assay. Extraction of compounds from the broth using HP-20 resin, followed by 
purification by HPLC, led to the isolation of several compounds. 
Four new compounds 3.6-3.9 and two previously known metabolites 3-
formylindole123 3.10 and 3-cyanoindole124 3.11 were isolated from the culture broth  extract of 
HCC1088 (Figure 27). Compound 3.7 was identified as the molecule potentially responsible for 
the BACE1 inhibitory activity in the enzyme fragment complementation assay as well as the 
homogeneous affinity assay based on prior work by former members of the Williams research 
group.  
 
Figure 27. Structures of metabolites isolated from the culture broth of HCC1088 
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3.4 Elucidation of Structures of Metabolites of HCC1088 
Structure elucidation of 3.6. The molecular formula of compound 3.6, which was 
isolated as optically active ([𝛼]𝐷
21 +15 (c 0.2, CH3OH)) yellow crystalline needles, was 
established as C11H9NO2 from its HRESIMS signal at m/z 210.0525 [M+Na]
+. The infrared 
stretches at 3303 cm-1 and 3210 cm-1 were indicative of the presence of O-H and N-H bonds, 
whereas the stretch at 1678 cm-1 suggested that 3.6 contained an α,β-unsaturated carbonyl 
(ketone) unit. The latter conclusion was supported by the signal at 194.4 ppm in the 13C NMR 
spectrum. A total of eleven carbon signals were observed, including two sp3 carbons and eight 
sp2 carbons in addition to the conjugated ketone, and they were classified into methine, 
methylene and quaternary carbons using the HSQC spectrum (Table 5). The 1H NMR signals at 
δH 4.53, 3.48 and 2.69 constitute an AMX pattern, indicating the presence of an isolated CH-CH2 
fragment bearing an oxygen atom on the methine carbon. The splitting patterns of the four 
aromatic proton signals, i.e., δH 7.65, 7.41, 7.31 and 7.08, show the presence of a 1,2-
disubstituted benzene ring, which accounts for six of the eight unassigned sp2 carbons. The 
benzene ring was proposed to be a part of a 2,3-disubstituted indole ring based on the remaining 
atoms, which included two quaternary sp2 carbons, one nitrogen and two exchangeable protons, 
one of which was assigned as the hydroxyl proton. This satisfied all but one degree of 
unsaturation, which suggested the presence of a third ring in the molecule. The HMBC 
resonances from δH 3.48 and 2.69 (3’) to δC 123.2 (3a) were used as the key evidence in 
establishing the planar structure of compound 3.6 (Figure 28). 
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Table 5. NMR Spectroscopic Data of Compound 3.6 in DMSO-d6 (500 MHz) 
Position δC, type δH (J in Hz) COSY HMBC
a
 
1 (NH)  11.60, brs   
2 136.3, C    
3 141.0, C    
3a 123.2, C    
4 121.6, CH 7.65, dt (8.1, 1.0) 5 3, 3a, 6, 7a 
5 120.3, CH 7.08, ddd (8.0, 7.0, 1.0) 4, 6 3a, 6, 7 
6 127.1, CH 7.31, ddd (8.2, 6.9, 1.2) 5, 7 4, 7a 
7 113.8, CH 7.41, dt (8.3, 0.9) 6 3a, 5 
7a 143.9, C    
1’ 194.4, C    
2’ 77.0, CH 4.53, dd (6.3, 2.6) 3’ 1’, 3, 3’ 
3’ 30.7, CH2 3.48, dd (16.2, 6.4) 2’ 1’, 2, 2’, 3, 3a 
  2.69, dd (16.2, 2.8) 2’ 2, 2’, 3, 3a 
2’-OH  5.85, brs   
 
a HMBC correlations, optimized for 7 Hz, are from proton(s) stated to the indicated carbon. 
 
 
Figure 28. Important HMBC correlations that were used to establish the planar structures of 
compounds 3.6 and 3.7 
 
Mosher’s method125 is an established protocol in determining the absolute 
configuration of a chiral secondary alcohol, however, the Δδ (δS – δR) values cannot be used to 
conclusively assign the absolute configuration at C-2’ of compound 3.6 because of the lack of 
proximal non-exchangeable protons on one side of the secondary alcohol (Figure 29a). 
Subsequent reductions of the MTP-esters of compound 3.6 (3.12 and 3.13) using the Luche 
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protocol126  to compounds 3.14 and 3.15 introduce an additional proton at C-1’, allowing for a 
more definitive assignment of absolute configuration at C-2’ (Scheme 2). In each reduction, 3.14 
or 3.15 is formed as a single diastereomer, which may be rationalized by a chelation model in 
which cerium coordinates to both the ketone and the ester carbonyls, facilitating a hydride attack 
from one face. While the relative stereochemistry of this single diastereomer was not determined, 
it likely has the syn configuration.127 Formation of a single diastereomer in each reduction is not 
critical to the success of Mosher’s analysis, but it results in a cleaner spectrum, eliminates the 
need for difficult separation and makes the analysis straightforward. The Δδ (δS – δR) values 
computed from the 1H NMR spectra of compounds 3.14 and 3.15 suggest an S-configuration at 
C-2’ of compound 3.6 (Figure 29b). This assignment is further supported by density functional 
theory (DFT) calculations. The computed specific rotation of compound 3.6 ([𝛼]𝐷
25 +19, MeOH 
solvation) at the B3LYP/6-311+G(d,p) level was a close match with the experimental value. 
 
Scheme 2. Mosher esterification of compound 3.6 and subsequent reductions. 
NOTE: Based on CIP rules, the S-ester 3.12 is synthesized from the R-acid chloride. Likewise, the R-ester 3.13 is 
synthesized from the S-acid chloride 
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Figure 29. Δδ (δS – δR) values for (a) Mosher’s esters and (b) reduced Mosher’s esters of 
compound 3.6 suggest an (S)-configuration at the carbinol stereogenic center. 
 
The octant rules128 predict compound 3.6 to exhibit a positive Cotton effect in its 
electronic circular dichroism (ECD) spectrum (Figure 30a). A positive Cotton effect was also 
observed in the ECD spectrum generated by SpecDis129 using the data obtained from TDDFT 
calculations (see experimental section) at the B3LYP/6-311+G(d,p) level as well as the 
B3LYP/aug-cc-pVDZ level (Figure 30b). However, the experimental ECD spectrum of 3.6 
showed a negative Cotton effect, implying an anti-octant behavior (Figure 30b). Anti-octant 
behavior is not an uncommon phenomenon and is often observed with compounds containing 
axial substituents and, particularly, fluorine.130 Moreover, compounds with oxygen- and nitrogen-
containing substituents have been identified as capable of exhibiting either octant or inverse 
octant behavior and the roles of the substituents are not clear.131 In compound 3.6, the presence 
of a hydroxyl group on the lone stereogenic center (C-2’) of an otherwise planar and rigid 
molecule may be deemed responsible for the apparent anti-octant behavior seen in its ECD 
spectrum. 
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Figure 30. (a) Compound 3.6 is predicted to show a positive Cotton effect based on octant rules; 
(b) Calculated (red) and experimental (blue) ECD spectra of compound 3.6 show positive and 
negative Cotton effects, respectively. 
 
A plausible biosynthetic route of compound 3.6 involves an intramolecular 
electrophilic aromatic substitution (Friedel-Crafts acylation) of tryptophan, transamination to a 
dione, and subsequent reduction to the α-hydroxy ketone moiety. It must be noted that Friedel-
Crafts alkylation is a common occurrence in biological systems132 but acylation is quite rare.133 
While compound 3.6 is reported here for the first time, a close analogue, in which the hydroxyl 
group is substituted by an amino group, has been prepared by synthesis and is known to be an 
anti-inflammatory agent and a central nervous system drug.134  
Structure elucidation of 3.7. Compound 3.7 was isolated as an amorphous white 
solid and its molecular formula was determined to be C12H12N2O2 from its HRESIMS signal at 
m/z 239.0782 [M+Na]+. The 13C NMR spectrum of 3.7 indicated the presence of ten unique 
carbons, which were classified into four quaternary sp2 carbons, four sp2 methines, one sp3 
methylene group, and one methyl group using the HSQC spectrum (Table 6). The signal at δC 
170.1 (C-2) was assigned to the carbonyl carbon of an amide or an ester.  Analysis of the HMBC 
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spectrum helped establish both the identity of the amide functional group and its connectivity 
with the methyl group (C-1) based on the correlations from the singlet methyl at δH 2.10 (H-1) to 
δC 170.1 (C-2) and 37.1 (C-4). These resonances ruled out the possibility of a direct connectivity 
of C-1 with the methylene C-4 or of C-4 with an oxygen atom, the latter based on the chemical 
shift of the carbon. The relative integrations and multiplicities of the signals at δH 7.61, 7.42 and 
7.33 suggested that a mono-substituted benzene ring was present in the molecule. The proton 
signal at δH 7.26 (H-6) did not show resonances in the HSQC spectrum (optimized for 140 Hz) 
but its connectivity to C-7 was established from the HMBC spectrum, which was also used to 
extract the 1JC-H value of 194 Hz, indicating that this methine was part of a heteroaromatic ring. 
An oxazole ring was speculated based on the remaining fragments, and the structure of 
compound 3.7 was proposed following analysis of chemical shifts and some key HMBC 
resonances (Figure 28). These included correlations from δH 7.26 (H-6) to δC 152.0 (C-8), 160.1 
(C-5) and 37.1 (C-4), and from δH 4.65 (H-4) to δC 160.1 (C-5), 170.1 (C-2), 152.0 (C-8), 121.6 
(C-7) and 23.1 (C-1). Since several of these are four-bond correlations, an alternate structure 
3.16 was also considered (Figure 31b). The HMBC resonances were more in line with 3.16, 
however, chemical shifts and examination of biosynthetic routes suggested that 3.7 was the more 
likely structure. While compound 3.7 has plausible biosynthetic precursors in 
phenylethanolamine and N-acetylglycine (or glycine and an acetate unit), there is no 
straightforward pathway for compound 3.16 (Figure 31a). Nevertheless, the presence of 
ambiguous data necessitated the confirmation of the structure via other methods. 
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Figure 31. (a) Biosynthetic precursors of compound 3.7 and (b) an alternate structure 3.16 
 
Due to degradation of the compound during the analysis steps, which precluded us 
from carrying out further characterization and biological evaluation, compound 3.7 was 
synthesized through acetylation of its commercially available amine hydrochloride precursor, 
3.17 (Scheme 3). The 1H and 13C NMR data of synthetic 3.7 were nearly identical to those 
acquired from natural product isolated from the culture broth of the cyanobacterium, confirming 
the structure of compound 3.7.  
Table 6. NMR Spectroscopic Data of Compound 3.7 in CDCl3 (500 MHz) 
Position δC, type δH (J in Hz) COSY HMBC 
1 23.1, CH3 2.10, s  2, 4 
2 170.1, C    
3 (NH)  6.19, brs   
4 37.1, CH2 4.65, d (5.4) 3 1, 2, 5, 7, 8 
5 160.1, C    
6 (N)     
7  121.6, CH 7.26
a
, s  5, 8 
8 152.0, C    
9 127.5, C    
10, 10’ 124.2, CH 7.61, d (7.8)  8, 12b 
11, 11’ 128.9, CH 7.42, t (7.7) 10, 10’, 12 10, 10’, 9b 
12 128.6, CH 7.33, t (7.4)  10, 10’ 
 
a C-H connectivity established from HMBC experiment (
1
JC-H = 194 Hz) 
b Observed when optimized for 7.0 Hz and recorded in CD3OD (other HMBC signals observed when optimized 
for 4.0 Hz and recorded in CDCl3) 
 56 
 
5
6 
Scheme 3. Preparation of compound 3.7 via acetylation of 3.17 
 
 
Structure elucidation of 3.8. The molecular formula of compound 3.8 was 
determined to be C18H17NO5 based on its HRESIMS signal at m/z 328.1184 [M+H]
+. Two 
benzene rings, ortho- and para-disubstituted, were identified from the coupling patterns of the 
proton signals in the aromatic region. Analysis of the 1H, 13C, and HSQC NMR spectra of 
compound 3.8 further revealed the presence of a CH-CH2 fragment with oxygenation at the 
methine, and an isolated CH2 fragment (Table 7). A carbonyl moiety – an amide or an ester – was 
established from the signal at 175.5 ppm in the 13C NMR spectrum. Also observed in the 13C 
NMR spectrum were two downfield quaternary carbons, at 104.3 ppm and 91.3 ppm, indicative 
of sp3 carbons connected to oxygen atoms and/or other deshielding atoms or functional groups. 
The carbon framework of compound 3.8 was completed on the basis of various 
HMBC resonances (Figure 32). The correlation from δH 7.49 (H-5) to δC 104.0 (C-7) established 
C-7, assigned as a ketal or a hemiketal carbon based on its chemical shift, as a substituent on the 
1,2-disubstituted benzene ring. Correlations from δH 2.38, 2.18 (H-8) and δH 4.31 (H-9) to δC 
104.0 (C-7), and from δH 2.38, 2.18 (H-8) to δC 136.0 (C-6), helped connect C7, C8 and C9 in 
order. Likewise, the HMBC resonances from δH 4.31 (H-9) to δC 91.3 (C-10), 175.5 (C-11) and 
40.3 (C-12) extended the framework as shown on the structure. C-12 was connected to the 1,4-
disubstituted benzene ring based on HMBC signals from δH 7.17 (H-14) to δC 40.3 (C-2). The 
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hydroxyl substituent on C-16 of the 1,4-disubstituted benzene ring was inferred from its 13C shift 
of 157.2 ppm. 
 
Table 7. NMR Spectroscopic Data of Compound 3.8 in CD3OD (500 MHz) 
Position δC, type δH (J in Hz) COSY HMBC
a
 
1 136.9, C    
2 120.0, CH 6.94, dd (8.0, 0.9) 3 4, 6 
3  129.6, CH 7.16, m  1, 5 
4 123.3, CH 6.97, td (7.6, 1.1) 3, 5 2, 3, 6 
5 125.8, CH 7.49, dd (7.8, 1.5)  1, 3, 7 
6  136.0, C    
7 104.0, C    
8 47.8, CH2 2.38, dd (13.7, 8.7) 9 6, 7, 9, 10 
  2.18, dd (13.7, 8.7) 9 6, 7, 9, 10 
9  78.0, CH 4.31, t (8.8)  7, 8, 10, 11, 12 
10 91.3, C    
11 175.5, C    
12 40.3, CH2 3.30, d (14.2)  9, 10, 11, 13, 14 
  3.05, d (14.3)  9, 10, 11, 13, 14 
13 128.4, C    
14, 14’ 133.0, CH 7.17, d (8.6) 15, 15’ 12, 14, 15, 16 
15, 15’ 115.6, CH 6.64, d (8.6)  13, 15, 16 
16 157.2, C    
 
a HMBC correlations, optimized for 7 Hz, are from proton(s) stated to the indicated carbon. 
 
With the carbon framework completed, the remaining planar structure of compound 
3.8 was deduced based on a few key evidences. In addition to the ketal/hemiketal at C-7, oxygen 
atoms were connected to C-9 and C-10, based on their 13C shifts. Moreover, one of the oxygen 
atoms on C-7, C-9 and C-10 had to be connected to two of the carbon atoms, based on the 
molecular formula. An ether linkage between C-7 and C-10 was thus established. The nitrogen 
was then determined to be part of an anilide moiety, as opposed to an aniline as shown in 
structure 3.18, because closer inspection of 13C NMR signals of C-1 (136.9 ppm), C-2 (120.0 
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ppm) and C-6 (136.0 ppm) revealed that the chemical shift values were more reasonable with the 
placement of an amide substituent at C-1 instead of an amine moiety.135 Computations of NMR 
shifts using the gauge-independent atomic orbital (GIAO) method also agreed with the 
conclusion that compound 3.8 contained an anilide moiety instead of aniline. 
  
Figure 32. Two structures were proposed (3.8 and 3.18), based on the COSY (bold lines) and the 
HMBC (red arrows) correlations shown on the right. 
 
In our computational studies, which we adopted from the protocol published by 
Willoughby et al.,89 we constructed all possible diastereomers, i.e. four each, of compounds 3.8 
and 3.18, and conducted a global search for conformers of each diastereomer within 5 kcal/mol 
of the respective lowest energy conformer. For each non-redundant conformer within the energy 
windows, GIAO NMR shifts were computed at the B3LYP/6-311+G//M06-2X/6-31+G levels. 
Statistical comparisons of the computed 1H and 13C NMR shifts and the experimental values, 
using both the DP497 and the sDP4+136 probability methods, support the anilide structure, 
including the relative configuration as shown (Figure 33). 
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Isomer DP4 probability sDP4+ probability 
(7S,9R,10S)-3.8 0.00 0.00 
(7S,9S,10R)-3.8 0.97 0.98 
(7S,9R,10R)-3.8 0.03 0.02 
(7R,9R,10R)-3.8 0.00 0.00 
(7S,9R,10S)-3.18 0.00 0.00 
(7S,9S,10R)-3.18 0.00 0.00 
(7S,9R,10R)-3.18 0.00 0.00 
(7R,9R,10R)-3.18 0.00 0.00 
 
  
Figure 33. Relative configuration of compound 3.8, as suggested by statistical analyses of the 
computed and experimental 1H and 13C NMR shifts of all possible diastereomers of 3.8 and 3.18. 
 
Compound 3.8, which has been reported for the first time here, has plausible building 
blocks in anthranilic acid, both a precursor to and a degradation product of tryptophan,137 an 
acetate unit, and tyrosine (Scheme 4). We propose that a series of transformations, including 
cyclization, epoxidation and nucleophilic attack on the epoxide, eventually results in the 
biosynthesis of compound 3.8. While we have neither carried out rigorous mechanistic studies 
nor isolated the intermediates, LCMS analysis of the culture broth extract does show components 
with m/z values of 294 and 310 [M+H]+, which may represent the proposed intermediates. 
 
Scheme 4. A sketch of a possible biosynthetic route to compound 3.8. 
     
Structure elucidation of 3.9. Compound 3.9, which had an HRESIMS signal at m/z 
310.1062 [M+H]+, suggesting a molecular formula of C18H15NO4, appeared to be structurally 
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related to compound 3.8 based on the similarities in the NMR spectra of the two compounds 
(Table 8). Notable differences include the presence of a ketone functional group, as indicated by 
the signal at 207.7 ppm in the 13C NMR spectrum, and the lack of an oxygenated methine signal 
in compound 3.9, suggesting that an alcohol functional group in compound 3.8 was oxidized to a 
carbonyl unit in compound 3.9. An additional quaternary sp2 carbon resonance at 112.4 ppm, 
coupled with signals at 207.7 ppm and 180.0 ppm, suggested the presence of a cyclopentane-1,3-
dione core in a non-interconverting keto enol ether form. Both compounds 3.8 and 3.9 possessed 
similar carbon frameworks, however, the molecular formula of compound 3.9 contained one 
oxygen atom and two hydrogen atoms fewer than that of compound 3.8. This necessitated the 
placement of an additional ring, which was proposed to connect the nitrogen atom to the oxygen 
atom of the enol ether to form a 1,2-oxazine ring. The chemical shifts of carbon and proton 
nuclei in the ortho-disubstituted benzene rings of compounds 3.8 and 3.9 suggest difference in 
electronic properties of the nitrogen substituents of these compounds, i.e. more electron donating 
in the latter, and the placement of the oxazine ring in 3.9 in place of the lactam ring in 3.8 is 
consistent with these observations. The 1,2-oxazine motif, albeit very rare and unusual, is present 
in the natural products trichodermamide A138/penicillazine A139 3.19, aspergillazine A140 3.20 and 
paeciloxazine141 3.21, which were all isolated from fungi (Figure 35). It is unclear at this point 
whether these metabolites, particularly compounds 3.8 and 3.9, are synthesized by cyanobacteria, 
fungal or bacterial contaminants, or via symbiotic efforts of these cohabitating organisms.   
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Table 8. NMR Spectroscopic Data of Compound 3.9 in CD3OD (500 MHz) 
Position δC, type δH (J in Hz) HMBC
a
 
1 148.2, C   
2 112.3, CH 6.93, d (7.9) 4, 6 
3  131.1, CH 7.24, td (7.8, 1.3) 1, 5 
4 123.0, CH 6.96, t (7.5) 2, 6 
5 125.7, CH 7.41, d (7.5) 1, 3, 7 
6  133.3, C   
7 81.7, C   
8 48.0, CH2 2.77, d (15.7) 6, 7, 9, 10, 11 
  2.72, d (15.7) 6, 7, 9, 10, 11 
9  207.7, C   
10 112.4, C   
11 180.0, C   
12 27.9, CH2 3.30, d (15.3) 9, 10, 11, 13, 14 
  3.05, d (15.3) 9, 10, 11, 13, 14 
13 131.6, C   
14, 14’ 130.3, CH 7.07, d (8.5) 12, 14, 16 
15, 15’ 116.1, CH 6.67, d (8.5) 13, 15, 16 
16 156.6, C   
 
a HMBC correlations, optimized for 7 Hz, are from proton(s) stated to the indicated carbon. 
 
   
Figure 34. Key COSY (bold lines) and HMBC (red arrows) correlations used in establishing the 
structure of compound 3.9. 
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Figure 35. Oxazine containing fungus-derived natural products 
 
Computed NMR shifts of 3.9 using the gauge-independent atomic orbital (GIAO) 
method at the B3LYP/6-311+G//M06-2X/6-31+G levels are in reasonable agreement with the 
observed shifts. The mean absolute error of 0.15 ppm between the observed and computed 1H 
NMR shifts of the compound is within the 0.20 ppm window desired for the correct structure.89 
Furthermore, the 1H and 13C chemical shifts in the aromatic ring of the benzoxazine fragment of 
3.9 are in close agreement with the corresponding shifts of paeciloxazine,141 providing additional 
support to the proposed structure (Table 9).  
 
Table 9. Comparison of relevant NMR shifts between paeciloxazine 3.21 and compound 3.9 
Position δC, 3.9 δH, 3.9 δC, 3.21 δH, 3.21  
1 148.2  148.2   
2 112.3 6.93 112.1 6.71  
3  131.1 7.24 128.3 7.21  
4 123.0 6.96 121.9 6.97  
5 125.7 7.41 127.2 7.43  
6  133.3  129.3   
 
The metabolites 3-formylindole 3.10 and 3-cyanoindole 3.11 were identified from 
their 1H NMR spectra and ESIMS data. The 1H NMR data are in close agreement with the data 
found in the literature.123-124  
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3.5 Evaluation of Biological Activity of Metabolites of HCC1088 
The main objective of growing this strain of cyanobacteria and isolating the 
metabolites found in the culture broth was to discover novel BACE1 inhibitors. While the natural 
product believed to be active against BACE1, 3.7, was isolated early on during the course of the 
research, its structure was proposed and confirmed by synthesis much later. In an unfortunate 
turn, the in-house BACE1 assay that we relied upon for much of our research was no longer 
available as the commercial vendor stopped supplying the assay kit. Efforts to validate other 
commercial BACE1 assay kits have been unsuccessful to date.142 In that context, the evaluation 
of the intended primary biological activity remains incomplete until a robust assay becomes 
available. 
Nonetheless, compounds 3.6, 3.7, 3.10 and 3.11 were evaluated for activity in other 
assays available to us. These compounds failed to show any promising activity in cytotoxicity 
assay against Panc-1 and U251MG cell lines, Ca-signaling assay or the vascular permeability 
assay run by our collaborators. Evaluation of antimicrobial properties of these metabolites has 
been planned. 
 
3.6 Producers of the HCC1088 Metabolites 
The microscopic image shown in Figure 25b revealed the strong presence of fungal 
contaminants in the culture of the cyanobacterial strain, and it naturally begs the question as to 
whether the metabolites described in this chapter are produced by the cyanobacterium, fungus or 
even a bacterium, which are likely contaminants as well. Cyanobacterial secondary metabolites 
typically accumulate in the biomass and it is unusual for them to be found in the culture medium. 
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The only known instances are a few, such as the antifungal compounds tolybyssidin A and B143 
from Tolypothrix byssoidea (Hass) Kirchm. (Scytonemataceae), antibacterial compounds 
noscomin144 and comnostin A-E145 from Nostoc commune Vaucher (Nostocaceae), and an 
algicidal β-carboline from various species of cyanobacteria of the Nostocaceae family.146  
Furthermore, the rare oxazine moiety, as present in 3.9, has been reported primarily in fungus-
derived natural products. Combination of these evidences certainly gives rise to the possibility 
that a fungus is the main producer of these natural products. Other questions remain to be 
answered, such as, could these compounds be produced by the cyanobacteria in defense against 
the other organisms in the culture? We set out on conducting a series of experiments to reveal 
more about the production of these metabolites. 
 In efforts to isolate the fungi from the cyanobacteria, we attempted two experiments. 
The heavily contaminated HCC1088 cellular suspension was inoculated with nitrate absent BGM 
media, in order to deprive the heterotrophs of a nitrogen source and to eventually get rid of fungi 
and bacteria that cannot fix nitrogen. Likewise, colonies of contaminated cyanobacteria/fungi 
composites were grown on an agar plate containing chloramphenicol, an antibiotic, to induce a 
pure culture of fungus. Remarkably, both experiments succeeded in achieving the intended goals. 
The cyanobacterial culture in nitrate absent BGM media was free of fungal strains, as 
observed by light microscopy (Figure 36a). Meanwhile, the fungal strain thrived and the 
cyanobacterial strain vanished on the agar plate laden with antibiotic (Figure 36b). Following 
these encouraging observations, the axenic cultures of both cyanobacterium and fungus were 
grown in appropriate media with the purpose of monitoring the formation of metabolites in each. 
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Figure 36. (a) Microscopic image of HCC1088 culture grown in nitrate absent BGM medium (b) 
Fungal colonies isolated from the HCC1088 culture growing on an agar plate 
 
Extraction of the fungal cell mass and its culture medium at different time intervals 
(5, 10, 30 d) showed no presence of the metabolites 3.6-3.9. Likewise, these compounds were 
not detected in the cell extract of HCC1088 over an extended period of time (30 d). The oxazole 
3.7 was detected in the culture broth but not in the cell extract of the axenic HCC1088 culture 
grown in nitrate absent medium, suggesting that it is indeed produced by the cyanobacterium and 
released in the culture medium. The oxazine 3.9, presumed to be a fungal metabolite based on 
the occurrences in fungal strain, was not detected in either culture. These observations suggest 
that the oxazine 3.9 is produced by either the fungus or the cyanobacterium in presence of the 
other organism, or by unknown bacterial contaminants. 
Next, we propagated a portion of this axenic culture to a large 20 L culture containing 
regular BGM medium (with nitrate present) to monitor any metabolic changes using LC-MS 
methods. [Note: It is extremely difficult to keep a culture of this size axenic, especially when 
aliquots are removed in periodic intervals. Therefore, contaminants are likely to populate this 
culture over time.] Compounds 3.6, 3.7, 3.8, and 3.9 were monitored by their extract ion 
chromatogram (EIC) signals at m/z 188 (ESI+), 217 (ESI+), 326 (ESI-) and 308 (ESI-), 
a b 
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respectively. Compound 3.6, which is the most abundant of these metabolites, was monitored by 
its prominent UV absorption at 280 nm as well. The LC-MS analysis of the aliquots of this 
culture in regular time intervals (2 or 4 days) revealed some notable trends. 
 Compound 3.7, which was produced by the cyanobacterium in the nitrate absent 
medium, showed a gradual and consistent growth starting day 20 and continuing this trend 
through the end of the study, i.e. 54 days (Figure 37b). The compounds 3.6, 3.8 and 3.9, 
however, appeared to follow mirroring trends of increased production beginning on day 30 and 
plateaued growth around day 50 (Figure 37a, d, c). Furthermore, in an observation that may be 
relevant or entirely coincidental, growth of white fungus under the rubber stopper of the culture 
vessel was observed on day 28. [This was confirmed to be fungus following development of the 
culture on an agar plate and inspection by light microscopy.] Remarkably, the cyanobacterial 
culture medium did not show presence of fungal strains under the light microscope. These are 
interesting observations that suggest that compounds 3.6, 3.8 and 3.9 may be produced as 
antifungal agents, but must not be interpreted as definite trends in the absence of further 
supporting evidence and more robust analytical methods. It is also very plausible that bacterial 
contamination in the cultures may be driving the production of these metabolites. 
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Figure 37. LC-MS monitoring of HCC1088 metabolites in periodic intervals 
 
Efforts to determine whether these compounds are produced by the cyanobacteria as 
an antifungal response are underway. Four cultures of HCC1088, two of which were inoculated 
with fungal cell matter, are being sampled in periodic intervals and the culture broth is extracted 
with HP-20 to monitor the levels of compounds 3.6-3.9. Multiple reaction monitoring (MRM) 
methods are being employed to get a more accurate quantitation of these metabolites. 
 
3.7 Conclusions and Outlook 
Four new metabolites (3.6-3.9) and two known compounds (3.10 and 3.11) were 
isolated from the extract of the culture broth of HCC1088, an as yet unidentified 
cyanobacterium. Computations of NMR chemical shifts using density functional theory methods 
c 
a 
d 
b 
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have been central to the elucidation of the structures of 3.8 and 3.9. Isolation of fungus from the 
cyanobacterial culture has revealed that metabolites 3.6, 3.8 and 3.9 are not produced by either 
the cyanobacterium or the fungus alone. Work is underway to determine whether the 
cyanobacterium HCC1088 produces these compounds as a defense mechanism in response to the 
detection of fungal cells. This concept has prior precedence, as demonstrated by Patterson and 
Bolis, who established enhanced production of the antifungal compound tolytoxin when fungal 
cell wall preparations containing chitin oligomers were introduced into the cultures of Scytonema 
ocellatum Lyngby (Scytonemataceae).28 Moreover, cyanobacterial oligopeptides such as 
microcystins, microviridins, anabaenopeptins have been widely regarded as allelochemicals. A 
recent study shows that oligopeptide knockout mutant cyanobacterial strains of the genus 
Planktothrix are more susceptible to fungal infections than the wildtype strains, further 
suggesting the involvement of oligopeptides in defense mechanisms.147  
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CHAPTER 4 
Investigation of Areca catechu for Ca-Signaling Activity in Immune Cells 
4.1 Significance of Areca catechu 
Areca catechu L. (Arecaceae), commonly known as betel nut (also referred to as 
Areca nut), is consumed by approximately 700 million people worldwide,148 ranking fourth 
among the most commonly used psychoactive substances, behind caffeine, nicotine and alcohol. 
It is chewed in various forms – ripe, unripe, fresh, dried – and often as “betel quid” in 
combinations with slaked lime, aromatic spices, tobacco and other ingredients wrapped in Piper 
betle leaf.  
The most frequent practice of betel nut consumption is found in South and South East 
Asia, East Africa and the Western Pacific, areas where the nut has sociocultural significance.149 
In many countries in these regions, betel nut is a common offering at ceremonies, including 
engagements, weddings, and funerals. Social pressure is a significant reason for consumption of 
betel nut in various islands of the Western Pacific as it is viewed as a socializing activity 
identifiable with those communities.149a Some unusual practices involving the Areca nut include 
formal pronunciation of a divorce when a North Sumatran Muslim man hands his wife three 
pieces of the nut, one at a time.149b In many rural communities of Nepal, acceptance of a dried 
Areca nut is a formal acceptance of an invitation to a religious or a social function, such as a 
wedding. Many other accounts of sociocultural significances are provided in a book written by 
Henry Brownrigg.150 
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4.2 Health Benefits and Concerns from Consumption of Betel Quid 
Sushruta, the historical medical text in Sanskrit, claimed as early as the first century 
that betel nut tends to ‘cleanse the mouth, impart a sweet aroma to it, enhance its beauty and 
cleanse and strengthen the voice, tongue and teeth, the jaws and the sense organs’.150 It is, to 
date, used as a digestive remedy and a mouth freshener in populations across the Indian 
subcontinent that cater to the Ayurvedic medicine. Modern medicinal research, however, portrays 
betel quid consumption in a decidedly negative light as a global health issue and links its usage 
to various systemic diseases.    
Chewing of betel quid has been established as a cause of oral lesions and pathological 
epidermal changes within the oral cavity that increase the likelihood of malignant 
transformations and development of esophageal and oral cancers.151 A clear causal relationship 
has been established between betel quid chewing and diseases such as leukoplakia and oral 
submucous fibrosis.152 Various other studies have implicated betel quid consumption to 
numerous diseases, including liver cirrhosis, hepatocellular carcinoma, obesity, hypertension, 
type 2 diabetes, chronic kidney disease, hyperlipidemia, metabolic syndrome, cardiovascular 
disease, aggravation of asthma, and complications in reproductive health.152a, 153 In Pacific 
islands, including Hawai’i, betel nut consumption is more prevalent in minority groups such as 
the Chamorros and the Micronesians. In light of health disparities between these groups and the 
rest of the populations, betel nut consumption has attracted scrutiny from the health 
community.154  
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4.3 Molecular Components of Areca catechu and their Effects on Human 
Health 
Despite the strong association of betel quid consumption with various oral diseases 
and cancer, the identity of the responsible components and the underlying mechanisms are not 
fully understood. Areca catechu is known to contain different classes of molecules, including 
alkaloids, tannins, flavones, triterpenes, steroids, and fatty acids. The major alkaloids of Areca 
nuts are arecoline 4.1, arecaidine 4.2, guvacine 4.3 and guvacoline 4.4, with arecoline the most 
abundant, whereas catechin 4.5 and epi-catechin 4.6 are the most dominant flavonoids (Figure 
38). Oligomeric and polymeric proanthocyanidins (polyflavonoids) found in Areca nuts 
primarily comprise these two monomers. Steroids such as 5,8-epidioxyergosta-6,22-dien-3β-ol 
(ergosterol peroxide), stigmast-4-en-3-one, β-sitosterol, and cycloartenol have also been isolated 
from Areca catechu.155  
 
Figure 38. Major alkaloids and flavonoids from Areca catechu 
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Many pharmacological effects, ranging from beneficial medicinal purposes to serious 
health risks, have been identified from extracts or compounds isolated from Areca nut.156  Areca 
nut components have been most frequently studied for their potential carcinogenic effects using 
both in vitro and in vivo assays.152a, 156-157 Polyphenols and tannins isolated from Areca nuts have 
been reported to behave as both carcinogenic and anti-carcinogenic agents.152c, 157a, 158  
Areca alkaloids show mutagenic and genotoxic effects in many short-term assays, 152c, 156, 159 but 
genotoxicity to oral fibroblasts and keratinocytes, the target cells of betel quid, has not been 
clearly established.157a These reports do not provide an unambiguous picture and hence the 
toxicity from Areca nuts cannot be attributed specifically to polyphenols, tannins or alkaloids but 
rather suggest that additional factors may be involved. 
4.4 Areca catechu and Inflammation 
An important observation in the context of the study described in this chapter is that 
Areca nut consumption triggers release of various mediators from host cells that contribute to a 
chronic inflammatory microenvironment in the oral cavity,160 thus promoting the development of 
oral lesions and tissue damage. It is now widely acknowledged that chronic inflammation plays 
an important role in carcinogenesis,161 but the biological mechanisms that link Areca nut 
metabolites to immune cell activation, cytokine production, inflammation, and cancer remain 
underexplored and are the focus of this study.  
There are two types of inflammation – acute and chronic. The process of acute 
inflammation is a short-lived response that is commonly initiated by resident mast cells, dendritic 
cells, and monocytes/macrophages, and followed by the infiltration of polymorphonuclear 
leukocytes (PMN).162 Over time, usually 1 to 2 days, monocytes predominate and begin to 
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differentiate into macrophages, which then attract lymphocytes.162-163 Persistence of this process 
can lead to chronic inflammation and severe tissue damage. During chronic inflammation, there 
is an abundance of monocytes, macrophages, and lymphocytes, and a favorable environment for 
the release of pro-inflammatory cytokines164 and reactive oxygen species, which in turn 
facilitates an environment for the growth of cancer cells.165  
Despite some reports of anti-inflammatory effects of Areca nut extracts,166 there is a 
general consensus, driven by several scientific observations, that consumption of betel nut and 
betel quid leads to an increased risk of periodontal diseases, oral submucous fibrosis, and oral 
squamous cell carcinoma.152a, 153c, 157b, 167 The components in Areca nut may trigger immune 
responses to establish an inflammatory environment in the oral cavity that can initiate and/or 
contribute to these diseases. This was shown in a previous study in which the treatment of 
polymorphonuclear leukocytes with Areca nut extracts resulted in phosphorylation of p38 
mitogen-activated protein kinase (MAPK) and Ca2+ mobilization, resulting in the release of pro-
inflammatory lipid mediators such as leukotriene B4.54 However, it remains unclear what the 
source of calcium is and which leukocytes (neutrophils, basophils, eosinophils, mast cells) are 
responsive to the extracts. Furthermore, questions like whether Areca nut extracts activate other 
immune cells, including those found in the adaptive immune system, remain unanswered. In this 
study, we demonstrate that Areca nut extracts are capable of mobilizing Ca2+ in various cells of 
the innate and adaptive immune system (T lymphocytes, mast cells, and monocytes), which may 
cause chronic inflammation and play a potentially important role in oral diseases seen in betel 
quid chewers. 
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4.5 Calcium Regulation in Cells and Ca-Signaling Assay 
Cytosolic calcium is regulated by various pumps and receptors (Figure 39). Calcium 
efflux from the cytosol is caused by the actions of plasma membrane calcium ATPase (PMCA), 
sarco-endoplasmic reticulum calcium ATPase (SERCA), sodium-calcium exchanger, and 
mitochondrial uptake, whereas influx mechanisms include store operated calcium entry (SOCE) 
through the calcium channels in the plasma membrane, and release of calcium through the 
ryanodine receptor channel and the inositol 1,4,5-triphosphate (IP3) receptor channel across the 
endoplasmic reticulum membrane. The receptor operated calcium channels are known to be 
activated by metal cations and small molecules.168 
 
Figure 39. Calcium regulation mechanisms in cells. 
Image obtained from Pearson Education, Inc. (2012). 
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Cellular calcium concentration was measured using a fluorimetric assay depicted in 
Figure 40. A calcium indicator dye, Fura-2 acetoxymethyl ester (Fura-2 AM) 4.7 is introduced 
into the cell medium in a 96-well plate and incubated for 1 hour. The culture medium is then 
substituted for the standard Ringer’s solution with known calcium concentrations. A high 
throughput instrument (Hamamatsu FDSS 7000 EX) equipped with scientific camera detects 
[Ca2+] based on the ratio of fluorescence signals at 340 nm and 380 nm. In a typical assay, the 
basal levels of calcium are measured for 30 – 60 seconds before a stimulus of a control or an 
extract is introduced into the wells. A continuous measurement of the ratio of fluorescence 
signals at the two wavelengths generates calcium response curves as shown in the bottom left of 
Figure 40. Thapsigargin 4.8, a SERCA pump inhibitor originally isolated from Thapsia 
garganica L. (Apiaceae),169 is used as a positive control while ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (commonly abbreviated as EGTA and also known as 
egtazic acid) 4.9, an inhibitor of the store operated calcium entry across the plasma membrane, 
blocks the influx of Ca2+ in the cytosol. 
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Figure 40. Schematic representation of the Ca-signaling assay 
  
4.8 
(4.9) 
extracts 
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4.6 Ca-Signaling Activity from Components of Areca catechu 
Calcium mobilization in immune cells by areca nut extracts. To assess the Ca2+ 
mobilizing activity of the components of betel nut, we treated the rat mast cell line RBL-2H3 to 
extracts of the betel leaf, Areca nut and areca husk (Figure 41). Each component (kernel and 
husk) was extracted using a mixture of chloroform (CHCl3), methanol (MeOH) and water 
(12:5:3), a solvent system known to generate the highest mass of extracts from certain plant 
specimens.170 Areca nut extract (ANE) increased intracellular Ca2+ concentrations in RBL-2H3 
cells at 50 µg/mL (Figure 42a), while Areca husk and betel leaf extracts failed to induce any 
significant Ca2+ signals at the same concentrations (Figure 42b,c). This finding indicates that 
Areca catechu is indeed capable of mobilizing cytosolic calcium in immune cells and that the 
Ca2+-mobilizing components are localized in the Areca nut kernels. 
 
  
Figure 41. Betel leaf and Areca nut obtained from a local market 
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Figure 42. Calcium mobilization in RBL-2H3 cells by betel quid components. 
 
We then sought to optimize the extraction protocol of Areca nuts. Extracts of Areca 
nut obtained from acetone, dichloromethane, methanol, and ethanol were tested using the Ca-
signaling assay in the same cell line and the response was compared to the signals obtained from 
the use of a mixture of chloroform, methanol and water. While the ethanol and methanol extracts 
showed considerable Ca2+ signals, extracts obtained from acetone (2.5-fold increase in response) 
and methanol/chloroform/water mixture (2-fold increase in response) were more potent (Figure 
42d). The dichloromethane extract was inactive in the assay. Furthermore, extractions performed 
in acidic (pH 4), neutral (pH 7) and basic (pH 10) aqueous ethanolic solutions offered no 
improvement in Ca-signaling activity. Based on these findings, we used acetone as the standard 
solvent in the extraction protocol throughout the entire study. 
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Following the observations of calcium mobilization in immune cells by the whole 
extract of Areca catechu nut, we sought to identify the fractions or components responsible for 
the activity.  A liquid-liquid partitioning of the extract in chloroform and water, and subsequent 
tests on various immune cell lines, unequivocally demonstrated that the Ca-signaling activity of 
the Areca nut extract arises from the components present in the water soluble fraction. ANE and 
its aqueous fraction increased intracellular Ca2+ concentrations in the rat mast cell line RBL-2H3 
(Figure 43a), the human T lymphocyte line Jurkat (Figure 43b), the human monocyte line U937 
(Figure 43c), but not in the human neutrophil line HL-60 (Figure 43d). The lipophilic fraction, 
however, shows little to no effect on calcium concentrations in these cell lines. These data 
indicate that water soluble ANE components are capable of mobilizing Ca2+ in various important 
pro-inflammatory immune cell types. The lack of response from the HL-60 cells is a surprising 
observation which may suggest that these cells may lack the signaling mechanism responsible 
for the Ca2+ mobilization observed in human primary neutrophils.171 However, the selectivity 
may also suggest that the Ca-signaling activity is due to some specific mechanisms.  
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Figure 43. Ca-signaling responses generated by Areca catechu extracts in various immune cells. 
The following cell lines were used: (a) RBL-2H3, rat mast cells, (b) Jurkat, human T cells, (c) U937, human 
monocytes and (d) HL-60, human neutrophils. 
 
In order to identify the source of elevated calcium in the immune cells in the presence 
of Areca nut extracts, we applied the cells with the extracts dissolved in standard Ringer’s 
solution containing 2 mM Ca2+ or no calcium. Figure 43a shows that elevated levels of calcium 
are observed in the mast cell line RBL-2H3 treated under both conditions, suggesting that both 
intracellular release and entry of extracellular Ca2+ contribute to the ANE-induced calcium 
signal. The differences in the shapes of the Ca2+ signals observed under the two conditions 
a b 
c d 
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indicate that several mechanisms may be involved. Interestingly, the responses in Jurkat T 
lymphocytes and U937 monocytes appear to be caused primarily by influx mechanisms. 
Fractionation of Areca nut extract for identification of active components. In 
attempts to isolate the active component(s) responsible for Ca-signaling activity in immune cells, 
the aqueous fraction of the Areca nut extract was separated by reversed phase high performance 
liquid chromatography on a Phenomenex C18 Gemini column (Figure 44). Fractions were 
collected at regular time intervals (1.5 min) and each fraction was subjected to the fluorimetric 
Ca-assay.  
 
Figure 44. HPLC fractions of aqueous fraction of young Areca nut extract. 
Detection at 280 nm (UV); separation conditions are outlined in the experimental section. 
 
Various fractions showed Ca-mobilizing effects in the U937 (Figure 45a) and Jurkat 
(Figure 45b) cell lines but no activity in the HL-60 cell line, consistent with our previous 
observations. Activity from the fractions was observed primarily in three regions – fractions 14-
20, 22-28 and 31-32.    
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Figure 45. HPLC fractions of Areca nut extract show Ca-signaling in immune cells. 
 
Spectroscopic characterization of the active fractions, e.g. fraction 16, proved 
challenging, as high resolution mass spectrometry failed to generate readily discernible signals 
whereas 1H NMR spectra were very poorly resolved. Closer inspection of the signals in the 1H 
NMR spectra showed close resemblances, in terms of chemical shifts, to those observed from 
fraction 11, which lacked Ca-signaling activity in human immune cells but was identified as 
catechin 4.5 from its spectroscopic data. Distinct differences were seen in the δ 2-3 ppm region, 
indicating that the active component may have been formed after a chemical transformation at 
the 4 position of catechin (Figure 46).  
a 
b 
Cell line: U937 Monocytes 
Cell line: Jurkat T lymphocytes 
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Figure 46. Comparison of 1H NMR spectra of HPLC fractions 11 and 16 
 
The poor resolution in the 1H NMR signals of the active fractions may be attributed to 
a number of factors, such as, presence of paramagnetic impurities, multiple compounds with 
similar spectroscopic profile, or material that is highly oligomeric or polymeric. In the latter 
case, it would also mean the possibility of a presence of a complex mixture of components. 
Various ion exchange filtration experiments, aimed at removing paramagnetic impurities, did not 
afford improved resolution. The nature of the 1H NMR signals and the difficulty in obtaining 
discernible mass spectrometry signals by LC-ESIMS suggested that the fractions that mobilized 
H-2’, 5’, 6’ 
H-6, 8 
H-2 
H-3 H-4 
 84 
 
8
4 
Ca2+ in immune cells may be oligomeric or polymeric flavonoid in nature. Flavonoids 
polymerize primarily in two ways – an A-type linkage in which bonds are formed between C4 
and C8’ as well as between C2 and O7’, as shown in 4.10, or a more common B-type linkage 
between C4 and C8’ with α or β configuration, as present in 4.11 and 4.12, respectively (Figure 
47). B-type linkage between C4 and C6’ is also prevalent in some plant polyflavonoids. In 
absence of resolved NMR spectra, it is difficult to ascertain which linkages are present in the 
Areca polyflavonoids. Nonetheless, each linkage involves transformation at C4 of the flavonoid 
monomer, causing a downfield shift in the 1H NMR chemical shift of H-4. The absence of 
signals in the δ 2-3 ppm region of the 1H NMR spectra of the active fractions is likely tied to 
polymerization of these molecules.  
 
Figure 47. Different types of linkages in flavonoid oligomers and polymers 
 
To further explore the possibility of attributing the Ca-signaling activity to polymeric 
flavonoids, we turned to dialysis of the aqueous extract and the active fractions using cellulose 
membranes with nominal molecular weight cutoff (MWCO) values of 3,500 Da and 10,400 Da. 
Interestingly, the activity remained with the higher molecular weight fraction after each dialysis 
experiment (Figure 48). Basic hydrolysis or methylation of an active fraction resulted in loss of 
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all Ca-signaling activity, lending credence to our preliminary assessment that oligomeric or 
polymeric flavonoids may be responsible for elevated intracellular calcium in immune cells. The 
loss of activity from methylation suggests that the hydroxyl moieties may be essential for the 
pharmacological effects of the polymeric flavonoids, whereas, hydrolysis under basic conditions 
depolymerizes these molecules into monomers and lower order oligomers, which appear inactive 
in this assay.   
 
 
Figure 48. Ca-signaling responses in Jurkat T lymphocytes using dialyzed samples 
Key: The x-axis labels refer to the sample ID. 136-1: whole extract; 136-2: aqueous fraction; 136-3: chloroform 
fraction. 140-25 and 140-32 are active fractions obtained from HPLC (see Figure 44). 146-1 (MW<3500) and 146-2 
(MW>3500) are dialysis fractions of 140-25. 146-3 (MW<3500) and 146-4 (MW>3500) are dialysis fractions of 
140-32. 147-1 and 147-2 are organic and aqueous fractions obtained from hydrolysis of 144-2. Active fractions are 
highlighted in bold and red in the flowchart. 
 
Ca2+ signals are not caused by known small molecule Areca nut metabolites. 
While the results discussed thus far strongly hinted at oligomeric or polymeric flavonoids being 
the components responsible for Ca-mobilization in immune cells, we could not readily discount 
the possibility of an extremely active Areca nut metabolite being present in miniscule quantities. 
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To that end, we screened various commercially available Areca nut alkaloids, flavonoids and 
steroids to assess their ability to mobilize Ca2+ in RBL-2H3, Jurkat, U937, and HL-60 cells. 
Areca alkaloids are not known to mobilize Ca2+ in immune cells but arecoline and guvacoline 
have been reported as agonists of the muscarinic receptor172 and they could potentially exhibit 
signaling effects in cells that overexpress this receptor. Therefore, we tested these alkaloids and 
carbachol, a known agonist used as a positive control, against the RBL-2H3 mast cell 
overexpressing muscarinic acetylcholine receptor M1 (RBL-M1) as well.  Our results were 
consistent with the fact that Areca alkaloids are unlikely to exhibit Ca-signaling effects as none 
of the four alkaloids, when tested at 100 µM, led to any significant Ca2+ signals to appear in the 
four cell lines (Fig. 49). This excludes these alkaloids from being responsible for the Ca2+ 
elevation induced by the Areca nut extract. Furthermore, as expected, the RBL-M1 cells were 
responsive to 100 µM carbachol as well as arecoline and guvacoline, both of which are known 
agonists of muscarinic receptors (Fig. 49a). RBL-M1 also showed a small Ca2+ response when 
perfused with the chloroform extract. The response observed in the organic fraction is likely 
caused by arecoline, the most abundant Areca nut alkaloid, typically constituting 0.1-0.63% of 
the dry weight of the nut.173  
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Figure 49. Ca-signaling responses of Areca alkaloids on immune cell lines 
 
After eliminating the alkaloids as the constituents responsible for inducing the 
observed Ca2+ signals, we considered and tested other chemical constituents that have been 
identified in Areca nuts. Several commercially available flavonoids (catechin 4.5, quercetin 4.13, 
liquiritigenin 4.14, isorhamnetin 4.15), other phenolic metabolites (trans-resveratrol 4.16, ferulic 
acid 4.17, vanillic acid 4.18) and steroids (ergosterol peroxide 4.19, stigmast-4-en-3one 4.20, β-
sitosterol 4.21) were acquired for these purposes (Figure 50). 
a b 
c d 
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Figure 50. Some commercially available Areca nut metabolites 
 
None of these commercially available metabolites were observed to induce significant 
calcium signals at concentrations of 10 µM (Figure 51). Quercetin 4.13 showed a small biphasic 
change in Ca2+ response with a transient initial spike followed by a decrease (Figure 51b), 
consistent with previous reports that describe its ability to bind to ryanodine receptor in Jurkat 
cells and release Ca2+ from intracellular stores.174   
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Figure 51. Ca-signaling profiles from selected Areca nut metabolites in immune cells  
  
a b 
c d 
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4.7 Characterization, Purification and Activity of Polymeric Flavonoids 
The preponderance of evidence suggesting that proanthocyanidins (oligomeric and 
polymeric flavonoids; procyanidins belong to a subgroup with only catechin and epi-catechin as 
monomers) are responsible for the Ca-signaling effects in immune cells led us to work toward 
obtaining more specific structural information on the active component(s) present in Areca nut 
extract. Proanthocyanidins have been described in a litany of literature reports and they exist in 
various sizes, from dimers to higher order oligomers (n > 10). A study estimated the average 
molecular weight of the peracetate derivatives of proanthocyanidins derived from various plant 
sources to be in the 1600-5500 Da range.175 Lower order procyanidin oligomers (dimers and 
trimers) from various plant sources have been isolated, purified and characterized176 but there is 
little to no information on higher order polymers. In this context, the results from our dialysis 
experiments, which implied that the molecular weights of the active polyflavonoids isolated from 
Areca catechu may be higher than 10 kDa, were unusual because receptor-operated calcium 
channels are not known to be activated by large polymers. This could stem from two reasons, 
i.e., higher order polymers from Areca catechu have not been properly characterized or the 
dialysis membranes in our experiments have retained a majority of the components with 
molecular weights lower than the MWCO. Literature on dialysis membranes shows that MWCO 
is not a sharply defined value and more than 50% of molecules with molecular weights much 
smaller than the MWCO could be retained in the membranes.177 Consequently, dialysis 
experiments are not suitable gauges for estimation of molecular weights of components. 
Therefore, we sought to address the questions regarding the size of the molecules and the number 
of components present in the active sample by employing MALDI mass spectrometry and 
chromatographic methods. 
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 MALDI-MS of the dialyzed aqueous Areca extract fraction (RPN-3-145-2) retained 
in the dialysis membrane with MWCO of 10 kDa showed a cluster of signals at m/z values in the 
2900-3000 range (Figure 52). Many species present in this cluster appear to be singly charged 
and, therefore, have molecular weight values around 3 kDa. This suggests that the polymeric 
procyanidins comprise of approximately 10 monomer units (molecular weights of catechin and 
epi-catechin are 290 Da). However, there is also indication that other species may be triply 
charged (based on m/z spacing of 0.3 between peaks), which would imply that their molecular 
weights are in the neighborhood of 9 kDa. The latter value is a little surprising as it is not 
consistent with literature reports that describe quantification and estimation of various plant-
derived procyanidins.  
  
Figure 52. MALDI mass spectrum of Areca extract fraction retained in dialysis (MWCO: 10.4 
kDa) 
 
We turned to gel permeation (size exclusion) chromatography to provide additional 
evidence to corroborate the information obtained from MALDI-MS. Based on the size exclusion 
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chromatographic separation of protein standards and methyl cobalamin (Figure 53, top), the 
highest molecular weight of the earliest eluting component (Figure 53, bottom) in the dialyzed 
Areca extract sample (RPN-3-145-2) appeared to be approximately 3.1 kDa, which is in close 
agreement to the MALDI-MS data. The resolution, however, was pretty poor, indicating that 
these components may not be separated easily by gel permeation chromatography.    
  
Figure 53. Size exclusion chromatograms of standards (top) and Areca sample (bottom) 
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The most common method of chromatographic separation of procyanidin samples 
utilize the reversed phase solid support, however, normal phase HPLC has been found to be 
better suited at resolving higher oligomeric forms of procyanidins.178 Several studies have 
adopted this strategy in purifying procyanidin oligomers isolated from Areca catechu179 and 
other plant sources.180 We resorted to an identical approach in efforts to purify polymeric 
procyanidin components from the active dialyzed sample (RPN-3-145-2) for further biological 
evaluation. The active dialyzed sample appeared to be comprised primarily of polymers (> 10 
monomers) of flavonoids based on the analysis by Gu et al.180 (Figure 54). In Gu et al.’s and our 
chromatographic separations, the polymers eluted as a single peak after 54 min. Approximately 
700 µg of the polymeric sample was obtained from purification of 2 mg of the dialyzed fraction. 
 
Figure 54. Normal phase HPLC trace of dialyzed Areca extract fraction, detected at 280 nm 
 
The polymeric procyanidins purified from Areca nut extract (ANE opc) were unable 
to induce Ca-signals in the immune cells, whereas, commercially available oligomeric 
procyanidins isolated from grape seeds (GS opc) showed activity resembling those exhibited by 
the active Areca nut extracts (Figure 55a). Moreover, the activity from the grape seed 
procyanidin oligomers persists even after addition of EGTA, an inhibitor of SOCE, akin to how it 
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responds with the active Areca nut extracts (Figure 55b). These results show that Areca nut 
extracts have the same active components as oligomeric procyanidins obtained from grape seeds. 
Additionally, there were no discernible differences between the 1H NMR spectra of oligomeric 
procyanidins obtained from grape seeds and active Areca fractions. However, the inactivity of 
polymeric procyanidins obtained from purification of Areca extract is inconsistent, which may be 
a result of a few different scenarios. The amount of the polymers obtained from purification by 
HPLC may have been much less than 700 µg, due to errors in weighing sub-milligram quantities 
of material. Alternatively, lower order oligomers, which look to be present in the Areca extract 
(Figure 54, tR 21-23 min) but were not collected during the purification, may be responsible for 
the Ca-signaling activity. The possibility that the active oligomers may have polymerized over 
time, losing activity in the process, was considered but appears unlikely. Catechin, one of the two 
monomers of procyanidins, was not observed to polymerize in acetonitrile-water solutions (with 
or without 0.1% formic acid) when monitored by 1H NMR spectroscopy over a period of 10 
days. Overall, the results obtained from these studies indicate strong likelihood that procyanidin 
oligomers or polymers are responsible for Ca-mobilization in immune cells. Further work is 
necessary to identify the molecular structure of the active component. Specifically, the normal 
phase HPLC purification of the aqueous Areca extract and its dialyzed fraction on a larger scale 
to obtain appreciable quantities of purified flavonoid components, i.e. monomers, oligomers and 
polymers, for rigorous characterization and biological evaluation is crucial for the identification 
of the active component. MALDI-MS must be incorporated in the characterization methods for 
an accurate assessment of the molecular weights of the components. Additionally, access to 
commercially available natural or synthetic standards of oligomers and polymers would support 
the findings from our experiments. 
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Figure 55. Ca-signaling activity from Areca nut extracts and commercially obtained grape seed 
oligomeric procyanidins 
4.8 Conclusions and Outlook 
Areca nut extracts are capable of mobilizing intracellular calcium in immune cell 
lines and may be responsible for inflammation-mediated carcinogenesis in oral cancers. 
Preliminary research suggests that oligomeric or polymeric procyanidins may be responsible for 
the Ca-signaling observed in these cells. Further purification and isolation of oligomeric and 
polymeric procyanidins is necessary to unambiguously identify the specific active component(s) 
present in Areca catechu. Dr. Reinhold Penner and Dr. Malika Faouzi, the lead collaborators, are 
also conducting various studies to determine the mechanism of action triggered by these 
components to induce Ca-signaling activity.   
 
  
b a 
 96 
 
9
6 
CHAPTER 5 
Isolation of Known Natural Products from Other Organisms 
Bioactivity-guided isolation of active natural products may not come to fruition very 
often because of several reasons. Firstly, an extract may contain compounds that are ineffective 
against the target of a particular assay but could show biological effects in other assays. These 
extracts would be considered inactive but in reality they may not have been screened against the 
most suitable targets, in most cases due to lack of access. Secondly, an organism may produce a 
biologically active natural product but in such small quantities that it is very difficult to isolate 
enough for full characterization of the molecule. Lack of availability of enough biomass of the 
organism producing an active natural product may also lead to similar issues. This is a chronic 
problem faced by many natural product researchers. Sometimes, an active natural product may 
be unstable in the laboratory settings and could decompose during the course of the investigation 
because of its exposure to solvents, acids and bases that could cause chemical transformations. 
Likewise, a lack of a robust screening method would lead to conflicting biological assessment 
due to inherent variations associated with the screening method. For example, in cell-based 
assays that have not been previously optimized, it is difficult to get uniformity in the behavior of 
the cells across various replications.  In many instances of these unsuccessful ventures, natural 
product researchers resort to spectroscopy-guided isolation of natural products. Very often, this 
simply leads to re-isolation of known natural products. Some of those examples are discussed 
briefly in this chapter, organized by the producing organism. 
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5.1 Sponge 12-Maui-38 
12-Maui-38, a very hollow lavender/pink sponge (Figure 56a) tentatively identified as 
Callyspongia sp., was collected from a depth of 28 feet off Black Rock Point in Maui 
(Coordinates: 20°55'35.85" N; 156°41'49.40" W) on July 12, 2012. Lyophilization of the sample 
resulted in 1 g of dry biomass.  
  
Figure 56. Photographs of (a) 12-Maui-38 and (b) 13-Maui-75, sponges collected from Black 
Rock Point, Maui 
 
The 75% methanol fraction obtained from the solid phase extraction of the crude 
extract of 12-Maui-38 showed significant inhibition (88%) of BACE1 in the chemiluminescent 
assay. Purification by HPLC led to the isolation and characterization of callyspongynic acid181 
5.1 (Figure 57).  
 
 
Figure 57. Structure of callyspongynic acid 
b a 
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Callyspongynic acid was originally isolated from Callyspongia truncate Lindgren 
(Callyspongiidae), which was collected off the Kii Peninsula, 450 km west of Tokyo. It displayed 
potent selective inhibition of α–glucosidase but was inactive against β–glucosidase and β-
galactosidase.181  
In this study, callyspongynic acid was evaluated for activity against BACE1 
following its full structural characterization and, surprisingly, was found to be inactive in the 
chemiluminescent assay. Further examination revealed degradation of the compound into 
unknown components. This led to a repeat collection trip to Maui. 13-Maui-75 was collected 
from the same location and identified as the same sponge (Figure 56b). Work on this specimen, 
which was carried out by Dr. Stephen Parrish, led to the isolation of callyspongynic acid and its 
decarboxy analogue.142 Callyspongynic acid displayed 96% inhibition of BACE1 at 64 µM but 
no IC50 value was obtained because of the discontinuation of the assay kit by the commercial 
vendor, as stated in Chapter 3. Callyspongynic acid was cytotoxic to Panc-1 cells, with a CC50 
value of 15 µM.142 
5.2 Sponges 13-Maui-52 and 14-Maui-05 
An assay plate containing extracts of various organisms collected from Maui in 2013 
was screened against the vascular permeability assay run by our collaborators, as described in 
section 1.6. The extracts in the following wells (A5, B9, C4 and F10) exhibited reduced 
permeability relative to the DMSO control (Figure 58). The extracts were identified as follows: 
A5 – isopropanol fraction of the extract of the algae 13-Maui-01; B9 – isopropanol fraction of 
the extract of the sponge 13-Maui-52; C4 – isopropanol fraction of the extract of the algae 13-
Maui-08; F10 – 75% methanol fraction of the extract of the sponge 13-Maui-04. 
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Figure 58. Inhibition of vascular permeability by various extracts 
 
Attempts to isolate inhibitors of vascular permeability from these extracts were 
unsuccessful primarily because of two reasons – the activity data from the assay was inconsistent 
with noticeable fluctuations even when the same sample was run multiple times and in some 
instances, chromatograms from HPLC separations were also inconsistent. The latter could be 
because of operator error or other chromatographic issues. Furthermore, the bioassay portion of 
the project was carried out by multiple users and there was lack of consistency in the results 
obtained by different users. Cell-based assays generally need careful optimizations and 
consistent handling, and it is not ideal for the assay to be run by different users over short periods 
of time. Moreover, there was no obvious way to validate the assay because a positive control was 
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not available. Typically, assays are validated based on their z-factors, which depend on the mean 
and standard deviation values of readings obtained from the positive and negative controls. 
Nonetheless, two sponge samples were investigated further and their extracts were 
purified by HPLC. 13-Maui-52 (Figure 59a) is an undescribed cave sponge species of the genus 
Myrmekioderma, which was collected at a depth of 40-60 feet near the second cathedral dive site 
off the south shore of Lana‘i (coordinates: 20°44'05.0" N, 156°55'25.7" W). 14-Maui-05 (Figure 
59b) was a re-collection sample of the sponge 13-Maui-04, which was taken from a depth of 10 
feet near the Ulua beach dive site in Maui and identified as Hyrtios sp. 
 
Figure 59. Photographs of (a) 13-Maui-52 and (b) 14-Maui-05, sponges collected from Maui 
county 
 
β-Sitosterol 4.18, a ubiquitous sterol found in many plants and sponges, was isolated 
from the sponge 13-Maui-52 and psammaplysin A 5.2, a tetrabrominated alkaloid originally 
discovered from the Palauan sponge Psammaplysilla purpurea Carter (Pseudoceratinidae),182 
was isolated from the sponge 14-Maui-05 (Figure 60). Additionally, other sterol derivatives were 
identified from 13-Maui-52 by Dr. Stephen Parrish.142  
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Figure 60. β-sitosterol and psammaplysin A 
 
5.3 Cyanobacterium CN-16-1 
CN-16-1 is a cyanobacterial strain, obtained from the Patterson collection, which was 
originally collected from the Western Caroline Islands in Palau and identified as Hapalosiphon 
sp. Extracts of CN-16-1 were tested against BACE1 in our in-house chemiluminescent assay and 
determined to be inactive. Further purification of the hexanes and the dichloromethane fractions 
(obtained from modified Kupchan partitioning) led to the isolation of Fischerellin A183 5.3, 
Fischerellin B184 5.4 and loliolide185 5.5 (Figure 61). Fischerellin A, which has antifungal and 
herbicidal properties, and Fischerellin B, an algicidal natural product, were isolated from the 
cyanobacterium Fischerella muscicola (Thuret) Gomont (Hapalosiphonaceae). Loliolide is an 
ant repellent186 originally isolated from the English ryegrass Lolium perenne L. (Poaceae). 
 
Figure 61. Compounds isolated from the cyanobacterium CN-16-1 
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5.4 Fungus Isolated from the HCC1088 Culture 
Previously, we showed that the compounds 3.6-3.9 were not produced by the fungus 
present in the culture of the cyanobacterium HCC1088. Extraction of the fungal cell mass from 
an axenic culture and subsequent separation by HPLC yielded several compounds, including 5.6 
(Figure 62). Compound 5.6 was isolated from the fungi Penicillium brevicompactum Dierckx 
(Trichocomaceae)187 and Penicillium citrinum Thom (Trichocomaceae)188 and reported to exhibit 
anti-juvenile hormone activity.187a Preliminary 1H NMR and LCMS analyses suggest that some 
of the other compounds in the extract are structurally related to 5.6 and have molecular weight 
values in the same vicinity. For example, one of the compounds with molecular weight that is 34 
units higher than that of 5.6 may have been produced by dihydroxylation of the olefin in the 
hydrocarbon chain of 5.6. The elucidation of these compounds is in progress. Work is also 
underway toward obtaining a taxonomic identification of this fungal strain. 
 
 
Figure 62. A metabolite isolated from the culture of a fungus separated from HCC1088 culture 
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CHAPTER 6 
Conclusions and Significance 
Chemical investigations of several organisms toward the discovery of biologically 
active secondary metabolites led to the isolation of several known and new natural products. 
Nine known sesquiterpene quinones and hydroquinones 2.3 – 2.11 isolated from the sponge 
Dactylospongia elegans showed strong to moderate cytotoxicity against the human glioma 
(U251MG) cancer cell line. Additionally, four of these compounds exhibited moderate 
cytotoxicity against the human pancreatic carcinoma (Panc-1) cell line. Furthermore, 
ilimaquinone and smenospongine displayed moderate inhibition of BACE1, an enzyme 
implicated in the pathogenesis of the Alzheimer’s disease. The significance of these findings is 
that they represent new reports of biological activity of the known compounds against previously 
untested targets. A new 11-membered heterocycle, kauamide 2.12, was also isolated from the 
sponge extract. Literature reports of isolation of structurally similar metabolites from 
cyanobacteria of the genus Moorea, however, suggest that kauamide is in most likelihood 
biosynthesized by a cyanobacterium. Regardless, the discovery of kauamide illustrates the 
potential in the discovery of new natural products from the marine environment. 
Investigation of the extract from the broth of the culture of an as yet unidentified 
cyanobacterium (HCC1088) led to the isolation of four new molecules 3.6 – 3.9. Compound 3.7 
was identified in the early stages of the investigation as a probable BACE1 inhibitor. However, 
due to discontinuation of the assay kit by the commercial vendors, further biological assessment 
of the compound against the BACE1 target has not been completed yet. Early suggestions that 
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compounds 3.6, 3.8 and 3.9 may be produced by the cyanobacterium in defense against fungal 
invasion remain unverified but experiments to determine the legitimacy of these indications are 
ongoing. Nonetheless, the finding that these compounds may be produced by the cyanobacterium 
and released into the growth medium is in itself unusual, as there are not many accounts of the 
isolation of cyanobacterial metabolites from the culture broth. Isolation of compounds with rare 
functional groups and structural features from the culture broth of HCC1088 show that the 
cyanobacterial culture medium may be an untapped source for the discovery of novel classes of 
polar natural products.   
Mobilization of intracellular calcium by the extracts of Areca catechu in immune cell 
lines (Jurkat, U937, RBL-2H3) has been attributed to the presence of oligomeric or polymeric 
flavonoids found in the nuts of the plant. Furthermore, the extracts of grape seeds and other plant 
specimens (not described in this dissertation) showed similar mobilization of intracellular 
calcium in immune cells. While the identity of the specific component(s) responsible for this 
activity may be revealed by future experiments, the current findings may provide a breakthrough 
in our quest to gain important insights into the role of Areca catechu in oral diseases, including 
inflammation and cancer. Further investigations are necessary before we can reach firm 
conclusions but these discoveries are significant in that they may demonstrate the ability of the 
ubiquitous flavonoids to activate pathways in humans that have not yet been described. 
Finally, prediction of 1H and 13C NMR chemical shifts by density functional theory 
computation has been demonstrated to be a viable strategy for the determination of the planar 
structure and the relative configuration of new molecules. This is an especially advantageous 
approach in the structure elucidation of molecules isolated in very low yields because, unlike 
conventional methods, it does not require irreversible chemical modifications.  
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CHAPTER 7 
Experimental Section 
7.1 General Experimental Procedures 
General experimental procedures. Optical rotations were measured on a JASCO 
DIP-370 polarimeter at 589 nm using a sample cell of path length 0.1 dm. UV spectra were 
obtained on a Varian Cary 50 Bio UV-Visible spectrophotometer. IR spectra of the compounds, 
as thin films on CaF2 discs, were recorded using a Shimadzu IRAffinity-1 Fourier Transform 
spectrophotometer. NMR spectra were acquired on a Varian Inova 500 MHz spectrometer 
operating at 500 (1H) or 125 (13C) MHz using the residual solvent signals as internal references 
(CD3OD δH 3.30, δC 49.0; DMSO-d6 δH 2.50, δC 39.5; CDCl3 δH 7.26, δC 77.0). Samples were 
placed in 3-mm Shigemi NMR tubes as necessary. HRMS data were obtained from Agilent 6210 
LC/TOF and Agilent 6545 LC/QTOF instruments using electrospray ionization in positive and 
negative modes. ESIMS data were also obtained using Agilent 6410 QQQ instrument. Samples 
were purified using a combination of chromatographic techniques, including high performance 
liquid chromatography. Purity of the compounds was assessed from their UV absorptions at 
appropriate wavelengths, or from their 1H NMR spectra. Percent yields of natural products were 
based on the amount of freeze-dried biological material or crude extract from the culture broth. 
Chemicals and reagents. Assays were performed according to manufacturer's 
instructions. The BACE1 assay kit was purchased from DiscoveRx. ACS grade solvents were 
distilled and filtered before use. HP-20 resin, flash column stationary phases, and HPLC columns 
were purchased from Supelco, Sorbent Technologies, and Phenomenex, respectively. The amine 
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hydrochloride precursor 3.17 was obtained from Enamine Limited and used as received. 
Mosher’s acid chlorides (R and S), sodium borohydride, cerium(III) chloride heptahydrate, and 
other chemical reagents were obtained from Sigma-Aldrich and Acros, and used as received. 
BACE1 assay. The HitHunter BACE1 enzyme fragment complementation 
chemiluminescence assay was purchased from DiscoveRx.  The proteolytic cleavage of amyloid 
precursor protein was assayed as described by Naqvi.63 Test compounds were solubilized in 
DMSO at the desired concentration and incubated with the enzyme in triplicates for 16 h in 96-
well plates. A DMSO control (1.5 μL) and an inhibitor standard (β-secretase inhibitor IV from 
Calbiochem used as a positive control) were also tested in triplicates. The chemiluminescence 
signal was read using a Fluostar Optima spectrophotometer. Data were analyzed using GraphPad 
Prism. BACE1 activity was calculated as a percent of the positive control using a nonlinear 
regression analysis function that corresponded to a best one-fit model. 
Cytotoxicity assays. Human glioblastoma (U251MG) cell lines were maintained in 
RPMI 1640 Medium (Gibco, REF: 11875-093) supplemented with 10% premium fetal bovine 
serum (Atlanta biological, Cat. No.: S11150) and 100 U/mL penicillin and 100 µg/mL 
streptomycin (Gibco, REF: 15140-122). A day prior to treatment, cancer cells were seeded at 
4,000 cells per well into a 96-well tissue culture plate. Twenty hours post seeding, the serially 
diluted compounds were added to the cells for the cytotoxicity assay, and co-incubated with 5% 
CO2 at 37 
oC for 72 h. Then the medium with compounds were replaced with 1 × dye binding 
solution prepared according to the manufacturer’s instruction (CyQuant NF Cell Proliferation 
Assay Kit [C35006, Invitrogen]) and incubated with 5% CO2 at 37 
oC for 60 minutes. After that, 
cell viability data were collected with a PerkinElmer Multimode Plate Reader according to the 
manufacturer’s instruction. CC50 curves were generated using GraphPad Prism 5. 
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Human pancreatic carcinoma (Panc-1) cell lines were maintained in DMEM media 
supplemented with 10% premium fetal bovine serum and 50 U/mL penicillin and 50 µg/mL 
streptomycin. One day before treatment, cancer cells were seeded at 5,000 cells per well into a 
96-well tissue culture plate. Twenty four hours post seeding, the serially diluted compounds were 
added to the cells for the cytotoxicity assay, and incubated at 37 oC with 5% CO2 for 72 h. Then 
40 µL MTS dye (CellTiter aqueous One Solution Cell Proliferation Assay) was added to each 
well and incubated with 5% CO2 at 37 
oC for 90 minutes. Cell viability data were collected with 
a Modulus Microplate Reader and CC50 curves were generated using GraphPad Prism 5. 
NMR shift computations. Conformers within 5 kcal/mol of the lowest energy 
conformer were searched using the Monte Carlo multiple minimum (MCMM) method and the 
OPLS-2005 force field in MacroModel (Schrodinger Inc.). Each conformer within 5 kcal/mol of 
the lowest energy conformer was optimized in Gaussian09189 at the M06-2X/6-31+G level and 
the geometries of all conformers with similar energies were checked for redundancy. NMR 
shielding tensors of all unique conformers within the energy window were computed using the 
gauge-independent atomic orbital (GIAO) method at the B3LYP/6-311+G level and 1H and 13C 
chemical shifts were obtained after applying appropriate scaling factors (1H: intercept = 31.9477, 
slope = -1.0767; 13C: intercept = 181.2412, slope = -1.0522). Statistical comparisons of the 
computed shifts with the experimental data were carried out using the applet provided by 
Goodman97 and the spreadsheet provided by Sarotti136. 
Computations of ECD and optical rotation. Density functional theory (DFT) was 
used to perform calculations, which were carried out in Gaussian 09.189 All ground-state 
geometries were optimized at the B3LYP/6-31+G level. The same DFT level was employed to 
evaluate the effects of solvation in methanol using the SCRF/PCM method.190 TDDFT191 
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calculations at the B3LYP/6-31+G and the B3LYP/aug-cc-pVDZ levels were conducted to 
calculate the electronic excitation energies and rotational strengths in methanol. 
7.2 Extraction and Isolation of Metabolites from Dactylospongia elegans 
Biological material. A specimen of the sponge Dactylospongia elegans (Sample ID: 
10-Kauai-08) was collected from a depth of 40 feet at the Sheraton Caverns, Kauai by SCUBA 
diving on June 09, 2010. The sponge was fouled green in its natural habitat and exuded red 
solution in the collection bag. Recollection of the same sponge (Sample ID: 11-Kauai-80) from 
the same location on May 29, 2011 was confirmed upon comparison of collection details, sample 
description and pictures, and LC-MS profiles of their crude extracts. The biological material was 
freeze-dried and stored in a freezer prior to extraction. A voucher sample of 10-Kauai-08 was 
preserved in aqueous alcohol and deposited with Mary Kay Harper (University of Utah) for 
taxonomic identification. 
Extraction and isolation of metabolites from Dactylospongia elegans. The freeze-
dried sponge sample (40 g) was extracted three times in a 1:1 mixture of methanol and 
dichloromethane to yield 6.82 g of crude extract, which was then partitioned with hexanes, 
dichloromethane, butanol and aqueous methanol.  
The fraction obtained from the partition with hexanes (1.32 g) was subjected to solid 
phase extraction on C8 support, in which the extracts were eluted sequentially with an increasing 
concentration of methanol in water, followed by isopropanol. The extract obtained from the 
elution with methanol (0.45 g) was divided into six fractions by Flash chromatography (Silica, 
250 x 50 mm, eluted in the following order: 0:10, 1:9, 2:8, 3:7, 10:0 mixtures of ethyl acetate to 
hexanes, and isopropanol.) The second fraction (52 mg) was purified by RP-HPLC (Phenomenex 
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Luna C18, 150 x 4.6 mm, 5 μm particle size, 100 Å; eluted with MeCN/H2O at 0.7 mL/min 
using a gradient of 70% to 100% MeCN over 20 min followed by a wash with MeCN for 10 
min) to afford kauamide (2.12, tR 16.0 min, 2.0 mg, 0.005 % yield, >95% purity by 
1H NMR). 
The third fraction (110 mg) was purified by RP-HPLC (Phenomenex Luna C18, 250 x 10 mm, 5 
μm particle size, 100 Å; eluted with MeCN/H2O at 2.5 mL/min using the following gradient: 
70% to 90% MeCN over 15 min, held at that composition for 10 min, then increased to 100% 
MeCN over 5 min and washed with MeCN for an additional 15 min) to afford dictyoceratin C 
(2.11, tR 26.7 min, 3.5 mg, 0.009 % yield, >90% purity by 
1H NMR), dictyoceratin B (2.10, tR 
29.3 min, 4.0 mg, 0.01 % yield, >99% purity at 272 nm), smenospongorine (2.6, tR 38.0 min, 3.5 
mg, 0.009 % yield, >99% purity at 313 nm) and smenospongiarine (2.7, tR 41.3 min, 5.5 mg, 
0.014 % yield, 99% purity at 313 nm). The fifth fraction (27 mg) obtained from the Flash 
chromatographic separation was subjected to an identical purification scheme to afford 
dictyoceratin A (2.9, tR 24.1 min, 4.5 mg, 0.011 % yield, >99% purity at 260 nm). 
The fraction obtained from partition with dichloromethane (0.98 g) was also 
subjected to solid phase extraction on C8 support, in which the extracts were eluted sequentially 
with an increasing concentration of methanol in water, followed by isopropanol. The extract 
obtained from the elution with 75% methanol (0.28 g) was purified by RP-HPLC (Phenomenex 
Luna C18, 150 x 4.6 mm, 5 μm particle size, 100 Å; eluted with MeCN/H2O at 2.5 mL/min 
using a gradient of 90% to 100% MeCN over 25 min followed by a wash with MeCN for 10 
min) to afford 5-epi-ilimaquinone (2.4, tR 20.1 min, 10.0 mg, 0.025 % yield, 78% purity by 
1H 
NMR), ilimaquinone  (2.3, tR 21.7 min, 98.0 mg, 0.245 % yield, >99% purity at 310 nm), 
smenospongine (2.5, tR 22.5 min, 3.5 mg, 0.009 % yield, 95% purity at 310 nm) and 
smenospongidine (2.8, tR 29.8 min, 6.5 mg, 0.016 % yield, >99% purity at 310 nm). 
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Synthesis of smenospongidine 2.8 from ilimaquinone 2.3. This protocol was 
adapted from Ling et al.103 To a solution of 13 mg (36 μmol, 1 equiv.) of ilimaquinone 2.3 in 6.5 
mL methanol in a round bottomed flask were added a solution of 1.3 mL methanol containing 7 
μL (54 μmol, 1.5 equiv.) of phenethylamine, followed by 6 mg NaHCO3. The contents of the 
flask were stirred for 10 h at 40 oC.  After cooling the purple-colored reaction mixture to room 
temperature, a few drops of 1N HCl were added to slightly acidify the solution, which turned 
red. The solvent was removed in vacuo and the crude mixture was dissolved in 4 mL tert-butyl 
methyl ether and extracted with 4 mL of water. The organic layer was separated and after 
removal of solvent in vacuo, 16.3 mg of a crude red solid was obtained. Purification by HPLC 
(Silica, 250 x 10 mm, 3.0 mL/min flow, elution with ethyl acetate/hexanes using the following 
gradient: 15% – 30% ethyl acetate over 15 min, held at that composition for 10 min, followed by 
a wash with ethyl acetate for an additional 10 min) afforded synthetic smenospongidine (2.8, tR 
11.7 min, 8.6 mg, 52.8 % yield, >95% purity by 1H NMR) and smenospongidinimine (2.24, tR 
31.0 min, 5.3 mg, 26.7 % yield, >95% purity by 1H NMR). 
Hydrolysis of kauamide 2.12 and advanced Marfey’s analysis. A solution of 200 
μg (0.6 μmol, 1 equiv.) of kauamide 2.12 in 0.5 mL 6N HCl in a capped reaction vial was stirred 
for 24 h at 110 oC. Solvent was removed by streaming N2 (g) over the reaction mixture and the 
residue was analyzed by ESIMS in negative mode to confirm the presence of signals at m/z 247 
and 249. To the dried hydrolysate in the vial were added a solution of 500 μg (1.6 μmol, 2.7 
equiv.) 1-fluoro-2,4-dinitrophenyl-5-L-leucinamide (L-FDLA) in acetone (160 μL), H2O (100 
μL) and 1N solution of NaHCO3 (50 μL). The contents in the vial were warmed to 40 
oC for 1 h, 
cooled to room temperature, and analyzed by LC-MS (EclipsePlus C18 column, 2.1 x 50 mm, 
1.8 µm particle size; eluted with acetonitrile and water (+0.1% formic acid in each) at 0.4 
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mL/min flow using the following gradient: 20-50% acetonitrile (0-10 min), 50-100% acetonitrile 
(10-12 min), 100% acetonitrile (12-16 min); detection at 340 nm). The LC-MS data was 
compared to the data obtained from similar protocols on the standard amino acids DL-N-
methylleucine and L-N-methylleucine, which were obtained from the amino acid standards 
collection in the Williams laboratory. The retention times for the LL-adduct and the DL-adduct 
were 9.2 min and 10.3 min, respectively. 
Ilimaquinone 2.3: yellow, crystalline solid; [𝛼]𝐷
22 -25 (c 1.12, CHCl3); UVs 
(CH3OH) λmax (log ε) 286 (4.21), 214 (4.06) nm; 
1H NMR (CDCl3, 500 MHz) δ 5.84 (1H, s), 
4.44 (1H, brs), 4.42 (1H, brs), 3.86 (3H, s), 2.53 (1H, d, J = 13.7 Hz), 2.46 (1H, d, J = 13.7 Hz), 
2.31 (1H, tdt, J = 13.8, 5.5, 1.8 Hz), 2.11-2.04 (2H, m), 1.86 (1H, m), 1.52-1.28 (5H, m), 1.20-
1.10 (2H, m), 1.03 (3H, s), 0.97 (3H, d, J = 6.4 Hz), 0.84 (3H, s), 0.75 (1H, dd, J = 11.9, 2.2 Hz) 
ppm; 13C NMR (CDCl3, 125 MHz) δ 182.3, 182.0, 161.7, 160.5, 153.3, 117.3, 102.5, 102.0, 56.9, 
50.1, 43.3, 40.4, 38.0, 36.6, 32.9, 32.3, 28.6, 27.9, 23.1, 20.5, 17.8, 17.4 ppm; HRESIMS m/z 
359.2206 [M+H]+ (calcd for C22H31O4, 359.2217); HREIMS m/z 358.2128 (calcd for C22H30O4, 
358.2144).  All spectroscopic data were consistent with literature reports.80b, 82-83 (Notebook ID: 
RPN-2-56-1 and RPN-2-100-1) 
5-epi-Ilimaquinone 2.4: yellow, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 
5.87 (1H, s), 4.70 (1H, brs), 4.67 (1H, brs), 3.88 (3H, s), 2.59 (1H, d, J = 13.7 Hz), 2.49 (1H, d, J 
= 13.7 Hz), 2.46-2.40 (1H, m), 2.17-2.08 (2H, m), 2.03-1.99 (1H, m), 1.90-1.72 (2H, m), 1.22-
1.06 (4H, m), 1.05 (3H, s), 0.94 (3H, d, J = 6.3 Hz), 0.88 (3H, s) ppm; HRESIMS m/z 359.2211 
[M+H]+ (calcd for C22H30O4, 359.2217). 
1H NMR data were consistent with literature reports.83 
(Notebook ID: RPN-2-88-7 and RPN-2-91-1) 
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Smenospongine 2.5: red, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 5.64 (1H, 
s), 4.46 (1H, brs), 4.45 (1H, brs), 2.51 (1H, d, J = 13.9 Hz), 2.42 (1H, d, J = 13.9 Hz), 2.34 (1H, 
td, J = 13.8, 5.5 Hz), 2.13-2.06 (2H, m), 1.86 (1H, m), 1.54-1.35 (5H, m), 1.21-1.15 (2H, m), 
1.06 (3H, s), 0.98 (3H, d, J = 6.4 Hz), 0.88 (3H, s), 0.79 (1H, dd, J = 11.9, 2.2 Hz) ppm; 
HRESIMS m/z 344.2210 [M+H]+ (calcd for C21H30NO3, 344.2226). 
1H NMR data were 
consistent with literature reports.82-83 (Notebook ID: RPN-2-91-2) 
Smenospongorine 2.6: red, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 6.52 
(1H, brs), 5.36 (1H, s), 4.44 (1H, brs), 4.43 (1H, brs), 2.98 (2H, t, J = 6.5 Hz),  2.48 (1H, d, J = 
13.8 Hz), 2.40 (1H, d, J = 13.8 Hz), 2.40-2.28 (2H, m), 2.12-1.82 (7H, m), 1.46-1.32 (2H, m), 
1.04 (3H, s), 0.99 (3H, d, J = 6.7 Hz),  0.98 (3H, d, J = 6.7 Hz), 0.97 (3H, d, J = 6.4 Hz), 0.83 
(3H, s), 0.78 (1H, dd, J = 11.8, 2.0 Hz) ppm; 13C NMR (CDCl3, 125 MHz) δ 182.8, 178.0, 160.5, 
157.3, 150.3, 113.5, 102.5, 91.5, 49.8, 42.9, 41.2, 40.4, 37.8, 36.8, 36.6, 33.0, 32.4, 28.6, 27.9, 
25.9, 23.2, 22.3, 20.5, 17.9, 17.3 ppm; HRESIMS m/z 400.2851 [M+H]+ (calcd for C25H38NO3, 
400.2846). All data were consistent with literature reports.82 (Notebook ID: RPN-3-25-3) 
Smenospongiarine 2.7: red, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 6.42 
(1H, brs), 5.38 (1H, s), 4.46 (1H, brs), 4.45 (1H, brs), 3.18 (2H, td, J = 6.7, 6.5 Hz),  2.49 (1H, d, 
J = 13.9 Hz), 2.41 (1H, d, J = 14.0 Hz), 2.34 (1H, td, J = 13.8, 5.5 Hz), 2.13-2.06 (3H, m), 1.87 
(1H, m), 1.78-1.12 (9H, m), 1.06 (3H, s), 0.99-0.93 (9H, overlapping d, d, d), 0.84 (3H, s), 0.79 
(1H, dd, J = 11.8, 2.0 Hz) ppm; 13C NMR (CDCl3, 125 MHz) δ 182.8, 178.0, 160.5, 157.2, 
150.3, 113.4, 102.5, 91.4, 49.8, 42.9, 41.2, 40.4, 37.8, 36.8, 36.6, 33.0, 32.4, 28.6, 27.9, 25.9, 
23.2, 22.4, 22.3, 20.5, 17.9, 17.4 ppm; HRESIMS m/z 414.2999 [M+H]+ (calcd for C26H40NO3, 
414.3003). All spectroscopic data were consistent with literature reports.82-83 (Notebook ID: 
RPN-2-89-2) 
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Smenospongidine 2.8: red, amorphous solid; [𝛼]𝐷
22 +125 (c 0.1, CHCl3); UVs 
(CH3OH) λmax (log ε) 488 (2.91), 323 (4.04), 248 (3.65) nm; IR (CaF2 disc) νmax 3269, 2922, 
1642, 1589 and 1581 cm-1; 1H NMR (CDCl3, 500 MHz) δ 8.35 (1H, brs), 7.33 (2H, t, J = 7.3 
Hz), 7.26 (1H, m), 7.18 (2H, d, J = 7.0 Hz), 6.47 (1H, brs), 5.40 (1H, s), 4.45 (1H, brs), 4.44 
(1H, brs), 3.42 (2H, q, J = 6.8 Hz),  2.95 (2H, t, J = 7.0 Hz), 2.49 (1H, d, J = 14.0 Hz), 2.39 (1H, 
d, J = 14.0 Hz), 2.32 (1H, m), 2.08 (1H, m), 2.06 (1H, m), 1.83 (1H, m), 1.51 (1H, m), 1.43 (1H, 
m), 1.38 (2H, m), 1.35 (1H, m), 1.18 (1H, m), 1.11 (1H, m), 1.06 (3H, s), 0.97 (3H, d, J = 6.5 
Hz), 0.84 (3H, s), 0.77 (1H, dd, J = 11.9, 2.0 Hz) ppm; 13C NMR (CDCl3, 125 MHz) δ 182.7, 
178.2, 160.5, 157.0, 150.0, 137.4, 128.9, 128.6, 127.0, 113.6, 102.5, 91.8, 49.8, 44.0, 42.9, 40.4, 
37.8, 36.6, 34.2, 33.0, 32.4, 28.6, 27.9, 23.2, 20.5, 17.9, 17.3 ppm; HRESIMS m/z 448.2846 
[M+H]+ (calcd for C29H38NO3, 448.2846). (Notebook ID: RPN-2-91-5 and RPN-2-99-1) 
Dictyoceratin A 2.9: white, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 7.50 
(1H, d, J = 1.9 Hz), 7.39 (1H, d, J = 1.9 Hz), 6.56 (1H, brs), 5.98 (1H, brs), 4.41 (1H, brs), 4.36 
(1H, brs), 3.86 (3H, s), 2.68 (1H, d, J = 14.3 Hz), 2.65 (1H, d, J = 14.4 Hz), 2.34 (1H, td, J = 
13.8, 5.3 Hz), 2.09 (2H, m), 1.92 (1H, m), 1.57 (1H, qd, J = 13.2, 3.3 Hz), 1.50-1.19 (6H, m), 
1.06 (3H, s), 1.03 (3H, d, J = 6.4 Hz), 0.95 (1H, dd, J = 12.1, 1.7 Hz), 0.87 (3H, s) ppm; 13C 
NMR (CDCl3, 125 MHz) δ 167.6, 160.1, 148.7, 142.3, 127.3, 125.1, 120.3, 113.9, 102.7, 52.0, 
48.0, 42.1, 40.2, 36.9, 36.5, 36.3, 33.0, 27.8, 27.7, 23.1, 20.6, 17.6, 17.6 ppm; HRESIMS m/z 
373.2375 [M+H]+ (calcd for C23H33O4, 373.2373). All spectroscopic data were consistent with 
literature reports.84 (Notebook ID: RPN-3-30-1) 
Dictyoceratin B 2.10: white, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 10.71 
(1H, brs), 7.14 (1H, s), 5.87 (1H, brs), 5.42 (1H, brs), 4.42 (1H, dd, J = 1.8, 1.8 Hz), 4.38 (1H, 
brs), 3.90 (3H, s), 2.60 (1H, d, J = 14.3 Hz), 2.57 (1H, d, J = 14.4 Hz), 2.34 (1H, td, J = 13.9, 5.4 
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Hz), 2.08 (2H, m), 1.90 (1H, m), 1.59-1.50 (1H, m), 1.47 (1H, dt, J = 12.4, 3.2 Hz), 1.42-1.20 
(5H, m), 1.06 (3H, s), 1.00 (3H, d, J = 6.4 Hz), 0.94 (1H, dd, J = 11.9, 2.1 Hz), 0.84 (3H, s) ppm; 
13C NMR (CDCl3, 125 MHz) δ 170.6, 160.2, 148.9, 147.0, 130.3, 124.6, 117.1, 104.4, 102.7, 
52.0, 47.8, 41.8, 40.1, 36.6, 36.2, 36.2, 33.1, 27.8, 27.7, 23.0, 20.6, 17.6, 17.5 ppm; HRESIMS 
m/z 411.2142 [M+Na]+ (calcd for C23H32O5Na, 411.2142). All spectroscopic data were consistent 
with literature reports.84 (Notebook ID: RPN-3-25-2) 
Dictyoceratin C 2.11: white, amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 7.76 
(2H, m), 6.73 (1H, d, J = 9.0 Hz), 5.22 (1H, brs), 4.41 (1H, dd, J = 1.8, 1.8 Hz), 4.36 (1H, brs), 
3.86 (3H, s), 2.67 (1H, d, J = 14.5 Hz), 2.62 (1H, d, J = 14.3 Hz), 2.34 (1H, td, J = 13.6, 5.4 Hz), 
2.08 (2H, m), 1.93 (1H, m), 1.59-1.17 (7H, m), 1.06 (3H, s), 1.03 (3H, d, J = 6.5 Hz), 0.95 (1H, 
dd, J = 12.0, 2.0 Hz), 0.88 (3H, s) ppm; HRESIMS m/z 357.2423 [M+H]+ (calcd for C23H33O3, 
357.2424). 1H NMR data was consistent with literature reports.85b (Notebook ID: RPN-3-25-1) 
(3S,6S,11S,9E)-9-(chloromethylene)-3-isobutyl-4,6-dimethyl-11-propyl-1-oxa-4-
azacycloundecane-2,5-dione (kauamide) 2.12: white, amorphous solid; [𝛼]𝐷
22 +20 (c 0.1, 
CHCl3); UVs (CH3OH) λmax (log ε) 201 (4.08) nm; IR (CaF2 disc) νmax 2958, 2927, 2870, 1734, 
1653 and 1641 cm-1; 1H NMR (CDCl3, 500 MHz) and 
13C NMR (CDCl3, 125 MHz) see Table 1; 
HRESIMS m/z 358.2140 [M+H]+ (calcd for C19H33ClNO3, 358.2143). (Notebook ID: RPN-2-89-
1 and RPN-3-7-1) 
Smenospongidinimine 2.24: blue, amorphous solid; [𝛼]𝐷
22 +126 (c 0.1, CHCl3); UVs 
(CH3OH) λmax (log ε) 354 (4.33), 254 (3.91) nm; IR (CaF2 disc) νmax 3185, 2923, 2857, 1635 and 
1591 cm-1; 1H NMR (CDCl3, 500 MHz) δ 8.40 (2H, brs), 7.32 (4H, t, J = 7.7 Hz), 7.25 (2H, m), 
7.18 (4H, d, J = 7.9 Hz), 4.79 (1H, s), 4.44 (1H, brs), 4.43 (1H, brs), 3.51 (4H, t, J = 7.3 Hz),  
2.95 (4H, t, J = 7.3 Hz), 2.45 (1H, d, J = 13.8 Hz), 2.40 (1H, d, J = 13.7 Hz), 2.32 (2H, m), 2.05 
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(1H, m), 1.83 (1H, m), 1.50 (1H, m), 1.42-1.10 (6H, m), 1.04 (3H, s), 1.03 (3H, d, J = 6.7 Hz), 
0.88 (1H, dd, J = 11.8, 2.2 Hz), 0.80 (3H, s) ppm; 13C NMR (CDCl3, 125 MHz) δ 171.2, 161.8, 
156.6, 137.2, 129.0, 128.6, 127.1, 109.1, 101.6, 80.1, 49.7, 44.6, 42.6, 40.5, 37.8, 37.0, 34.8, 
33.4, 33.2, 29.0, 28.1, 23.4, 20.7, 18.1, 17.4 ppm; HRESIMS m/z 551.3635 [M+H]+ (calcd for 
C37H47N2O2, 551.3632). (Notebook ID: RPN-2-99-3) 
 
7.3 Extraction and Purification of Metabolites from HCC1088 Nostoc sp. 
Biological material. HCC1088 (Nostoc sp.), originally a part of the Mitsui-Miami 
collection (Mitsui 102201), was obtained from the cyanobacterial collection housed at the 
University of Hawaii at Manoa. The strain was cultured in twelve 20 L carboys containing 18 L 
BG-11 media with MOPS buffer, under continuous illumination and aeration (no CO2 added; 3-4 
L air/min; without shaking) for 4 weeks. HCC1088 was also cultured in flasks containing 1 L or 
4 L of BG-11 media with MOPS buffer but lacking sodium nitrate. Cultures in nitrate absent 
media were not aerated and grown for 2 – 6 months.  
16S rRNA gene sequencing. About 100 mg of cell mass was pre-treated with 10 mM 
Tris.HCl, 0.1 M EDTA, 0.5% SDS, 10 μg/mL RNase A and 1 mg/mL lysozyme for 30 min at 37 
oC. Genomic DNA was extracted from the cells and cleaned up using MoBio’s PowerPlant DNA 
Isolation Kit. The 16S rRNA gene was PCR amplified by the primer pair 27F/1492R, and the 
amplicon was purified using QiaQuick column. The purified PCR products were sequenced 
using ABI3730XL with four primers (27F, 533R, 981R and 1492R). The sequences were then 
assembled to a full 16S rRNA gene using DNAStar SeqMan. 
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16S rRNA gene sequence of HCC1088. ACGGTGTCTTAGGACATAGTGGCGGACGGGTGAGTAACGCGTg 
AgAATCTGGCTTCAGGTCGGGGACAACCATTGGAAACGGTGGCTAATACCGGATATGCCGAGAGGTGA
AAGATTTATTGCCTGAAGATGAGCTCGCGTCTGATTAGCTAGTTGGGAGTGTAAGAGACTACCAAGGC
GACGATCAGTAGCTGGTCTGAGAGGATGATCAGCCACACTGGGACTGAGACACGGCCCAGACTCCTA
CGGGAGGCAGCAGTGGGGAATTTTCCGCAATGGGCGAAAGCCTGACGGAGCAATACCGCGTGAGGGA
GGAAGGCTCTTGGGTTGTAAACCTCTTTTCTCAAGGAAGAAAAAAATGACGGTACTTGAGGAATAAGC
ATCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGATGCAAGCGTTATCCGGAATGATTGGGC
GTAAAGCGTCCGCAGGTGGCTGTGAAAGTCTGCTGTTAAAGAGTGAGGCTCAACCTCATAAGAGCAGT
GGAAACTACACGGCTAGAGTGCGTTCGGGGTAGAGGGAATTCCTGGTGTAGCGGTGAAATGCGTAGA
TATCAGGAAGAACACCGGTGGCGAAGGCGCTCTACTAGGCCGCAACTGACACTGAGGGACGAAAGCT
AGGGGAGCGAATGGGATTAGATACCCCAGTAGTCCTAGCCGTAAACGATGGATACTAGGCGTGGCTT
GTATCGACCCGAGCCGTGCCGTAGCTAACGCGTTAAGTATCCCGCCTGGGGAGTACGCACGCAAGTGT
GAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGTATGTGGTTTAATTCGATGCAACGC
GAAGAACCTTACCAAGACTTGACATGTCGCGAATCTGCCTGAAAGGGGAGAGTGCCTTCGGGAGCGC
GAACACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGC
GCAACCCTCGTTTTTAGTTGCCAGCATTAAGTTGGGCACTCTAAAGAGACTGCCGGTGACAAACCGGA
GGAAGGTGGGGATGACGTCAAGTCAGCATGCCCCTTACGTCTTGGGCTACACACGTACTACAATGCTA
CGGACAAAGGGCAGCTACACAGCGATGTGATGCAAATCTCAGAAACCGTAGCTCAGTTCAGATCGCA
GGCTGCAACTCGCCTGCGTGAAGGAGGAATCGCTAGTAATTGCAGGTCAGCATACTGCAGTGAATTCG
TTCCCGGKCCTTGTACACACCGCCCGTCACACCATGGAAGCTGGCAACGCCCGAAGTCATTACTCCAA
C 
 
Phylogenetic tree. The tree with the highest log likelihood (-3158.6529) is shown in 
Figure 26 (Section 3.2). The percentage of trees in which the associated taxa clustered together is 
shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by 
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using 
the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with 
superior log likelihood value. A discrete Gamma distribution was used to model evolutionary rate 
differences among sites (5 categories (+G, parameter = 0.6264)). The rate variation model 
allowed for some sites to be evolutionarily invariable ([+I], 70.1785% sites). The tree is drawn to 
scale, with branch lengths measured in the number of substitutions per site. The analysis 
involved 92 nucleotide sequences. All positions containing gaps and missing data were 
eliminated. Evolutionary analyses were conducted in MEGA7.192 
Extraction and isolation of metabolites from the culture broth of HCC1088. 
Upon termination of aeration in the culture vessels, HP-20 resin (1g/L) was added to the culture 
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broth and allowed to sit overnight. The resin was then separated from the culture broth by 
filtration and soaked in CH3OH (5 mL/g resin; extracted once; shaken on a mechanical shaker) 
for 1 h. Filtration and removal of solvent in vacuo generated the crude media extract. A 
concentrated solution of 198 mg crude media extract in methanol was filtered using a Whatman 
syringe filter and purified by RP HPLC (Phenomenex Luna C18, 250 x 10 mm, 5 μm particle 
size, 100 Å; eluted with H2O/CH3OH at 2.75 mL/min using the following gradient: 35% CH3OH 
for 5 min, increased to 50% CH3OH over the next 30 min and to 100% CH3OH over the 
subsequent 5 min, washed with 100% CH3OH for 20 min.) The compounds 3.8 (tR 24.4 min, 0.8 
mg, 0.4% yield, > 95% purity by LC-UV detection at 280 nm), (3-formylindole 3.10 (tR 26.8 
min, 3.5 mg, 1.8 % yield, ~75% purity by 1H NMR), 3.7 (tR 36.9 min, 0.9 mg, 0.5 % yield, ~90% 
purity by 1H NMR), 3-cyanoindole 3.11 (tR 41.7 min, 2.1 mg, 1.1 % yield, ~85% purity by 
1H 
NMR), 3.9 (tR 44.2 min, 0.8 mg, 0.4% yield, > 90% purity by 
1H NMR),  and 3.6 (tR 45.8 min, 
21.2 mg, 10.7% yield, > 95% purity by LC-UV detection at 230 nm) were isolated and 
characterized. 
Compound 3.6: pale yellow, crystalline solid; [𝛼]𝐷
21 +15 (c 0.2, CH3OH); UVs 
(CH3OH) λmax (log ε) 304 (4.26), 235 (4.11), 204 (4.18) nm; ECD (c 0.1, CH3OH) λmax (Δε) 304 
(+90.7), 345 (-50.5) nm; IR (CaF2 disc) νmax 3303, 3210 and 1678 cm
-1; 1H NMR (CD3OD, 500 
MHz) δ 7.69 (1H, dt, J = 8.2, 1.1 Hz), 7.46 (1H, dt, J = 8.4, 1.0 Hz), 7.37 (1H, ddd, J = 8.3, 7.1, 
1.2 Hz), 7.14 (1H, ddd, J = 8.1, 7.1, 1.1 Hz), 4.67 (1H, dd, J = 6.3, 2.8 Hz), 3.62 (1H, dd, J = 
16.4, 6.3 Hz), 2.83 (1H, dd, J = 16.4, 2.8 Hz) ppm; 1H (DMSO-d6, 500 MHz) and 
13C NMR 
(DMSO-d6, 125 MHz), Table 5; HRESIMS m/z 210.0525 [M+Na]
+ (calcd for C11H9NO2Na, 
210.0531). (Notebook ID: RPN-1-38-1 and RPN-1-41-4) 
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Synthesis of compound 3.7. To 15 mg (71 μmol) of 3.17 in a reaction vial, under N2 
atmosphere, were added 2 drops of pyridine, 10 μL acetic anhydride, and 1 mL dry CH2Cl2. The 
mixture was stirred at room temperature for 1 h. An additional 1 mL of CH2Cl2 was added to the 
vial and the contents were washed with 2 mL sat. NaHCO3 and 2 mL brine. The resultant organic 
layer was dried over anhydrous MgSO4. Upon removal of the solvent using a stream of N2 (g), 
15.7 mg of crude product was obtained, 85% of which was purified by RP HPLC (Phenomenex 
Luna C18, 250 x 10 mm, 5 μm particle size, 100 Å; eluted with H2O/CH3CN at 3.0 mL/min using 
the following gradient: 10-60% CH3CN over 10 min, maintained an isocratic 60% CH3CN  
composition for the next 5 min, increased to 100% CH3CN over the next 5 min, and washed at 
100% CH3CN for 10 min) to obtain compound 3.7 (tR 11.0 min, 12.0 mg, 55 μmol, 92% yield) as 
white, crystalline needles. 
Compound 3.7: white amorphous solid; 1H (CDCl3, 500 MHz) and 
13C NMR 
(CDCl3, 125 MHz), Table 6; HRESIMS m/z 239.0782 [M+Na]
+ (calcd for C12H12N2O2Na, 
239.0791). Compound 3.7 (synthetic): white crystalline needles; UVs (CH3OH) λmax (log ε) 272 
(4.23), 266 (4.24), 204 (4.19) nm; IR (CaF2 disc) νmax  3273, 3085, 1659, 1645, 1564 cm
-1; 1H 
NMR (CDCl3, 500 MHz) δ 7.62 (2H, d, J = 7.3 Hz), 7.43 (2H, t, J = 7.6 Hz), 7.35 (1H, t, J = 7.4 
Hz), 7.26 (1H, s), 6.87 (1H, brs), 4.66 (2H, d, J = 5.5 Hz), 2.11 (3H, s) ppm and 13C NMR 
(CDCl3, 125 MHz) δ 170.3, 160.2, 151.9, 128.8, 128.5, 127.4, 124.1, 121.4, 36.9, 22.9 ppm; 
HRESIMS m/z 217.0979 [M+H]+ (calcd for C12H13N2O2, 217.0972). (Notebook ID: RPN-1-88-1 
and RPN-3-123-1) 
Synthesis of compound 3.7-F3. To 15 mg (71 μmol) of 3.17 in a reaction vial, under 
N2 atmosphere, were added 2 drops of pyridine, 20 μL trifluoroacetic anhydride, and 1 mL dry 
CH2Cl2. The mixture was stirred at room temperature for 1 h. An additional 1 mL of CH2Cl2 was 
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added to the vial and the contents were washed with 2 mL sat. NaHCO3 and 2 mL brine. The 
resultant organic layer was dried over anhydrous MgSO4. Upon removal of the solvent in vacuo, 
16.6 mg of crude yellow oily residue was obtained. The residue was purified by RP HPLC 
(Phenomenex Luna C18, 250 x 10 mm, 5 μm particle size, 100 Å; eluted with H2O/CH3CN 
containing 0.1% formic acid at 2.75 mL/min using the following gradient: 10-100% CH3CN over 
18 min, and washed at 100% CH3CN for 12 min) to obtain compound 3.7-F3 (tR 17.5 min, 3.3 
mg, 12 μmol, 17% yield) as an off-white powder. Majority of the starting material remained 
unreacted, presumably due to degradation of the trifluoroacetic anhydride reagent, which was not 
purified prior to use. Reaction was not optimized because 3.7-F3 was obtained in sufficient 
quantity for various experiments. 
Compound 3.7-F3: off-white powder; 
1H NMR (CDCl3, 500 MHz) δ 7.61 (2H, dd, J 
= 7.1, 1.2 Hz), 7.43 (2H, t, J = 7.0 Hz), 7.43 (1H, brs), 7.36 (1H, t, J = 7.3 Hz), 7.28 (1H, s), 4.73 
(2H, d, J = 5.2 Hz) ppm and 13C NMR (CDCl3, 125 MHz) δ 157.8, 157.3 (q, J = 37.0 Hz), 152.7, 
129.0, 128.9, 127.2, 124.3, 121.7, 115.7 (q, J = 287.2 Hz), 37.1 ppm; HRESIMS m/z 271.0687 
[M+H]+ (calcd for C12H10F3N2O2, 271.0689). (Notebook ID: RPN-4-7-5) 
Compound 3.8: white amorphous solid; 1H (CD3OD, 500 MHz) and 
13C NMR 
(CD3OD, 125 MHz), Table 7; HRESIMS m/z 328.1184 [M+H]
+ (calcd for C18H18NO5, 
328.1180). Other spectroscopic data were not acquired due to degradation of the compound. 
(Notebook ID: RPN-1-57-1 and RPN-1-79-1) 
Compound 3.9: yellow amorphous solid; 1H (CD3OD, 500 MHz) and 
13C NMR 
(CD3OD, 125 MHz), Table 8; HRESIMS m/z 310.1062 [M+H]
+ (calcd for C18H16NO4, 
310.1074). Other spectroscopic data were not acquired due to degradation of the compound. 
(Notebook ID: RPN-1-57-5) 
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3-Formylindole 3.10: white amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 9.90 
(1H, s), 8.17 (1H, d, J = 7.3 Hz), 8.11 (1H, s), 7.49 (1H, d, J = 7.9 Hz), 7.29 (1H, td, J = 7.2, 1.4 
Hz), 7.25 (1H, td, J = 7.4, 1.1 Hz) ppm; ESIMS m/z 146.2 [M+H]+; 1H NMR data was consistent 
with literature reports.123 (Notebook ID: RPN-1-86-1) 
3-Cyanoindole 3.11: white amorphous solid; 1H NMR (CD3OD, 500 MHz) δ 7.94 
(1H, s), 7.64 (1H, d, J = 7.7 Hz), 7.51 (1H, d, J = 8.1 Hz), 7.28 (1H, td, J = 7.1, 1.4 Hz), 7.24 
(1H, td, J = 7.1, 1.1 Hz) ppm; 13C NMR (CD3OD, 125 MHz) δ 137.0, 134.5, 128.5, 124.7, 122.9, 
119.6, 117.3, 113.6, 86.2 ppm; ESIMS m/z 143.2 [M+H]+; 1H and 13C NMR data was consistent 
with literature reports.124 (Notebook ID: RPN-1-89-1) 
Reaction of compound 3.6 with MTPA-Cl. To a solution of 1.5 mg (8.0 μmol) of 
compound 3.6 in 0.5 mL dry CH2Cl2 in a reaction vial were added 50 μL (0.62 mmol) pyridine, 
and 20 μL (0.11 mmol) (R)-(-)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride. The reaction 
vial was capped and its contents were shaken and allowed to sit overnight. A 20 μL (0.16 mmol) 
aliquot of 3-(N,N-dimethylamino)-propylamine was added to the reaction vial and the mixture 
was allowed to sit for 10 min. Addition of 1 mL tert-butyl methyl ether and 1 mL water was 
followed by separation of the organic and aqueous layers. The aqueous layer was extracted again 
with 1 mL tert-butyl methyl ether and the combined organic layers were washed with 1 mL 1N 
HCl, 1 mL sat. NaHCO3 and 1 mL brine, in succession. The resultant organic layer was dried 
over anhydrous MgSO4 and the solvent removed in vacuo to afford the (S)-ester 3.12 (2.3 mg, 
5.7 μmol, 71 % yield). The (R)-ester 3.13 (1.8 mg, 4.5 μmol, 56 % yield) was produced in a 
similar fashion using (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride instead of the 
(R)-derivatizing reagent. [Note the configuration changes because of CIP priority rules.] 
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Compound 3.12: white amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 9.17 (NH, 
brs), 7.70-7.64 (3H, m), 7.48-7.39 (5H, m), 7.21 (1H, ddd, J = 8.0, 6.5, 1.5 Hz), 6.02 (1H, dd, J = 
6.6, 2.8 Hz), 3.75 (1H, dd, J = 16.6, 6.6 Hz), 3.70 (3H, s), 2.98 (1H, dd, J = 16.6, 2.8 Hz) ppm; 
ESIMS m/z 426.2 [M+Na]+ (Notebook ID: RPN-1-58-1) 
Compound 3.13: white amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 9.21 (NH, 
brs), 7.71-7.65 (3H, m), 7.48-7.41 (5H, m), 7.22 (1H, ddd, J = 8.0, 5.7, 2.3 Hz), 5.88 (1H, dd, J = 
6.6, 3.0 Hz), 3.77 (1H, dd, J = 16.5, 6.7 Hz), 3.63 (3H, s), 3.17 (1H, dd, J = 16.5, 3.0 Hz) ppm; 
ESIMS m/z 426.2 [M+Na]+ (Notebook ID: RPN-1-58-2) 
Reduction of compounds 3.12 and 3.13. To 1 mg (2.5 μmol) of 3.12 in a reaction 
vial were added 1 mL CH3CN and 1 mg (2.7 μmol) CeCl3.7H2O and the mixture cooled in an ice 
bath. Three small portions of NaBH4, 1 mg (26.4 μmol) in total, were added to the vial and the 
reaction mixture was stirred for 15 min at 0oC. The vial was removed from the ice bath and the 
contents stirred for another 15 min before the reaction was quenched by addition of 2 drops of 
1N HCl. After addition of 1 mL H2O, two 1 mL portions of tert-butyl methyl ether were used to 
extract the organic product. The combined organic layers were washed with 1 mL sat. NaHCO3 
solution and 1 mL sat. NaCl solution, and dried over anhydrous Na2SO4. Solvent was removed in 
vacuo to afford compound 3.14, which, by 1H NMR analysis, appeared as a single diastereomer 
amidst other impurities. Following RP HPLC (Phenomenex Luna C18, 150 x 4.6 mm, 5 μm 
particle size, 100 Å pore size; eluted with H2O/CH3CN at 0.7 mL/min using a linear gradient of 
10%-100% CH3CN over 8 min and at 100% CH3CN for the next 7 min) of the mixture, the 
single diastereomer of 3.14 (tR 11.8 min, 0.5 mg, 1.2 μmol, 50% yield) was isolated. Compound 
3.13 was reduced and purified in a similar fashion to yield the single diastereomer of compound 
3.15 (tR 11.9 min, 0.4 mg, 1.0 μmol, 40% yield). 
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Compound 3.14: white amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 8.12 (NH, 
brs), 7.59-7.55 (2H, m), 7.47 (1H, d, J = 7.7 Hz), 7.45-7.41 (3H, m), 7.37 (1H, d, J = 8.3 Hz), 
7.21 (1H, ddd, J = 8.3, 7.1, 1.2 Hz), 7.12 (1H, ddd, J = 8.1, 7.1, 1.2 Hz), 5.65 (1H, ddd, J = 7.9, 
4.8, 3.3 Hz), 5.40 (1H, m), 3.59 (3H, s), 3.57 (1H, ddd, J = 15.2, 7.8, 1.3 Hz), 3.16 (OH, brs), 
2.89 (1H, dd, J = 15.2, 4.7 Hz) ppm; ESIMS m/z 428.2 [M+Na]+ (Notebook ID: RPN-1-68-1) 
Compound 3.15: white amorphous solid; 1H NMR (CDCl3, 500 MHz) δ 8.10 (NH, 
brs), 7.58-7.54 (2H, m), 7.47 (1H, d, J = 7.7 Hz), 7.45-7.41 (3H, m), 7.36 (1H, d, J = 8.2 Hz), 
7.20 (1H, m), 7.12 (1H, m), 5.68 (1H, ddd, J = 7.7, 4.5, 3.1 Hz), 5.32 (1H, m), 3.59 (3H, s), 3.59 
(1H, ddd, J = 15.1, 7.7, 1.3 Hz), 3.18 (OH, brs), 2.94 (1H, dd, J = 15.2, 4.6 Hz) ppm; ESIMS m/z 
428.2 [M+Na]+ (Notebook ID: RPN-1-69-2) 
Preparation of agar plates for growth of fungal culture. A solution of Hutner’s 
trace elements was prepared by mixing 80 mL of a solution containing 1.00 g iron(II) sulfate 
heptahydrate and 10.00 g EDTA with 80 mL of a solution containing 4.40 g zinc(II) sulfate 
heptahydrate, 2.20 g boric acid, 1.00 g manganese(II) chloride tetrahydrate, 0.32 g cobalt(II) 
chloride hexahydrate, 0.32 g copper(II) sulfate pentahydrate and 0.22 g ammonium molybdate 
tetrahydrate. The Hutner’s solution was diluted to 200 mL and the final pH adjusted to 6.5 with 
the addition of aqueous solution of potassium hydroxide. In a 2L Erlenmeyer flask were added 
6.00 g sodium nitrate, 0.52 g potassium chloride, 0.52 g magnesium sulfate heptahydrate, 1.52 g 
potassium phosphate (monobasic), 10.00 g dextrose, 15.00 g Difco agar and suspended in 1 L 
water. The mixture in the Erlenmeyer flask was treated in an autoclave following the addition of 
1 mL solution of Hutner’s trace elements. Upon completion of the autoclave procedure, 50 mg of 
chloramphenicol was added to the flask containing the agar medium. Immediately after 
dissolution of the antibiotic, media was poured on to 40 agar plates, which were allowed to cool 
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overnight in a laminar flow hood, sealed to prevent exposure to the atmosphere and stored at 2 – 
8 oC until further use. 
Isolation and growth of fungal culture. Cyanobacterial-fungal cell conjugates from 
an HCC1088 culture were streaked on an agar plate using an inoculating loop. The colonies were 
allowed to grow over 5 days, after which they were inoculated again on a new agar plate. After 4 
days of growth on the new agar plate, the contents of the plate (agar medium and the fungal cell 
colonies) were transferred into a 4 L Erlenmeyer flask containing 2 L of minimal medium with 
50 mg/L chloramphenicol. The minimal medium for fungal growth was prepared using the same 
ratios of agar medium nutrients (vide supra) except for Difco agar. The fungal culture was 
allowed to grow for 1 month, after which it was harvested for extraction.  
Extraction of fungal metabolites. The biomass was filtered and extracted three 
times with 350 mL ethyl acetate each. Removal of solvent in vacuo afforded 735 mg of the cell 
extract. The culture broth filtrate was also extracted three times with 400 mL ethyl acetate each, 
and the removal of solvent yielded 215 mg of the media extract.  
 
7.4 Extraction and Purification of Metabolites from Areca catechu 
Biological material. Young Areca catechu nuts and Piper betle leaves were obtained 
from a local convenience store in Honolulu. The areca nuts were cut into halves, scooped out of 
the husks, and freeze-dried for storage. Other variants of the nuts were obtained as ground dried 
powder from Guam.    
Cell cultures. Jurkat, U937 and HL-60 cell lines were maintained in RPMI 1640 
medium (Clontech) supplemented with 10% fetal bovine serum (FBS). RBL-2H3 cells (WT and 
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M1) were cultured in DMEM medium (Clontech) with 10% fetal bovine serum (FBS). All cells 
were cultured at 37 °C, 5% CO2, and 95% humidity. 
Fura-2AM based calcium bioassay. The effect of various extracts and chemicals 
was assessed using a high-throughput kinetic plate reader instrument (Hamamatsu FDSS-
7000EX). Cells that grow in suspension (Jurkat, U937 and HL-60) were incubated with the 
loading medium for one hour then plated in 96-well plates at a density of 100,000 cells/well 
before measurement. Adherent cells RBL-2H3 (WT and M1) were pre-plated overnight at a 
density of 60,000 cells/well, and then loaded in the same way. The loading medium is composed 
of the culture medium supplemented with 2 mM Probenecid, 0.1 % Pluronic and 2 µM Fura-2-
AM. Bath solutions contained in mM: 140 NaCl, 0 or 2 CaCl2, 2 MgCl2, 10 glucose, and 10 
Hepes (pH 7.2 with NaOH). Stock solutions of extracts and all the tested chemicals were 
prepared in DMSO. DMSO control was then included in all experiments to monitor the solvent 
effect. 
Preliminary extractions. Chopped young, wet Areca catechu nuts (~ 10 g each) 
were extracted three times (25 mL each) in acetone, dichloromethane, methanol, ethanol and a 
mixture of chloroform, methanol and water (12:5:3). Solvent was removed in vacuo, affording 
1.623 g, 0.132 g, 1.560 g, 1.719 g and 1.656 g of crude extract, respectively. The crude extracts 
were dissolved in 6 mL of aqueous methanol (1:1) and partitioned three times (6 mL each) with 
chloroform. Upon removal of solvent, aqueous and chloroform fractions of each crude extract 
were obtained. Based on Ca-mobilizing activity data of crude extracts and their fractions in three 
different cell lines (Jurkat, U937 and RBL-2H3), acetone was chosen as the optimal solvent for 
further extractions. 
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Areca nut husks (~ 20 g) and Piper betle leaves (~ 4 g) were also extracted three 
times (25 mL each) in a mixture of chloroform, methanol and water (12:5:3). Solvent was 
removed from the combined extracts to afford 0.276 g and 0.352 g of crude husk extract and 
crude leaf extract, respectively. 
Variable pH extractions. Aqueous solutions of pH 4.0, 7.0 and 10.0 were prepared 
using hydrochloric acid and sodium carbonate. In three separate flasks, 3.0 g each of lyophilized 
Areca nuts were mixed with 20 mL solutions at the three pH levels. The flasks were stirred 
overnight using a mechanical shaker. To each flask, 60 mL ethanol was added and sonicated for 
30 min. The extract was filtered and the nut residue was extracted two additional times using the 
same protocol. The combined extract was evaporated to a third of the volume using a rotary 
evaporator, and then partitioned four times between chloroform and water. Solvent was removed 
from each fraction to obtain lipophilic and hydrophilic extracts. 
Extraction and fractionation of Areca catechu nuts. Lyophilized Areca catechu 
nuts (21.0 g) were extracted in acetone three times (400 mL each) and solvent was removed from 
the combined extract in vacuo, affording 3.051 g of crude extract. The crude extract was 
dissolved in water (50 mL), partitioned three times (50 mL each) with chloroform, and the 
solvent evaporated, affording 2.445 g of aqueous extract and 0.459 g of chloroform extract. A 
portion of the aqueous extract (0.700 g) was dissolved in 2.5 mL of a mixture of acetonitrile and 
water (15:85), filtered using a Whatman syringe filter (0.45 micron), and fractionated using RP 
HPLC (Phenomenex Gemini C18, 250 x 21.2 mm, 5 μm particle size, 110 Å; eluted with water 
and acetonitrile (each with 0.1% formic acid) at 12.4 mL/min using the following gradient: 15% 
CH3CN (0-10 min), 15-20% CH3CN (10-15 min), 20% CH3CN (15-25 min), 20-30% CH3CN 
(25-30 min), 30% CH3CN (30-40 min), 30-50% CH3CN (40-45 min), 50% CH3CN (45-50 min), 
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50-100% CH3CN (50-55 min) and washed with 100% CH3CN for additional 15 min.) The first 
40 fractions were collected at 1.5 min intervals and solvent was removed using a centrifugal 
concentrator. Fraction 11 contained catechin (4.5, tR 16 min, 110 mg, 1.8% yield, > 90% purity 
by 1H NMR). 
Catechin 4.5: white powder; 1H NMR (CD3OD, 500 MHz) δ 6.83 (1H, d, J = 1.9 
Hz), 6.76 (1H, d, J = 8.2 Hz), 6.71 (1H, dd, J = 8.2, 2.0 Hz), 5.92 (1H, d, J = 2.3 Hz), 5.85 (1H, 
d, J = 2.3 Hz), 4.56 (1H, d, J = 7.5 Hz), 3.97 (1H, td, J = 7.9, 5.4 Hz), 2.84 (1H, dd, J = 16.2, 5.5 
Hz), 2.50 (1H, dd, J = 16.1, 8.2 Hz) ppm; HRESIMS m/z 291.0864 [M+H]+ (calcd for C15H15O6, 
291.0869). (Notebook ID: RPN-3-107-6, RPN-3-113-11 and RPN-3-140-11) 
Dialysis of extracts and fractions. Samples were dissolved in water and loaded onto 
cellulose dialysis tubing, manufactured by either Fisherbrand (19 mm x 12.1 mm; nominal 
molecular weight cutoff 3.5 kDa) or Sigma Aldrich (43 mm x 27 mm; molecular weight cutoff 
10.4 kDa). The dialysis tubing loaded with sample was placed in a chamber filled with distilled 
water, and stirred on a shaker. Water was replaced in the outer chamber every 12 h for a total of 
four times and the solvents were removed from the solutions in the dialysis tubing and the outer 
chamber to afford fractions of higher and lower molecular weights. 
MALDI-MS analysis of dialyzed aqueous extract. A 1.0 mg sample of dialyzed 
aqueous extract (RPN-3-145-2) was dissolved in 1 mL 50:50 LCMS grade MeCN:H2O. A 10 µL 
aliquot of the solution was mixed with 10 µL aliquot of 50:50 LCMS grade containing 0.1% 
trifluoroacetic acid. A 1 µL aliquot of this solution was spotted on the MALDI plate, followed by 
1 µL of matrix solution (α-cyano-4-hydroxycinnamic acid or 2,5-dihydroxybenzoic acid). 
MALDI-MS was performed on the Bruker Ultra Flex III using Flex Control v. 3.4. 
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Hydrolysis of dialyzed aqueous extract. A 36 mg sample of a dialyzed aqueous 
extract (RPN-3-144-2) in a capped reaction vial was treated with 3 mL of 2N NaOH at 60 oC for 
15 min. After cooling the mixture in an ice bath, the pH was adjusted to 6.5 using 4N HCl. The 
resulting solution was extracted with 10 mL hexanes to remove any lipids and the hexanes layer 
was discarded. Subsequent extractions with 10 mL ethyl acetate were performed twice and the 
solvent removed in vacuo to afford 4.5 mg residue. The aqueous layer was dried down to 
produce 503 mg of residue, which included salts produced from the basic hydrolysis and 
subsequent neutralization with acid. 
Methylation of dialyzed aqueous extract. This reaction was carried out using dry 
solvents and reagents in a nitrogen atmosphere using balloons. A 5 mg sample of the dialyzed 
aqueous extract (RPN-3-145-2) was dissolved in 3 mL methanol. A 2 mL solution containing 500 
µL trimethylsilyldiazomethane (2.0 M in hexanes) in toluene was prepared and half the solution 
was added to the methanolic solution of the dialyzed Areca extract. The mixture was stirred at 
room temperature for 5 h, upon which the remainder of the trimethylsilyldiazomethane solution 
was added. The reaction continued for 24 h with stirring. Solvents were removed in vacuo to 
afford 6 mg of crude product. 1H NMR analysis of the crude product showed a complex mixture 
of components. While new singlets in the 3-4 ppm region of the 1H NMR spectrum were visible, 
it was extremely difficult to estimate the degree of methylation. 
Size exclusion chromatography of dialyzed aqueous extract. A 10 mg/mL solution 
of the dialyzed aqueous extract (RPN-3-145-2) was prepared in water and subjected to size 
exclusion chromatography on a Superose 12 10/300 GL column (GE HealthCare Life Sciences; 
10 x 300 mm, 11 µm median particle size) with a mobile phase consisting of 0.05 M phosphate 
and 0.15 M NaCl at pH 7.2. The flow rate was 1.0 mL/min and a photodiode array detector was 
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used to monitor the progress of the chromatographic separation. A calibration curve was prepared 
from a standard mixture consisting of blue dextran (tR 8.3 min), bovine serum albumen (tR 13.4 
min), carbonic anhydrase (tR 15.1 min), RNase A (tR 16.2 min), aprotinin (tR 17.4 min) and 
methyl cobalamin (tR 19.1 min). 
Attempts to polymerize catechin. In separate vials, 25 mg of catechin was dissolved 
in 10 mL of three different solvents – 15% CH3CN in H2O, 15% CH3CN in H2O with 0.1% 
formic acid, and 30% CH3CN in H2O with 0.1% formic acid. The solutions were left to sit and 
from each vial, 2 mL aliquots were removed at four different time points (1 d, 2 d, 5 d, 10 d), 
solvent removed in vacuo and the residue analyzed by 1H NMR spectroscopy for any signs of 
polymerization. 
HPLC purification of dialyzed aqueous extract. A 2 mg portion of the dialyzed 
aqueous extract (RPN-3-145-2) was dissolved in 1 mL of a mixture of acetonitrile and water 
(15:85), filtered using a Whatman syringe filter (0.45 micron), and purified using HPLC 
(Phenomenex silica, 250 x 10 mm, 10 μm particle size, 100 Å; eluted with mixed solvent 
systems A (82% dichloromethane/14% methanol/2% acetic acid/2% water) and B (96% 
methanol/2% acetic acid/2% water) at 4 mL/min using the following gradient: 0.0-11.7% B (0-20 
min), 11.7-25.6% B (20-50 min), 25.6-87.8% B (50-55 min), 87.8% B (55-65 min), 87.8-0.0% B 
(65-70 min); UV detection at 280 nm). These conditions replicated those described in the 
literature for purification of proanthocyanidin oligomers and polymers.180 Fraction at retention 
time 54-56 min was collected and solvent removed in vacuo to afford 0.7 mg of the presumed 
polymeric (n > 10) proanthocyanidin sample. 
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7.5 Extraction and Isolation of Metabolites from Other Organisms 
Isolation of Callyspongynic Acid from the Sponge 12-Maui-38 
Extraction and fractionation of 12-Maui-38. A 1 g sample of freeze-dried biomass 
of the sponge 12-Maui-38 was cut into small pieces and extracted overnight three times with 1:1 
CH3OH:CH2Cl2 (15 mL each). The combined extract solutions were evaporated to afford 69.5 
mg of the crude extract. The crude extract was partitioned using a solid phase extraction 
procedure resulting in the isolation of 3.7 mg of the 75% methanol fraction.  
HPLC purification of callyspongynic acid. The 75% methanol fraction was 
separated by RP HPLC (Phenomenex Luna C8(2), 250 x 10 mm, 5 μm particle size, 100 Å; 
eluted with water and acetonitrile (each with 0.1% formic acid) at 2.75 mL/min using the 
following gradient: 50-80% CH3CN (0-15 min), 80-100% CH3CN (15-30 min), 100% CH3CN 
(30-40 min); photodiode array detection) to afford callyspongynic acid (5.1, tR 24.0 min, 1.2 mg, 
0.12% yield, > 95% purity by 1H NMR). 
Callyspongynic acid 5.1: white amorphous solid; [𝛼]𝐷
21 -1.4 (c 0.5, EtOH); 1H NMR 
(CDCl3, 500 MHz) δ 5.91 (1H, dtd, J = 15.3, 6.6, 1.2 Hz), 5.61 (1H, ddt, J = 15.3, 6.2, 1.5 Hz), 
4.85 (1H, d, J = 5.7 Hz), 2.58 (1H, d, J = 2.0 Hz), 2.36 (4H, m), 2.25 (8H, m), 2.16 (2H, m), 2.08 
(2H, m), 1.69 (2H, p, J = 7.0 Hz), 1.64 (2H, p, J = 7.0 Hz), 1.61 (2H, m), 1.50 (6H, m), 1.41 (4H, 
m) ppm; 13C NMR (CDCl3, 125 MHz) δ 156.2, 134.3, 128.5, 91.7, 83.1, 80.3, 80.3, 79.6, 79.3, 
77.5, 76.6, 74.1, 72.7, 65.7, 65.3, 62.8, 31.7, 28.5, 28.4, 28.2, 28.2, 28.0, 28.0, 27.8, 27.0, 19.1, 
18.7, 18.5, 18.3, 17.9, 17.9, 17.9 ppm; HRESIMS m/z 469.2734 [M–H]– (calcd for C32H37O3, 
469.2748). Spectroscopic data were generally consistent with literature values.181 (Notebook ID: 
RPN-1-97-1) 
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Isolation of β-Sitosterol from the Sponge 13-Maui-52 
Extraction and fractionation of 13-Maui-52. A 79 g sample of freeze-dried biomass 
of the sponge 13-Maui-52 was broken into small pieces and extracted overnight three times with 
1:1 CH3OH:CH2Cl2 (700 mL each). The combined extract solutions were evaporated to afford 
6.710 g of the crude extract. An 890 mg portion of the crude extract was partitioned using a solid 
phase extraction procedure resulting in the isolation of 104.7 mg of the 100% methanol fraction.  
HPLC purification of β-sitosterol. The 100% methanol fraction was separated by 
HPLC (Phenomenex Luna Silica, 250 x 10 mm, 10 μm particle size, 100 Å; eluted with ethyl 
acetate and hexanes at 3.0 mL/min using the following gradient: 15% ethyl acetate (0-10 min), 
15-40% ethyl acetate (10-25 min), 40-100% ethyl acetate (25-30 min), 100% ethyl acetate (30-
40 min); UV detection at 280 nm) to afford β-sitosterol (4.18, tR 22.3 min, 3.6 mg, 0.03% yield, 
> 95% purity by 1H NMR). 
β-Sitosterol 4.18: white amorphous powder; 1H NMR (CDCl3, 500 MHz) δ 5.35 (1H, 
m), 3.52 (1H, tt, J = 6.3, 4.8 Hz), 2.31-2.21 (2H, m), 1.99 (2H, m), 1.83 (4H, m), 1.68 (2H, m), 
1.60-1.42 (8H, m), 1.38-1.23 (6H, m,), 1.18-0.97 (5H, m), 1.00 (3H, s), 0.92 (3H, d, J = 6.6 Hz), 
0.85 (3H, t, J = 7.4 Hz), 0.83 (3H, d, J = 7.1 Hz), 0.80 (3H, d, J = 6.9 Hz), 0.67 (3H, s) ppm; 13C 
NMR (CDCl3, 125 MHz) δ  140.7, 121.7, 71.8, 56.7, 56.0, 50.1, 46.0, 42.3, 42.3, 39.7, 37.2, 
36.5, 36.2, 33.9, 31.9, 31.9, 31.6, 28.9, 28.2, 26.3, 24.3, 23.0, 21.1, 19.6, 19.4, 18.9, 18.8, 12.3, 
11.8 ppm; HRESIMS m/z 415.3949 [M+H]+ (calcd for C29H51O, 415.3934). Spectroscopic data 
were consistent with literature reports.193 (Notebook ID: RPN-3-43-3) 
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Isolation of Psammaplysin A from the Sponge 14-Maui-05 
Extraction and fractionation of 14-Maui-05. A 40 g sample of freeze-dried biomass 
of the sponge 14-Maui-05 was broken into small pieces and extracted overnight three times with 
4:1 CH3OH:CH2Cl2 (300 mL each). The combined extract solutions were evaporated to afford 
5.950 g of the crude extract. A liquid-liquid partitioning between hexanes, dichloromethane and 
aqueous methanol afforded 1.784 g of the dichloromethane fraction. A 325 mg portion of the 
dichloromethane fraction was further partitioned using a solid phase extraction procedure 
resulting in the isolation of 57.5 mg of the 75% methanol fraction.  
HPLC purification of psammaplysin A. The 75% methanol fraction was separated 
by RP HPLC (Phenomenex Luna C18, 250 x 10 mm, 5 μm particle size, 100 Å; eluted with 
acetonitrile and water (each with 0.1% formic acid) at 2.8 mL/min using the following gradient: 
10-100% CH3CN (0-15 min), 100% CH3CN (15-30 min), 100-10% CH3CN (30-35 min), 10% 
CH3CN (35-45 min); detection using a photodiode array detector) to afford psammaplysin A 
(5.2, tR 11.7 min, 2.7 mg, 0.04% yield, > 95% purity by 
1H NMR). 
Psammaplysin A 5.2: white crystalline solid; 1H NMR (CD3OD, 500 MHz) δ 7.53 
(2H, s), 7.13 (1H, s), 4.98 (1H, s), 4.07 (2H, t, J = 5.9 Hz), 3.63 (3H, s), 3.61 (2H, t, J = 7.0 Hz), 
3.38 (1H, d, J = 16.1 Hz), 3.14 (2H, t, J = 7.3 Hz), 3.05 (1H, d, J = 15.9 Hz), 2.89 (2H, t, J = 7.5 
Hz), 2.13 (2H, p, J = 6.2 Hz) ppm; 13C NMR (CD3OD, 125 MHz) δ 160.6, 158.7, 153.5, 149.8, 
146.7, 137.2, 134.3, 120.8, 119.5, 104.5, 104.3, 80.4, 72.1, 59.3, 41.4, 38.2, 37.9, 33.3, 30.5 
ppm; ESIMS m/z 729.9 [M+H]+ (calcd for C21H24Br4N3O6, 729.8). Spectroscopic data were 
consistent with literature reports.182 (Notebook ID: RPN-3-53-2) 
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Isolation of Fischerellins and Loliolide from the Cyanobacterium CN-16-1 
Biological Material. CN-16-1 (Hapalosiphon sp.), originally collected from the 
Western Caroline Islands in Palau, was obtained from the cyanobacterial collection housed at the 
University of Hawaii at Manoa. The strain was cultured in twelve 20 L carboys containing BG-
11 media with MOPS buffer, under continuous illumination and aeration for 4 weeks. Cells were 
filtered and lyophilized to obtain 18.60 g of dry biomass. 
Extraction and fractionation of CN-16-1. The entire freeze-dried biomass (18.60 g) 
was extracted overnight three times with 1:1 CH3OH:CH2Cl2 (400 mL each). The combined 
extract solutions were evaporated to afford 3.22 g of the crude extract. Modified Kupchan 
partitioning afforded 0.990 g of the hexanes fraction and 0.583 g of the dichloromethane fraction. 
A 207 mg portion of the hexanes fraction was further partitioned using a solid phase extraction 
procedure resulting in the isolation of 86.4 mg of the 100% methanol fraction. Likewise, solid 
phase extraction of a 294 mg portion of the dichloromethane resulted in isolation of 21.0 mg of 
the 25% methanol fraction and 7.0 mg of the 50% methanol fraction. 
HPLC purification of fischerellin A and fischerellin B. A 16 mg aliquot of the 
100% methanol fraction obtained from partitioning of the hexanes fraction was separated by RP 
HPLC (Phenomenex Luna C18, 150 x 4.6 mm, 5 μm particle size, 100 Å; eluted with methanol 
and water at 0.5 mL/min using the following gradient: 85% CH3OH (0-15 min), 85-100% 
CH3OH (15-35 min), 100% CH3OH (35-45 min); detection using a photodiode array detector) to 
afford fischerellin B (5.4, tR 24.6 min, 0.1 mg, 0.003% yield) and fischerellin A (5.3, tR 27.3 min, 
0.4 mg, 0.01% yield). Both fischerellin A and fischerellin B contained unidentified impurities (% 
purity undetermined). 
 
 133 
 
1
33 
Fischerellin A 5.3: amorphous white solid; mixture of conformers; 1H NMR (CDCl3, 
500 MHz) δ 9.94/9.67 (1H, brs/brs), 6.24 (1H, m), 5.49 (1H, d, J = 15.3 Hz), 3.90-3.80 (1H, m), 
3.71-3.52 (2H, m), 2.92/2.91 (3H, s), 2.52-2.43 (1H, m), 2.30 (2H, t, J = 7.0 Hz), 2.13 (2H, m), 
1.63-1.51 (4H, m), 1.48-1.44 (2H, m), 1.46 (3H, d, J = 7.3 Hz), 1.40 (3H, d, J = 7.2 Hz), 1.38-
1.30 (4H, m), 1.33/1.30 (3H, d/d, J = 6.9 Hz/7.0 Hz), 0.89 (3H, t, J = 7.3 Hz) ppm; HRESIMS 
m/z 409.2866 [M+H]+ (calcd for C26H37N2O2, 409.2850). 
1H NMR data were consistent with 
literature reports.183 (Notebook ID: RPN-2-24-3) 
Fischerellin B 5.4: amorphous white solid; 1H NMR (CDCl3, 500 MHz) δ 6.23 (1H, 
dt, J = 15.7, 7.2 Hz), 5.49 (1H, brd, J = 15.1 Hz), 2.76 (1H, m), 1.20 (3H, d, J = 6.7 Hz), 0.90 
(3H, t, J = 7.3 Hz) ppm (other signals were obscured by impurities); HRESIMS m/z 300.2318 
[M+H]+ (calcd for C20H30NO, 300.2322). (Notebook ID: RPN-2-24-2) 
HPLC purification of loliolide. The 25% and 50% methanol fractions obtained from 
the dichloromethane fraction were combined and separated by RP HPLC (Phenomenex Luna 
C18, 250 x 10 mm, 5 μm particle size, 100 Å; eluted with methanol and water at 2.75 mL/min 
using the following gradient: 30% CH3OH (0-5 min), 30-40% CH3OH (5-15 min), 40% CH3OH 
(15-20 min), 40-50% CH3OH (20-25 min), 50-75% CH3OH (25-30 min), 75% CH3OH (30-35 
min), 75-100% CH3OH (35-40 min), 100% CH3OH (40-55 min); detection using a photodiode 
array detector) to afford loliolide (5.5, tR 27.2 min, 1.0 mg, 0.01% yield) with other unidentified 
impurities (% purity undetermined). 
Loliolide 5.5: colorless oil; 1H NMR (CD3OD, 500 MHz) δ 5.74 (1H, s), 4.21 (1H, p, 
J = 3.4 Hz), 3.52 (1H, s), 2.41 (1H, ddd, J = 13.5, 2.7, 2.6 Hz), 1.98 (1H, ddd, J = 14.4, 2.8, 2.4 
Hz), 1.75 (3H, s), 1.73 (1H, dd, J = 14.4, 3.9 Hz), 1.52 (1H, dd, J = 14.5, 3.6 Hz), 1.45 (3H, s), 
1.26 (3H, s) ppm; 13C NMR (CD3OD, 125 MHz) δ 185.7, 113.3, 89.0, 67.2, 47.9, 46.4, 37.1, 
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31.0, 27.4, 26.9 ppm; HRESIMS m/z 219.0981 [M+Na]+ (calcd for C11H16NaO3, 219.0992). 
Spectroscopic data were consistent with literature reports.194 (Notebook ID: RPN-2-35-2) 
 
Extraction Isolation of Metabolites from the Fungal Culture 
Preparation of agar plates for growth of fungal culture. (See section 7.3) 
Isolation and growth of fungal culture. (See section 7.3) 
Extraction of fungal metabolites. (See section 7.3) 
HPLC separation of fungal cell extract. A 75 mg/mL solution of fungal cell extract 
was prepared in ethyl acetate and subjected to RP HPLC (Phenomenex Luna C18, 250 x 10 mm, 
5 μm particle size, 100 Å; eluted with H2O/CH3CN containing 0.1% formic acid at 2.75 mL/min 
using the following gradient: 10-100% CH3CN over 18 min, and washed at 100% CH3CN for 12 
min), affording several fractions that were collected based on signals detected by a photodiode 
array detector. Among these, the fraction eluting at 20.1 min afforded 1.3 mg of compound 5.6 
(~90% purity by 1H NMR) from injections totaling 1600 µL. Yield (1.1% of the crude extract) 
from the biological material was undetermined because the wet biomass was not weighed. 
Compound 5.6: amorphous white solid; mixture of conformers; 1H NMR (CDCl3, 
500 MHz) δ 6.95/6.53 (1H, dt/dt, J = 4.4, 2.3 Hz/4.4, 2.3 Hz), 5.43-5.33 (2H, m),  5.29 (1H, m), 
3.90-3.82 (2H, m), 3.57/3.47 (1H, q/q, J = 7.0 Hz/7.0 Hz), 2.77/2.64 (2H, ddt/ddt, J = 9.3, 8.0, 
2.4 Hz/10.3, 7.6, 2.4 Hz), 2.58-2.32 (2H, 4 sets of overlapping dt, J = 17.5, 7.4 Hz), 1.95 (2H, 
m), 1.63/1.62 (3H, brs/brs), 1.58-1.51 (2H, m), 1.39/1.38 (3H, d/d, J = 7.0 Hz/7.1 Hz), 1.35-1.26 
(2H, m) ppm; 13C NMR (CDCl3, 125 MHz) δ 207.1, 165.6, 130.9, 129.3/128.3, 125.1, 
113.1/111.7, 53.3/53.2, 45.9/45.5, 39.2/39.2, 33.4/32.3, 29.7/28.9, 28.9/28.1, 23.0, 17.9, 
13.4/13.1 ppm; HRESIMS m/z 250.1796 [M+H]+ (calcd for C15H24NO2, 250.1802). 
Spectroscopic data were consistent with literature reports.187a (Notebook ID: RPN-4-9-7)
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Appendix 21. Advanced Marfey’s analysis of the NMeLeu residue of kauamide 2.12 
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L-NMeLeu/L-FDLA D-NMeLeu/L-FDLA 
L-NMeLeu (Standard) + L-FDLA 
Analyte (NMeLeu from hydrolysis of kauamide) + L-FDLA 
HRMS at 9.2 min 
 
HRMS at 10.3 min 
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Appendix 22. 1H NMR spectrum of smenospongidinimine 2.24 in CDCl3 (500 MHz) 
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Appendix 23. 13C NMR spectrum of smenospongidinimine 2.24 in CDCl3 (125 MHz) 
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Appendix 24. 1H NMR spectrum of compound 3.6 in DMSO-d6 (500 MHz) 
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Appendix 25. 13C NMR spectrum of compound 3.6 in DMSO-d6 (125 MHz) 
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Appendix 26. gCOSY NMR spectrum of compound 3.6 in DMSO-d6 (500 MHz) 
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Appendix 27. gHSQC NMR spectrum of compound 3.6 in DMSO-d6 (500 MHz) 
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Appendix 28. gHMBC NMR spectrum of compound 3.6 in DMSO-d6 (500 MHz) 
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Appendix 29. 1H NMR spectrum of compound 3.6 in CD3OD (500 MHz) 
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Appendix 30. 1H NMR spectrum of compound 3.7 in CDCl3 (500 MHz) 
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Appendix 31. 1H NMR spectrum of compound 3.7 in CD3OD (500 MHz) 
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Appendix 32. 13C NMR spectrum of compound 3.7 in CDCl3 (125 MHz) 
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Appendix 33. gHMBC NMR spectrum of compound 3.7 in CDCl3 (500 MHz) 
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Appendix 34. 1H NMR spectrum of compound 3.8 in CD3OD (500 MHz) 
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Appendix 35. 13C NMR spectrum of compound 3.8 in CD3OD (125 MHz) 
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Appendix 36. gCOSY NMR spectrum of compound 3.8 in CD3OD (500 MHz) 
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Appendix 37. gHSQC NMR spectrum of compound 3.8 in CD3OD (500 MHz) 
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Appendix 38. gHMBC NMR spectrum of compound 3.8 in CD3OD (500 MHz) 
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Appendix 39. 1H NMR spectrum of compound 3.9 in CD3OD (500 MHz) 
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Appendix 40. 13C NMR spectrum of compound 3.9 in CD3OD (125 MHz) 
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Appendix 41. gHMBC NMR spectrum of compound 3.9 in CD3OD (500 MHz) 
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Appendix 42. 1H NMR spectrum of compound 3.10 in CD3OD (500 MHz) 
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Appendix 43. 1H NMR spectrum of compound 3.11 in CD3OD (500 MHz) 
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Appendix 44. 13C NMR spectrum of compound 3.11 in CD3OD (125 MHz) 
  
 181 
 
Appendix 45. 1H NMR spectrum of compound 3.12 in CD3OD (500 MHz) 
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Appendix 46. 1H NMR spectrum of compound 3.13 in CD3OD (500 MHz) 
  
 183 
 
Appendix 47. 1H NMR spectrum of compound 3.14 in CD3OD (500 MHz) 
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Appendix 48. 1H NMR spectrum of compound 3.15 in CD3OD (500 MHz) 
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Appendix 49. 1H NMR spectrum of compound 3.7-F3 in CDCl3 (500 MHz) 
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Appendix 50. 13C NMR spectrum of compound 3.7-F3 in CDCl3 (125 MHz) 
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Appendix 51. 1H NMR spectrum of catechin 4.5 in CD3OD (500 MHz) 
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Appendix 52. Stacked 1H NMR spectra from attempts to polymerize catechin 4.5 in 15% acetonitrile in water 
  
10 d 
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2d 
 
 
 
1d 
exchangeable 
protons 
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Appendix 53. Stacked 1H NMR spectra from attempts to polymerize catechin 4.5 in 15% acetonitrile in water (with 0.1% formic acid) 
  
10 d 
 
 
 
5d 
 
 
 
2d 
 
 
 
1d 
exchangeable 
protons 
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Appendix 54. Stacked 1H NMR spectra from attempts to polymerize catechin 4.5 in 30% acetonitrile in water (with 0.1% formic acid) 
  
10 d 
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1d 
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Appendix 55. 1H NMR spectrum after methylation of dialyzed aqueous Areca extract (RPN-3-145-2) in CDCl3 (500 MHz) 
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Appendix 56. 1H NMR spectrum of β-sitosterol 4.18 in CDCl3 (500 MHz) 
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Appendix 57. 13C NMR spectrum of β-sitosterol 4.18 in CDCl3 (125 MHz) 
  
 194 
 
Appendix 58. 1H NMR spectrum of callyspongynic acid 5.1 in CDCl3 (500 MHz) 
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Appendix 59. 13C NMR spectrum of callyspongynic acid 5.1 in CDCl3 (125 MHz) 
  
 196 
 
Appendix 60. 1H NMR spectrum of psammaplysin A 5.2 in CD3OD (500 MHz) 
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Appendix 61. 13C NMR spectrum of psammaplysin A 5.2 in CD3OD (125 MHz) 
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Appendix 62. 1H NMR spectrum of fischerellin A 5.3 in CDCl3 (500 MHz) 
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Appendix 63. 1H NMR spectrum of fischerellin B 5.4 in CDCl3 (500 MHz) 
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Appendix 64. 1H NMR spectrum of loliolide 5.5 in CD3OD (500 MHz) 
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Appendix 65. 13C NMR spectrum of loliolide 5.5 in CD3OD (125 MHz) 
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Appendix 66. 1H NMR spectrum of compound 5.6 in CDCl3 (500 MHz) 
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Appendix 67. 13C NMR spectrum of compound 5.6 in CDCl3 (125 MHz) 
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Appendix 68. Biological activity of metabolites isolated from Dactylospongia elegans 
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Appendix 69. CC50 curves for Dactylospongia elegans metabolites against Panc-1 cell line 
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Appendix 70. Boltzmann distribution of conformers of (3S,6S,11S)-2.19 
Conformer  energy (a.u.)  energy (kcal)  rel energy (kcal)  boltzmann factor  eq mole fraction 
18 -1286.7397 -807441.26 0.00 1.000 0.454 
16 -1286.7397 -807441.25 0.00 0.995 0.452 
4 -1286.7376 -807439.90 1.36 0.101 0.046 
2 -1286.7375 -807439.85 1.41 0.093 0.042 
20 -1286.7347 -807438.11 3.15 0.005 0.002 
19 -1286.7346 -807438.04 3.22 0.004 0.002 
5 -1286.7338 -807437.53 3.73 0.002 0.001 
17 -1286.7333 -807437.20 4.06 0.001 0.000 
15 -1286.7331 -807437.13 4.13 0.001 0.000 
9 -1286.7326 -807436.80 4.46 0.001 0.000 
14 -1286.7325 -807436.76 4.50 0.000 0.000 
12 -1286.7318 -807436.30 4.96 0.000 0.000 
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Appendix 71. Boltzmann distribution of conformers of (7S,9S,10R)-3.8 
Conformer  energy (a.u.)  energy (kcal)  rel energy (kcal)  boltzmann factor  eq mole fraction 
19 -1126.4073 -706831.18 0.00 1.000 0.220 
30 -1126.4072 -706831.11 0.07 0.890 0.196 
34 -1126.4071 -706831.01 0.17 0.754 0.166 
20 -1126.4070 -706830.95 0.23 0.673 0.148 
29 -1126.4068 -706830.85 0.33 0.573 0.126 
33 -1126.4067 -706830.77 0.41 0.497 0.109 
5 -1126.4038 -706828.97 2.21 0.024 0.005 
6 -1126.4037 -706828.88 2.31 0.020 0.004 
27 -1126.4034 -706828.71 2.47 0.015 0.003 
24 -1126.4031 -706828.53 2.65 0.011 0.003 
9 -1126.4030 -706828.49 2.70 0.011 0.002 
26 -1126.4030 -706828.43 2.75 0.010 0.002 
10 -1126.4027 -706828.30 2.88 0.008 0.002 
25 -1126.4026 -706828.22 2.96 0.007 0.001 
23 -1126.4026 -706828.20 2.99 0.006 0.001 
13 -1126.4022 -706827.94 3.24 0.004 0.001 
8 -1126.4021 -706827.90 3.28 0.004 0.001 
28 -1126.4020 -706827.86 3.32 0.004 0.001 
14 -1126.4020 -706827.85 3.33 0.004 0.001 
17 -1126.4020 -706827.84 3.34 0.004 0.001 
7 -1126.4019 -706827.79 3.39 0.003 0.001 
12 -1126.4019 -706827.75 3.43 0.003 0.001 
15 -1126.4018 -706827.74 3.45 0.003 0.001 
16 -1126.4018 -706827.70 3.48 0.003 0.001 
11 -1126.4016 -706827.58 3.60 0.002 0.001 
1 -1126.4015 -706827.54 3.64 0.002 0.000 
18 -1126.4014 -706827.48 3.70 0.002 0.000 
2 -1126.4014 -706827.46 3.72 0.002 0.000 
3 -1126.4011 -706827.24 3.94 0.001 0.000 
4 -1126.4010 -706827.24 3.95 0.001 0.000 
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Appendix 72. Summary of experimental and computed 1H and 13C NMR shifts of all diastereomers of 3.8 
  
Computed 
     Proton Experimental SSR SRR SRS RRR 
 
|δSSR-δExp| |δSRR-δExp| |δSRS-δExp| |δRRR-δExp| 
2 6.94 6.65 6.71 6.81 6.84 
 
0.29 0.23 0.13 0.10 
3 7.16 7.15 7.17 7.18 7.17 
 
0.01 0.01 0.02 0.01 
4 6.97 6.95 6.96 7.01 6.92 
 
0.02 0.01 0.04 0.05 
5 7.50 7.50 7.46 7.37 7.20 
 
0.00 0.04 0.13 0.30 
8 2.38 2.72 1.72 3.61 2.23 
 
0.34 0.66 1.23 0.15 
8 2.18 2.26 2.52 2.20 2.77 
 
0.08 0.34 0.02 0.59 
9 4.31 4.57 4.54 5.23 5.37 
 
0.26 0.23 0.92 1.06 
12 3.05 3.06 3.10 2.85 3.35 
 
0.01 0.05 0.20 0.30 
12 3.30 3.27 3.22 2.94 3.27 
 
0.03 0.08 0.36 0.03 
14 7.17 7.29 7.32 7.06 7.15 
 
0.12 0.15 0.11 0.02 
15 6.64 6.66 6.69 6.65 6.62 
 
0.02 0.05 0.01 0.02 
      
ƩABS[Δδ]= 1.17 1.86 3.18 2.63 
      
MAE= 0.11 0.17 0.29 0.24 
Carbon Experimental SSR SRR SRS RRR 
 
|δSSR-δExp| |δSRR-δExp| |δSRS-δExp| |δRRR-δExp| 
1 136.9 133.3 133.4 143.2 144.8 
 
3.6 3.5 6.3 7.9 
2 120.0 117.3 117.6 118.3 117.2 
 
2.7 2.4 1.7 2.8 
3 129.6 126.9 127.0 126.0 125.9 
 
2.7 2.6 3.6 3.7 
4 123.3 120.1 120.1 120.9 119.6 
 
3.2 3.2 2.4 3.7 
5 125.8 124.5 124.8 125.1 119.9 
 
1.3 1.0 0.7 5.9 
6 136.0 131.5 130.9 139.5 139.5 
 
4.5 5.1 3.5 3.5 
7 104.0 102.3 102.3 99.5 104.9 
 
1.7 1.7 4.5 0.9 
8 47.8 50.3 50.3 57.7 51.8 
 
2.5 2.5 9.9 4.0 
9 78.0 75.5 75.3 81.4 84.3 
 
2.5 2.7 3.4 6.3 
10 91.3 87.5 86.7 88.9 87.0 
 
3.8 4.6 2.4 4.3 
11 175.5 173.1 173.8 168.1 176.5 
 
2.4 1.7 7.4 1.0 
12 40.3 36.0 35.9 52.0 38.3 
 
4.3 4.4 11.7 2.0 
13 128.4 127.3 127.5 126.1 127.6 
 
1.1 0.9 2.3 0.8 
14 133.0 130.6 131.1 130.9 130.3 
 
2.4 1.9 2.1 2.7 
15 115.6 110.3 110.3 110.6 110.3 
 
5.3 5.3 5.0 5.3 
16 157.2 153.5 153.5 154.2 153.4 
 
3.7 3.7 3.0 3.8 
      
ƩABS[Δδ]= 47.8 47.3 69.9 58.6 
      
MAE= 3.0 3.0 4.4 3.7 
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Appendix 73. Boltzmann distribution of conformers of (7S,9S,10R)-3.18 
Conformer  energy (a.u.)  energy (kcal)  rel energy (kcal)  boltzmann factor  eq mole fraction 
33 -1126.3948 -706823.34 0.00 1.000 0.145 
3 -1126.3946 -706823.19 0.15 0.776 0.113 
36 -1126.3946 -706823.16 0.18 0.738 0.107 
8 -1126.3941 -706822.91 0.43 0.483 0.070 
6 -1126.3940 -706822.83 0.51 0.425 0.062 
30 -1126.3940 -706822.83 0.51 0.422 0.061 
4 -1126.3940 -706822.80 0.53 0.406 0.059 
35 -1126.3938 -706822.67 0.66 0.326 0.047 
1 -1126.3937 -706822.63 0.71 0.302 0.044 
5 -1126.3935 -706822.50 0.83 0.245 0.036 
22 -1126.3934 -706822.44 0.90 0.220 0.032 
2 -1126.3934 -706822.42 0.91 0.213 0.031 
24 -1126.3932 -706822.32 1.02 0.178 0.026 
25 -1126.3929 -706822.14 1.20 0.131 0.019 
15 -1126.3928 -706822.05 1.29 0.113 0.016 
19 -1126.3927 -706822.01 1.32 0.107 0.016 
11 -1126.3927 -706821.97 1.36 0.100 0.014 
39 -1126.3926 -706821.93 1.41 0.092 0.013 
26 -1126.3925 -706821.86 1.48 0.082 0.012 
38 -1126.3924 -706821.81 1.53 0.075 0.011 
12 -1126.3924 -706821.81 1.53 0.075 0.011 
21 -1126.3923 -706821.72 1.62 0.065 0.009 
20 -1126.3918 -706821.46 1.88 0.042 0.006 
34 -1126.3915 -706821.26 2.08 0.030 0.004 
23 -1126.3915 -706821.25 2.09 0.029 0.004 
14 -1126.3914 -706821.17 2.17 0.026 0.004 
17 -1126.3913 -706821.11 2.23 0.023 0.003 
10 -1126.3913 -706821.09 2.25 0.022 0.003 
29 -1126.3912 -706821.08 2.25 0.022 0.003 
18 -1126.3912 -706821.06 2.28 0.021 0.003 
13 -1126.3912 -706821.02 2.31 0.020 0.003 
9 -1126.3911 -706820.97 2.37 0.018 0.003 
31 -1126.3909 -706820.86 2.48 0.015 0.002 
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Appendix 74. Summary of experimental and computed 1H and 13C NMR shifts of all diastereomers of 3.18 
  
Computed 
  Proton Experimental SSR SRR SRS RRR 
 
|δSSR-δExp| |δSRR-δExp| |δSRS-δExp| |δRRR-δExp| 
2 6.94 6.72 6.72 6.72 6.70 
 
0.22 0.22 0.22 0.24 
3 7.16 7.15 7.16 7.14 7.14 
 
0.01 0.00 0.02 0.02 
4 6.97 6.65 6.64 6.64 6.63 
 
0.32 0.33 0.33 0.34 
5 7.50 7.28 7.30 7.28 7.26 
 
0.22 0.20 0.22 0.24 
8 2.18 2.62 2.22 2.24 2.41 
 
0.44 0.04 0.06 0.23 
8 2.38 2.42 3.04 2.81 2.73 
 
0.04 0.66 0.43 0.35 
9 4.31 4.31 4.35 4.38 4.39 
 
0.00 0.04 0.07 0.08 
12 3.05 3.33 3.26 3.31 3.24 
 
0.28 0.21 0.26 0.19 
12 3.30 3.25 3.43 3.27 3.37 
 
0.05 0.13 0.03 0.07 
14 7.17 7.25 7.32 7.26 7.26 
 
0.08 0.15 0.09 0.09 
15 6.64 6.74 6.71 6.73 6.73 
 
0.10 0.07 0.09 0.09 
      
ƩABS[Δδ]= 1.77 2.06 1.83 1.93 
      
MAE= 0.16 0.19 0.17 0.18 
           Carbon Experimental SSR SRR SRS RRR 
 
|δSSR-δExp| |δSRR-δExp| |δSRS-δExp| |δRRR-δExp| 
1 136.9 144.2 144.3 144.2 144.4 
 
7.3 7.4 7.3 7.5 
2 120.0 113.7 113.7 113.7 113.7 
 
6.3 6.3 6.3 6.3 
3 129.6 128.7 128.7 128.7 128.7 
 
0.9 0.9 0.9 0.9 
4 123.3 113.8 113.7 113.7 113.7 
 
9.5 9.6 9.6 9.6 
5 125.8 123.6 124.1 124.1 124.2 
 
2.2 1.7 1.7 1.6 
6 136.0 115.7 115.0 115.3 115.3 
 
20.3 21.0 20.7 20.7 
7 104.0 109.8 111.0 110.0 110.0 
 
5.8 7.0 6.0 6.0 
8 47.8 41.6 44.6 41.8 42.2 
 
6.2 3.2 6.0 5.6 
9 78.0 70.4 70.4 70.3 71.1 
 
7.6 7.6 7.7 6.9 
10 91.3 88.0 89.7 87.7 87.9 
 
3.3 1.6 3.6 3.4 
11 175.5 172.3 173.4 172.2 172.1 
 
3.2 2.1 3.3 3.4 
12 40.3 31.9 30.7 32.1 32.3 
 
8.4 9.6 8.2 8.0 
13 128.4 125.3 126.0 125.3 125.5 
 
3.1 2.4 3.1 2.9 
14 133.0 129.8 129.9 129.8 129.9 
 
3.2 3.1 3.2 3.1 
15 115.6 111.1 110.9 111.1 111.0 
 
4.5 4.7 4.5 4.6 
16 157.2 154.0 153.8 154.0 153.9 
 
3.2 3.4 3.2 3.3 
      
ƩABS[Δδ]= 95.0 91.5 95.3 93.8 
      
MAE= 5.9 5.7 6.0 5.9 
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Appendix 75. Boltzmann distribution of conformers of 3.9 
Conformer  energy (a.u.)  energy (kcal)  rel energy (kcal)  boltzmann factor  eq mole fraction 
1 -1049.9375 -658845.67 0.00 1.000 0.089 
6 -1049.9375 -658845.65 0.02 0.959 0.085 
4 -1049.9374 -658845.61 0.06 0.898 0.080 
2 -1049.9374 -658845.59 0.09 0.866 0.077 
7 -1049.9374 -658845.58 0.09 0.863 0.076 
12 -1049.9373 -658845.51 0.17 0.757 0.067 
24 -1049.9371 -658845.39 0.28 0.625 0.055 
25 -1049.9369 -658845.26 0.41 0.501 0.044 
14 -1049.9368 -658845.22 0.45 0.470 0.042 
15 -1049.9365 -658845.04 0.63 0.343 0.030 
18 -1049.9365 -658845.01 0.66 0.326 0.029 
40 -1049.9365 -658844.99 0.68 0.319 0.028 
26 -1049.9365 -658844.99 0.68 0.316 0.028 
28 -1049.9364 -658844.97 0.70 0.307 0.027 
17 -1049.9363 -658844.86 0.81 0.255 0.023 
19 -1049.9361 -658844.75 0.92 0.210 0.019 
43 -1049.9360 -658844.72 0.95 0.201 0.018 
13 -1049.9360 -658844.72 0.95 0.200 0.018 
29 -1049.9360 -658844.70 0.97 0.194 0.017 
16 -1049.9360 -658844.67 1.00 0.185 0.016 
20 -1049.9358 -658844.57 1.10 0.156 0.014 
44 -1049.9356 -658844.45 1.22 0.127 0.011 
37 -1049.9355 -658844.41 1.26 0.118 0.010 
38 -1049.9354 -658844.32 1.35 0.102 0.009 
21 -1049.9352 -658844.21 1.46 0.085 0.008 
45 -1049.9352 -658844.21 1.46 0.085 0.008 
27 -1049.9352 -658844.19 1.48 0.083 0.007 
33 -1049.9350 -658844.10 1.58 0.070 0.006 
11 -1049.9350 -658844.09 1.58 0.069 0.006 
32 -1049.9349 -658844.03 1.64 0.063 0.006 
30 -1049.9348 -658843.95 1.72 0.055 0.005 
47 -1049.9348 -658843.92 1.75 0.052 0.005 
9 -1049.9348 -658843.92 1.75 0.052 0.005 
36 -1049.9347 -658843.91 1.76 0.051 0.005 
10 -1049.9347 -658843.91 1.76 0.051 0.005 
23 -1049.9346 -658843.85 1.82 0.046 0.004 
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Appendix 76. Summary of experimental and computed 1H and 13C NMR shifts of 3.9 
No. δC, Exp. δC, Comp. |δComp-δExp| δH, Exp. δH, Comp. |δComp-δExp| 
1 148.2 142.5 5.7 
  
  
2 112.3 117.9 5.6 6.93 7.21 0.28 
3 131.1 127.5 3.6 7.24 7.40 0.16 
4 123.0 125.1 2.1 6.96 7.30 0.34 
5 125.7 123.2 2.5 7.41 7.48 0.07 
6 133.3 128.9 4.4 
  
  
7 81.7 70.7 11.0 
  
  
8 48.0 46.6 1.4 2.77 3.21 0.44 
   
  2.72 2.69 0.03 
9 207.7 199.4 8.3 
  
  
10 112.4 116.5 4.1 
  
  
11 180.0 177.1 2.9 
  
  
12 27.9 26.3 1.6 3.30 3.39 0.09 
   
  3.05 3.23 0.18 
13 131.6 131.1 0.5 
  
  
14 130.3 127.3 3.0 7.07 7.13 0.06 
15 116.1 111.2 4.9 6.67 6.64 0.03 
16 156.6 153.1 3.5       
  
ƩABS[Δδ]= 73.0 
  
1.77 
  
MAE= 4.0 
  
0.15 
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